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Abstract
Neuroblastoma (NB) is the most common extracranial paediatric tumour, and patients with 
disseminated disease have a poor long-term prognosis. Due to the significant mortality rate, 
alternative treatments to conventional therapies are continually sought. Using the A/J mouse 
model it has previously been demonstrated that a cellular vaccine of the syngeneic Neuro-2a 
NB cell line modified to express IL-2 and IL-12 abrogated the tumourigenicity of Neuro-2a 
cells, and mediated regression of established tumours. However, establishing cultures of 
primary NB cells can be problematic, making this approach difficult to implement clinically.
This thesis describes the development of an alternative cellular vaccine to treat murine NB 
using a synthetic vector. Firstly, transfection of primary dendritic cells was optimised. 
Dendritic cells are potent antigen presenting cells and studies have shown them to generate 
anti-cancer responses. Optimal transfection levels of 5% were obtained but antigen 
presentation by these cells was limited. Therefore, an alternative approach was developed 
using fibroblasts engineered to express IL-2 and IL-12. Cytokine-expressing fibroblasts could 
be used in place of transfected tumour cells to provide sustained, high-level cytokine 
expression in the tumour locale. Transfection of syngeneic and allogeneic murine fibroblasts 
was optimised in vitro to produce therapeutic levels of IL-2 and IL-12. Cytokine-transfected 
fibroblasts were compared with cytokine-transfected Neuro-2a cells to prevent engraftment of 
wild-type Neuro-2a cells in vivo. The allogeneic cells prevented tumour engraftment in a non­
specific, cytokine-independent manner. Syngeneic fibroblasts expressing IL-2 and IL-12 
inhibited tumour engraftment as effectively as cytokine expressing Neuro-2a cells, and this 
rejection was cytokine-dependent. The cytokine-transfected syngeneic fibroblasts induced 
protective immunity against rechallenge with wild-type Neuro-2a cells as effectively as 
cytokine-transfected-Neuro-2a cells. Intratumoural vaccination of cytokine-transfected 
syngeneic fibroblasts also demonstrated therapeutic efficacy against Neuro-2a-derived 
established tumours. Splenocytes from vaccinated mice demonstrated increased IL-2 and 
IFN-y expression and cytotoxicity compared with controls when co-cultured with wild-type 
Neuro-2a cells in vitro. Vaccinated tumours showed decreased vascularity and increased 
infiltration of CD45+ cells compared with controls. Therefore, cytokine-transfected syngeneic 
fibroblasts are a viable potential alternative vaccine for the treatment of minimal residual NB.
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Ch a pter  1
A im s  a n d  
In t r o d u c t io n
Chapter 1
1.1 N e u r o b l a s t o m a
1.1.1 Disease features
Neuroblastoma (NB) is the commonest extracranial solid tumour of childhood, affecting 
one in 7000 children. The tumours arise from any site where the neural crest cells are 
located, the most frequent locations being the adrenal medulla and the sympathetic 
ganglia. This tumour accounts for 8% to 10% of all cancers of childhood and for 15% of 
cancer related deaths in children (Young & Miller, 1975). An internationally accepted 
system for classifying tumour stage and facilitating comparison was agreed in 1988, then 
further modified in 1993 (Tablel.l). NB ffequendy presents as an aggressive malignant 
tumour, but is also distinctive, as the human tumour to most ffequendy undergo 
spontaneous regression. Alternatively, NB may differentiate into benign ganglioneuromas, 
and both features are most prevalent in stage 4-S tumours. The clinical prognosis of the 
disease depends on a number of factors. Age of diagnosis is critical, with infants 
diagnosed at <12months having a generally promising prognosis, even if they are suffering 
from metastatic disease. Those diagnosed over 1 year of age have a much more dismal 
oudook and often fail to respond to even the most aggressive combinations of therapy 
(Evans etal’, 1987).
NB is characterised by several features. The tumours metabolise catecholamines, resulting 
in the excretion of metabolites (Voorhess & Gardner, 1961) which are used as markers of 
tumour activity. These include normetanephrine (NME), vanillylmandelic acid (VMA) and 
homovanillic acid (HVA) (Nakano et al.t 1976; Brewster & Berry, 1979). The ratios 
between these two compounds can denote tumour differentiation (Fitzgibbon & Tormey, 
1994) and combined determination of NME with either VMA or HVA further enhances
18
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Table 1.1 International Neuroblastoma Staging System (INSS) (Brodeur et al., 1993)
Stage 1 Localised tumour with complete gross excision, with or without 
microscopic residual disease; representative ipsilateral and contralateral 
lymph nodes negative for tumour microscopically.
Stage 2a Localised tumour with incomplete gross excision; representative ipsilateral 
and non-adherent lymph nodes negative for tumour microscopically.
Stage 2b Localised tumour with complete or incomplete gross excision; with 
ipsilateral and non-adherent lymph nodes positive for tumour. Enlarged 
contralateral lymph nodes must be negative microscopically.
Stage 3 Unresectable unilateral tumour infiltrating across the midline with or 
without regional lymph node involvement; or localised unilateral tumour 
with contraleteral regional lymph node involvement; or midline tumour 
with bilateral extension by infiltration (unresectable) or by lymph node 
involvement.
Stage 4 Any primary tumour with dissemination to distant lymph nodes, bone, 
bone marrow, liver, skin and/or other organs (except as defined in stage
AS)
Stage 4S Localised primary tumour (as defined in stage 1, 2a or 2b) with 
dissemination limited to skin, liver and/or bone marrow (limited to infants 
less than one year old). Bone marrow involvement should be minimal; i.e. 
<10% of nucleated cells identified as malignant.
19
Chapter 1
their diagnostic power (Monsaingeon et al, 2003). It is these compounds that are analysed 
in population screening. Critical analysis of several such programs has shown that 
screening does not confer any benefit to patient outcome and may even be detrimental, 
leading to unnecessary treatment of stage 1 or 2 tumours and the morbidity and mortality 
associated with therapy of tumours that may well have regressed spontaneously (Schilling 
et al, 2002).
1.1.2 Genetic features
1.1.2.1 Chromosome 1 and chromosome 17
Genetic anomalies in chromosome 1 include rearrangements or deletions, leading to loss 
of material from the short arm (lp) or addition of segments to the long arm (lq) (Brodeur 
et al, 1977). Genetic loss in lp  is one of the most common chromosomal rearrangements, 
seen in ~33% of tumours, and indicates the loss of function of yet unidentified tumour 
suppressor genes (Caron et al, 1996). Screening regions of lp has identified putative 
candidate genes (Krona et al., 2003), and the p53 homologue p73 has also been localised to 
lp36, which is frequently deleted in NB.
Gain of 17q is the most common cytogenetic abnormality in NB, seen in over 50% of NB 
tumours, and is also strongly associated with other risk factors including age >1 year, 
unfavourable ploidy and N-myc amplification (Bown et al, 1999). The status of 17q is a 
powerful prognostic factor in NB; the five year survival of patients with 17q gain was 
~31%, compared with 86% for patients with normal 17q (Bown et al., 1999). The 
correlation between lp  loss, 17q gain and N-myc amplification is highly significant, as N- 
myc amplification is never seen in the absence of 17q gain or deletion of lp  (Caron et al, 
1996; Bown et al, 1999).
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1.12.1 N-Myc
Many genetic markers that predict prognosis can reflect the tumour’s ability to proliferate 
or differentiate. N-myc amplification is the best prognostic indicator in NB (Corvi et al 
1997), and is often found in the more aggressive stage 3 and 4 tumours. N-myc is a 
member of a small closely related family of genes and was first recognised by its similarity 
to c-myc and amplification in NB. The oncogene is located at chromosome 2p23-24, and 
encodes a 64-kDa DNA-binding transcriptional regulator that together with the 22-kDa 
Max protein forms N-myc/Max heterodimers (Facchini & Penn, 1998). The gene is 
expressed during normal embryogenesis and is involved with neuronal cell migration, early 
phases of ganglionic neural crest differentiation (Wakamatsu et al, 1997). Human 
embryonal sympathetic ganglia express N-myc up to week 8.5 (Jogi et al, 2002).
N-myc copy number appears to be constant throughout the tumour’s history; from tumour 
presentation to either regression or patient death (Brodeur et al., 1987) and many 
prognostic factors are correlated with N-myc amplification. Reduced expression of p73 is 
significandy correlated with N-myc overexpression. The p73 gene is deleted ~33% of NB 
tumours, while many other NB tumours expressed reduced levels of p73 protein (Zhu et 
al., 2002). A variety of other factors in poor prognoses NB are correlated with N-myc 
amplification, including silencing of CD44 expression (Combaret et al., 1996; Yan et al., 
2003), increased blood plasma levels of the growth factor midkine (Ikematsu et al., 2003), 
inactivation of caspase-8 (Teitz et al., 2000), high expression of TRKB, the receptor for 
brain derived neurotrophic factor (BDNF), (Nakagawara et al., 1994) and high telomerase 
activity (Hiyama et al, 1995).
Furthermore, N-myc amplification correlates with the angiogenic activity of NB. Amplified 
tumours promoted the development of significandy higher numbers of vessels in
21
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angiogenesis assays (Ribatti et al., 2002a). Overexpression of N-myc down regulates 
interleukin-6 (IL-6) and leukaemia inhibitory factor (LIF) expression (Hatzi et al., 2002a; 
Hatzi et al, 2002b). IL-6 and LIF do not direcdy inhibit NB cell growth, but inhibit 
endothelial cell proliferation and vascular endothelial growth factor (VEGF)-induced 
angiogenesis. Therefore down-regulation of IL-6 and LIF removes these inhibitory 
stimuli, resulting in increased angiogenesis and enhancement of tumour growth.
Up to 60% of primary NB tumours express the anti-apoptotic protein Bcl-2, conferring 
resistance to chemotherapy and radiation treatment (Noujaim et al, 2002). Co-expression 
of Bcl-2 and N-myc up-regulates expression and activation of matrix metalloproteinase-2 
(MMP-2) (Noujaim et al, 2002). MMPs are vital for tumour metastasis by either invading 
into surrounding tissues or intravastion through endothelial cells into the bloodstream 
(Stamenkovic, 2000) and increased MMP activity levels play a role in many cancers (Kelly 
et al, 2000; Kanayama, 2001).
Unusually for cancer, p53 mutations in NB are rare (Moll et al, 1995), and the vast majority 
of primary tumours contain wild-type p53. However, p53 was sequestered in the 
cytoplasm rather than the nucleus in many undifferentiated NB tumours, preventing it 
from functioning as a tumour suppressor.
1.1.3 Current NB Therapy
The current treatment for NB depends on the stage of the disease (Table 1.2). For 
patients with severe disease, induction chemotherapy is usually given, using a cocktail of 
several agents with different targets, followed by surgical resection, then high dose 
chemotherapy and stem cell rescue (Ninane & Pearson, 1997). One of the main barriers
22
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Table 1.2 Current Therapeutic Classification System (Ninane & Pearson, 1997)
Group Tumour stage Patient age 
(years)
Therapy
A 1,2,4S Any Surgery (Emergency therapy if symptomatic)
B 3* Any Conventional chemotherapy ± radiotherapy
4 <1 Surgery
C 4 >1 Intensive chemotherapy, surgery, high dose 
chemotherapy with haematopoietic stem 
cell rescue
* Patients with stage 3 tumours with N-myc amplification should be treated as stage 4 >lyr
to chemotherapy, particularly to repeated courses of treatment, is the induction of drug 
resistance. The best characterised mechanisms of multidrug resistance are the MDR1 
gene, encoding P-glycoprotein (Pgp) and the multidrug resistance-associated protein 
(MRP) gene. Both of these proteins encode ATP-dependent membrane transport 
proteins, which render cells resistant to treatment with a variety of chemotherapeutic 
agents (Grant et al1, 1994). Analysis of pre- and post-therapy patient-derived cell lines 
showed drug resistance to increase by up to 1000-fold in the post-therapy cell lines against 
certain agents following chemotherapy (Keshelava et al., 1997).
In addition to chemotherapy, retinoids are also used in the treatment of several 
malignancies, including NB. A recent study demonstrated the efficacy of an intensive 
high-dose triple-tandem chemotherapy regimen in combination with peripheral blood 
stem cell rescue, and a proportion of the patients also received 13-ar-retionoic acid, 
showing a 3-year survival rate of 79% (Kletzel et al., 2002).
23
Chapter 1
Retinoids are derivatives of vitamin A and are signalling molecules that regulate cell 
growth and differentiation, or can induce apoptosis. They mediate their effects at 
transcription level by binding to dimers of retinoic acid receptors (RAR) which function as 
transcription factors, resulting in the production of many intracellular and secreted growth 
inhibitors (Roninson & Dokmanovic, 2003). Prevention of tumour growth by retinoids 
has also been shown to be due to senescence rather than differentiation. However, as with 
so many drugs, tumour cells can become resistant to effects of retinoids and this is due to 
the inactivation of the RAR (Altucci & Gronemeyer, 2001).
Alternative retinoids have different effects; 9-ar-retinoic acid has been shown to be more 
effective than other isomers in inducing RAR expression. Additionally, certain RAR 
antagonists inhibit the expression of RAR-P in response to al\-trans- but not 9-6tr-retinoic 
acid, indicating different isomers have alternative mechanisms of gene induction (Lovat et 
al., 1997). The 9-cis isomer has also shown superior inhibition of differentiation and 
sustained differentiation of human NB cells in vitro. Due to the significant mortality rate 
still seen in NB, alternatives are continually being sought to improve patient prognosis.
1.2 Mechanisms of tumour progression
1.2.1 Angiogenesis and tumour growth
Angiogenesis is the process of forming new blood vessels and capillaries from pre-existing 
vasculature. This is an elaborate cascade of events, beginning with degradation of the 
basement membrane of the existing vessel. Endothelial cells are then able to migrate from 
the vessel and invade the extracellular matrix. Here they proliferate, ultimately resulting in 
the formation of the lumen of new capillaries. This process of neovascularisation occurs
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in normal physiological situations, such as wound healing, but is also found in pathological 
conditions. In the formation of solid tumours, the switch from the avascular to the 
vascular stage is seen as a specific clinical turning point in disease development (reviewed 
in Bergers & Benjamin, 2003). Once this blood supply is formed, oxygen and nutrients 
can be supplied and the tumour can grow almost indefinitely. Primary NB and metastases 
are well vascularised, thus angiogenesis plays a vital role in tumour development.
1.2.1.1 Pro-angiogenic factors
In order for this process to take place there is a requirement for the tumour cells to 
produce endothelial cell-specific growth factors, such as VEGF, which stimulate the 
development of host blood vessels (Senger et al.y 1993). VEGF signals through two 
tyrosine kinase receptors, Flt-1 and Flk-1 (Terman et al., 1991).
Analysis of clinical NB samples showed that VEGF expression by NB cells was 
significantly higher in tumours with unfavourable histology. Increased Flk-1 expression in 
NB cells and vascular endothelia was also related to unfavourable histology (Fukuzawa et 
al.t 2002). VEGF can also protect NB cells in vitro from apoptosis induced by serum 
starvation or the presence of tumour necrosis factor-a (TNFa), by up regulating Bcl-2 
production (Beierle et al., 2002). VEGF may also confer protection to cytotoxic drugs by 
inducing expression of multidrug-resistance proteins (Zhang et a l 2001) or the anti- 
apoptotic factor, survivin (Tran et al., 2002).
However, despite the presence of many angiogenic factors, tumours often have an 
insufficient blood supply, selecting for tumour cells that thrive under hypoxic conditions. 
This is clinically relevant because cells under hypoxia are less accessible to cytotoxic drugs 
or immunotherapeutic modulators and less susceptible to ionising radiation (reviewed in
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Rabatti et al, 2002b). Hypoxia has also been shown to result in a higher mutation rate and 
increased metastasis; the frequency of mutations in cells within tumours can be up to 5- 
fold higher than otherwise identical cells grown in culture (Reynolds et al., 1996).
1.2.1.2 Antiangiogenic therapy
Antiangiogenic strategies have been developed to treat many tumours. These are aimed at 
inhibiting the growth of endothelial cells rather than inhibiting the tumour cells directly. 
Endothelial cells are genetically stable and therefore do not develop drug resistance in the 
same manner as rapidly mutating tumour cells. Many antiangiogenic strategies have been 
investigated in the treatment of NB. Combination therapy of experimental NB using an 
anti-VEGF antibody and low-dose high-frequency chemotherapy has been shown to 
significandy reduce tumour mass and vascularity (Kim et al, 2002). Cytokines such as IL- 
12 and interferon-y-inducible protein-10 (IP-10) (Feldman et al., 2002) also display 
antiangiogenic activity.
1.2.2 Tumour mechanisms of immune escape
There is evidence from experimental tumours generated under certain conditions to 
support the theory of immunosurveillance in inhibiting the growth of very early tumours; 
tumours chemically-induced in immunodeficient mice are consistently less tumourigenic 
when transplanted into syngeneic immunocompetent mice (reviewed in Khong & Restifo, 
2002). The initial lesions that develop into aggressive tumours have “escaped” immune 
recognition, and the im m unological phenotype of the tumour has been “shaped” by the 
surveillance process.
There is evidence that surveillance against tumours fails due to immunological ignorance. 
One study revealed that tumours would grow if small pieces were transplanted, but if the
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equivalent cell number was transferred as a single cell suspension, a protective cytotoxic T 
lymphocyte (CTL) response developed. Tumour growth was tighdy correlated with the 
failure of tumour cells to reach the draining lymph nodes and the absence of primed 
CTLs. It was also shown that a response could be generated by direct immunisation into 
lymphoid tissue, hence CTLs were neither tolerant nor deleted (Ochsenbein et al., 1999). 
Tumours are inherently genetically unstable, and those that possess mutations that 
enhance proliferation or survival will have a growth advantage over other cells. Tumour 
escape is a passive process of natural selection where tumour subclones with favourable 
characteristics will outgrow others in response to conditions in the tumour 
microenvironment such as nutrient and oxygen supply and growth factors, in the setting of 
untreated tumours and those exposed to immuno- or chemotherapy. Malignant cells have 
evolved many m echanism s to escape immune detection, involving multiple cellular 
pathways.
1.2.2.1 Death Receptors
Death receptors are transmembrane proteins that belong to the TNF receptor family. Six 
have been identified so far in humans, and all contain a cytoplasmic “death domain” 
sequence which couples caspase cascades essential for the induction of apoptosis to each 
receptor (French & Tschopp, 1999).
1.2.2.1.1 Fas/Fas ligand
Various lymphocytes have been reported to mediate tumour immunity, such as CTL, 
natural killer (NK) and lymphokine activated killer (LAK) cells. These cells induce 
apoptosis of tumour cells by two methods; the granzyme/perforin pathway, which induces 
pores in the target cell membrane through which granzymes are secreted leading to
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apoptosis, and the Fas/Fas ligand (FasL) pathway. Fas (CD95) is a death receptor 
expressed by the target tumour cell which interacts with FasL expressed on the surface of 
the killer cell. The Fas-associated death domain (FADD) then activates caspase-8, which 
subsequendy activates itself and cleaves other downstream members of the caspase 
cascade such as caspase-3, -6 and —7 (Salvesen & Dixit, 1999).
Experiments in perforin-deficient mice have demonstrated the role of Fas in tumour 
rejection, where it was observed that in w/ft?-Fas-negative tumour cell lines upregulated Fas 
when the cells were vaccinated in vivo. Tumour cells transfected with a Fas anti-sense 
construct grew faster in the initial stages of tumour growth compared to Fas-expressing 
cells, although both groups of mice eventually succumbed to disease, suggesting a role for 
Fas in tumour immunity in the early stages of tumour growth (Rosen et al., 2000). At more 
advanced stages of malignancy, tumour cells have been demonstrated to become resistant 
to Fas-mediated apoptosis by down-regulation of Fas expression or function (Hahne et al
1996), lack of surface expression due to sequestration of Fas in the cytoplasm (Nambu et 
a l 1998) or by Fas splicing variants that result in truncated Fas lacking the intracellular 
death domain (Cascino etal., 1996).
Tumour cell Fas expression has been shown to be upregulated by irradiation of tumour 
cells in vitro and subcutaneous tumours in vivo, sensitising the tumour cells to apoptosis by 
antigen-specific CTLs. Combination treatment of experimental murine colon carcinoma 
with tumour irradiation and CTL adoptive transfer resulted in significantly decreased 
growth rate and tumour volume of established tumours compared to either treatment 
alone or controls (Chakraborty et al1, 2003). Transducing tumour cells to express higher 
levels of Fas-L, has also been shown to increase the level of induced apoptosis (Shimizu et 
al., 1999), demonstrating an important role of Fas in tumour cell rejection. CTL-mediated
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cytotoxicity via the perforin pathway can also be blocked by tumours through the 
overexpression of a serine protease inhibitor that inactivates granzyme B known as SPI-6 
(Medema et al, 2001).
1.2.2.1.2 FLIP
Murine models have directly shown that cellular FLICE (FADD-like IL-1 P-converting 
enzyme)-inhibitory protein (cFLIP) expression results in escape from T-cell immunity in 
vivo. Tumour cells with elevated cFLIP expression are selected for in vivo and blockade of 
Fas-dependant apoptosis can result in tumour escape even when the perforin pathway is 
operational (Medema et al., 1999). Furthermore, it has recently been shown that cFLIP can 
inhibit T-cell activation, proliferation and IL-2 expression (Tai et al.,2004). Several viruses, 
including oncogenic human herpesvirus-8 and Kaposi’s sarcoma-associated herpesvirus, 
express viral FLIP which mediates resistance to FasL (French & Tschopp, 1999).
cFLIP is also an inhibitor of caspase-8, a cysteine protease associated with apoptosis that 
signals through Fas/FasL (Irmler et al., 1997), while inactivating mutations of caspase-10 
have been detected in lymphoma patients (Shin et al., 2002).
1.2.2.1.3 TRAIL
TNF-related apoptosis-inducing ligand (TRAIL) is cancer cell-specific, killing many 
transformed cells but sparing most normal cells, sparking a great deal of interest in the use 
of TRAIL as a cancer therapeutic. TRAIL binds its receptor, DR5, which mediates its 
apoptotic effects through a FADD and caspase-8 dependent pathway (Bodmer et al., 
2000). TRAIL is highly expressed on activated NK cells, T-cells, C D llc+ dendritic cells 
(DC) and monocytes, and TRAIL-knock out mice have shown a direct role for NK cell- 
TRAIL in natural suppression of tumour metastases.
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A clear role for TRAIL in T-cell mediated immune defence against cancer has been shown 
in allogeneic haematopoietic cell transplantation. The donor T-cells exhibit anti-tumour 
effects, (graft-versus-tumour (GVT)), which have been postulated to provide the greatest 
indication of T-cell-mediated, clinically significant, anti-tumour activity, and TRAIL has 
been shown to be necessary for optimal donor T-cell GVT activity. As GVT activity is 
stimulated by detection of tumour-associated antigens or alloantigens, the main 
complication of this treatment is graft-versus-host-disease (GVHD), resulting in systemic 
illness and organ damage. However, TRAIL plays little or no role in GVHD, selectively 
killing malignant cells over normal cells, making TRAIL an exciting prospect for 
immunotherapy (Schmaltz et al., 2002).
Interferon-y (IFN-y) is also linked with TRAIL-mediated immuno surveillance, through the 
regulation of effector cell TRAIL expression and by augmenting the responsiveness of 
tumour cells to TRAIL-mediated cytotoxicity (reviewed in Smyth et al., 2003). 
Neutralisation of TRAIL promotes methylcholanthrene- (MCA)-induced tumour 
development in mice, and p53+/' mice were more prone to spontaneous sarcoma 
development when TRAIL-depleted (Takeda et al, 2002). Studies in TRAIL-deficient, 
IFN-y-deficient or NK depleted mice also showed the development of TRAIL-sensitive 
MCA-induced and spontaneous sarcoma cells is favoured, indicating that during tumour 
development, immunoselective pressure rejects TRAIL-sensitive cells (Takeda et al, 2002). 
Despite the therapeutic potential of TRAIL, cells from many leukaemia patients are 
insensitive to TRAIL in vitro (Wuchter et al, 2001). Tumour resistance to apoptosis 
mediated by TRAIL can be caused by loss of expression due to mutation or chromosomal 
loss, FADD mutation, post-transcriptional regulation leading to low expression of death 
receptors (Hersey & Zhang, 2001) or mutations in the TRAIL receptor (El-Deiry, 2001).
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1.2.2.2 Secreted Immunosuppressive Factors
Tumours secrete a variety of immunosuppressive cytokines that negatively effect immune 
cell maturation and function, allowing them to escape detection by the immune system. 
One such cytokine is transforming growth factor-P (TGF-P), and production of high 
levels of TGF-P by tumours inhibits lymphocyte proliferation and activation (Fontana et 
al., 1989) and has been correlated with progressive disease (Gorsch et al., 1992). TGF-P 
expression has also been linked to poor clinical and immunological responses following 
immunotherapy (Doran et al, 1997).
Prostaglandin E2 secretion by tumours decreases IL-12 production while enhancing the 
production of IL-10 in macrophages (Huang et al, 1998). The serum concentration of IL- 
10 is often elevated in cancer patients and IL-10 has been shown to inhibit the 
differentiation of stem cell precursors into DC and impede their subsequent activation and 
function (Almand et al., 2000). IL-12 production, antigen presentation and TH1 responses 
in vivo are also down regulated by IL-10 (Sharma et al., 1999), while spontaneous apoptosis 
of DC is increased (Ludewig et al., 1995), all of which contribute to an anti-inflammatory 
tumour environment.
Macrophage migration inhibitory factor (MIF) is an immunosuppressive cytokine 
produced by tumours, which can also directly inhibit NK cell activation. Both the murine 
Neuro-2a NB cell line, and patient derived cell lines have been shown to produce MIF, 
which can activate tumour cell migration (Bin et al., 2002). Many tumours express VEGF, 
which in addition to its angiogenic properties also suppresses DC differentiation and
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maturation through inhibition of the transcription factor NF-kB in haematopoietic stem 
cells (Oyama et al. ,1998).
Gangliosides are another group of molecules with immunosuppressive functions. They 
are carbohydrate molecules containing ceramide and their overexpression is a feature of 
many tumours. They are shed into the circulation from tumour cells, inhibiting DC 
generation from precursors and attenuating DC function (Shurin et al., 2001). 
Gangliosides also inhibit the functional activity of T and NK cells, contribute to tumour- 
induced bone marrow suppression and cause multiple alterations of haematopoiesis, 
resulting in pancytopenia (Dumontet et al., 1994; Niethammer & Handgretinger, 1995).
1.2.2.3 Loss of MHC I expression
The major histocompatibility complex (MHC) molecules are the major antigen presenting 
molecules. Antigen presentation in the context of MHC provides the first signal for the 
priming of naive T-cells. They are divided into two classes; MHC class I (MHC I) are 
found on many cells types, while MHC class II (MHC II) are restricted to specialised 
antigen presenting cells (APCs) such as DC and macrophages. The MHC molecule binds 
peptides in an intracellular location and delivers it to the cell surface where the combined 
ligand is recognised by a T-cell via the T-cell receptor (TCR).
Proteins found in the cytosol of virally infected cells, or proteins from certain bacteria that 
infect the cytosol are degraded by the proteosome into peptide fragments of 8-10 amino 
acids and presented on MHC I, which are recognised and eliminated by CD8+ CTLs. 
Tumour cells also present tumour antigens through MHC I to CD8+ CTLs, resulting in 
the elimination of the tumour cells.
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As a means of escaping recognition by the immune system, many tumours down regulate 
MHC I expression by inactivation of proteins essential for antigen processing such as 
TAP-1 and 2 (Transporters associated with Antigen Processing-1 and 2) (Ritz et al., 2001) 
or p2-microglobulin (P2m) (Cabrera et al., 2003).
IL-10 secretion by tumours has been shown to cause MHC loss by downregulating TAP-1 
and 2 (Zeidler et al., 1997), while defective expression of TAP subunits and p2m have been 
shown to contribute to MHC I loss in NB cell lines (Corrias et al., 2001). MHC I loss in 
these cases is due to transcriptional dysregulation, and expression can be restored 
following treatment with IFN-y (Propper et al., 2003; Corrias et al., 2001). N-mjc is known 
to contribute to loss of MHC I expression in NB by inhibiting nuclear factor binding to 
the enhancer-A element in the MHC I promoter. The p50 subunit of NF-kB has been 
shown to be suppressed by N-mjc, and MHC I expression is downregulated by suppression 
of p50 expression (van’t Veer et al., 1993).
However, mutations in the genes for structural elements of MHC I result in irreversible 
decrease or total loss of MHC I expression. Mutations in the P2m gene are frequent in 
melanoma and m some cases have been shown to be the result of successive mutational 
events affecting both copies of the P2m gene (Paschen et al., 2003). MHC I loss can be 
greater than 50% in some cancers (Cabrera et al., 1996), and is associated with invasive and 
metastatic lesions. Some tumours selectively down regulate expression of MHC I 
haplotypes, and c-myc overexpression in melanoma patients has been correlated with HLA- 
B loss (Versteeg et al, 1989) and block of MHC I expression is a barrier to immunotherapy 
in a number of cancer patients.
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NK cells recognise MHC I by killer inhibitory receptors (KIRs), preventing NK cells from 
killing normal cells. However, as NK cells normally lyse cells that do not express MHC, 
how do MHC-negative tumour cells escape recognition by NK cells? One hypothesis is 
the down regulation of NK-activating stress-induced ligands (MICA and MICB) by 
tumours, but this has not yet been demonstrated in humans (Garrido & Algarra, 2001). 
An alternative theory is the lack of pro-inflammatory mediators within the tumour, so NK 
cells are not activated (Gerosa et al., 2002).
1.2.2.4 Down-Regulation of Tumour Antigens
Tumours can suppress the expression of immunodominant antigens independendy of 
MHC I down regulation, resulting in a poorly immunogenic tumour not readily detected 
by the immune system. Expression of the melanoma differentiation antigens gplOO, 
MART-1 and tyrosinase is down regulated during disease progression (d’Vries et al., 1997), 
while antigen expression can also decrease following peptide vaccination therapy. 
Following immunotherapy with a gplOO peptide vaccine, the gplOO expression in tumours 
reduced from 47% to 38%, while other tumour antigens remained unchanged (Riker et al., 
1999), probably due to selective pressure allowing gp 100-negative cells to outgrow the 
vaccine-targeted gp 100-positive cell population.
Antigenic drift is another mechanism for tumour escape. This phenomenon was first 
identified in the selection of viral escape variants and occurs by mutations that cause 
replacement of residues within the antigenic epitope. It has recendy been shown that 
adoptive transfer of both polyclonal and monoclonal CTLs specific for a particular antigen 
selects for multiple antigenic epitope mutations, resulting in gready reduced T-cell 
recognition of the tumour antigen. This affects a variety of mechanisms including
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MHC:peptide interaction modulation and TCR binding to the MHC:peptide complex (Bai 
et al., 2003), leading to reduced immune recognition.
1.2.2.5 T-CellAnergy
Activation of naive T-cells requires two independent stimuli. The first stimulus is binding 
of the peptide:MHC complex to the antigen-specific TCR and CD4 or CD8 co-receptors. 
The second stimulus is the ligation of co-stimulatory molecules (CD80 and CD86) on the 
APC to CD28 on the T-cell. Both stimuli must be delivered by the same APC, and 
therefore, only APCs can activate and differentiate naive T-cells into effectors and induce 
clonal expansion. T-cell anergy is a state where the T-cell becomes refractory to activation 
by a specific antigen, even when the antigen is presented by an APC.
Antigen binding to the T-cell receptor in the absence of co-stimulation causes the anergic 
state, which is augmented by immunomodulatory cytokines such as IL-10 and TGF-P that 
are secreted by tumours into their microenvironment, and the lack of expression of co­
stimulatory molecules by tumour cells. Self-reactive T-cells, such as those specific for 
tumour antigens, can be functionally silenced as a result of TCR and/or co-receptor 
downregulation caused by persistent antigen exposure (Schonrich et al., 1991). Recently it 
has been shown that the growth of solid tumours can result in antigen-specific CD4+ T- 
cell tolerance. Cross-presentation of tumour antigens by bone marrow-derived APCs 
results in T-cell anergy during solid tumour growth, and this anergy to tumour antigens 
can limit the efficacy of therapeutic vaccination (Cuenca et al., 2003). Anergy abrogates IL- 
2 production, resulting in defective T-cell proliferation (Telander et al., 1999) and anergic 
T-cells can also inhibit the antigen presenting function of DC, mediating down regulation 
of CD80, CD86 and MHC II (Vendetti et al., 2000), collectively resulting in an 
immunosuppressed tumour environment. Providing IL-12 has been shown to reverse the
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anergic phenotype in vivo (Grohmann et al., 1997) and IL-2 stimulation rectifies anergy in 
vitro (Beverly et al., 1992).
1.2.2.6 Role of Suppressor T-Cells
During negative selection in the thymus, some self-reactive T-cells will escape. When 
these cells encounter self-antigens following infection or tissue injury, a means of limiting 
the activation of these cells is required and evidence suggests that immunoregulatory CD4+ 
CD25+ cells involved. Inhibition of the activation of autoreactive T-cells by peripheral 
tolerance also influences the induction of T-cell responses to tumour antigens, many of 
which are self-antigens.
CD4+ CD25+ regulatory T-cells comprise 5-10% of CD4 T-cells in humans and rodents 
and have been shown to prevent autoimmunity, playing a vital role to the tolerance of self- 
antigens. While their mechanism of action is unclear, depletion of these CD25+ cells can 
mediate autoimmune destruction of the mucosal lining of the stomach and small intestine, 
thyroid gland and accelerate diabetes in non-obese diabetic mice (Sakaguchi et al., 2001). 
CD25+ depletion also induces rejection of many transplantable murine tumour lines 
(reviewed in Gallimore & Sakaguchi, 2002). CD25+ regulatory cell suppression is generally 
considered to be antigen non-specific, indicating that responses to a spectrum of tumour 
antigens could be uncovered following the depletion of the regulatory cells. Additionally, 
these cells produce IL-10 and TGF-P, compounding the already immunosuppressed state 
of the tumour environment (Powrie et al., 1996; Asseman et al., 1999).
CD4+ NK1.1+ T-cells (NKT-cells) are another subset implicated in immunosuppression. 
These cells are decreased or absent in mice that suffer spontaneous autoimmune disease,
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and CTL-mediated tumour rejection by IL-13 via the IL-4R-STAT6 (signal transducers 
and activators of transcription6) pathway is inhibited by NKT-cells (Terabe et al.y 2000).
1.3 Immunotherapy for Cancer
The basic principle of tumour immunotherapy is to enable the immune system to 
recognise the tumour as non-self, rather than tolerate it. Numerous strategies are being 
developed for the treatment of cancer, which attempt to augment antigen presentation and 
increase the immunostimulatory capacity in the tumour microenvironment, with the aim 
of achieving a systemic response. Immunotherapy aims to exploit the differences between 
malignant and normal cells, such as the expression of mutated antigens or antigens that are 
of embryonic origin so are not present on differentiated tissues. This has been achieved 
by a variety of approaches that have been successful in many murine tumour models and 
shown efficacy in human cancers.
1.3.1 MHC and Co-stimulatory Molecules
As discussed above, MHC I and MHC II are the major antigen presenting molecules and 
they provide the first stimulus to prime naive T-cells. Expression of both MHC I 
(Prezioso et al.y 1995; Mandelboim et al. 1995) and MHC II (Armstrong et al. 1998; Leach 
& Callahan, 1995) on tumour cells has successfully generated tumour immunity.
Co-stimulatory molecules expressed on the surface of APCs provide the second stimulus 
for priming naive T-cells. The co-stimulatory molecules CD80 (B7.1) and CD86 (B7.2) 
are homodimeric members of the immunoglobulin superfamily. Both CD80 and CD86 
interact with CD28 on naive T-cells. Once T-cells are activated they express cytotoxic-T- 
lymphocyte-associated protein 4 (CTLA-4/CD152), which binds CD80 and CD86 with 
much higher avidity than CD28 and delivers an inhibitory signal, limiting the proliferative
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response of activated T-cells (Chambers et al., 2001). CTLA-4 knock-out mice develop 
massive proliferation of lymphocytes and fatal multi-organ degeneration, demonstrating 
the importance of CTLA-4 regulation (Tivol et al., 1995).
Expression of co-stimulatory molecules on tumour cells can augment antitumour immune 
responses, and this approach has shown efficacy in both murine models and human 
patients. Direct injection of adenovirally-encoded CD80 into rat osteosarcoma tumours 
demonstrated curative immunity of the primary tumour and lung metastases, provided 
protective immunity against rechallenge with parental CD 80-negative osteosarcoma cells 
and activated regional lymph node CD4+ T-cells (Tsuji et al., 2002). Similarly, lung tumour 
cells adenovirally modified to express CD80 were able to generate effector lymphocytes 
that were capable of lysing parental CD80-null lung cancer cells (Iwakami et al. 2001). This 
approach was also used in a phase I clinical trial of metastatic renal carcinoma, where 
tumour cells transduced to express CD80 were delivered in conjunction with systemic IL- 
2. Immunological and clinical responses were observed (Antonia et al. 2002), 
demonstrating the efficacy of co-stimulatory molecules in generating antitumour immune 
responses.
Delivery of costimulatory molecules with cytokine genes has also been effective tumour 
immunotherapy. In vivo gene delivery of CD80 and IL-12 encoded in a single adenoviral 
vector to murine mammary adenocarcinomas resulted in regression of 70% of primary 
tumours and the cured mice were immune to further tumour challenges (Piitzer et al.,
1997). Similarly, a bicistronic retroviral construct, encoding CD80 and IFN-y, was used to 
treat a murine model of human ovarian cancer, markedly reducing the tumourigenicity of 
the transduced tumour cells (Qian et al., 2002). In a variation of this approach, 
experimental NB has been successfully treated with adoptive transfer of CTL generated
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from CD86-expressing NB cells, and these were able to suppress multi-organ metastases in 
vivo (Enomoto et al. 1997). The use of co-stimulatory molecules has been particularly 
effective when co-transduced with MHC II genes (Heuer et al., 1996), showing that with 
the appropriate signals, T-cells can be effectively primed against tumour cells.
1.3.2 CD40 Ligand
CD40-ligand (CD40L/CD154) is a cell surface molecule important in T-cell activation. Its 
receptor, CD40, is found on B-cells and APCs. When CD40L binds CD40, it activates the 
CD40+ cells, inducing surface expression of CD80 and CD86. This enhances T-cell 
responses, making CD40L a potentially useful molecule in immunotherapeutic 
applications. Primary NB cells have been shown to express CD40, and incubation in vitro 
with rCD40L induced the cells into apoptosis, suggesting that CD40 could be targeted 
therapeutically in NB (Airoldi et al., 2003).
CD40L expression has also shown efficacy in vivo. CD40-L-transduced tumour cells have 
been used to treat experimental bladder cancer (Loskog et al, 2001) and murine lung cancer 
(Noguchi et al., 2001), showing increased survival of mice with established tumours and 
giving protective immunity to challenge with parental cells in syngeneic mice. This 
antitumour effect was further enhanced when co-inoculated with IFN-y-transduced cancer 
cells in vivo (Noguchi et al., 2001). CD40L gene therapy has also been used to treat chronic 
lymphocytic leukaemia (CLL) patients, where autologous CLL cells transduced to express 
CD40L increased the number of leukaemia-specific T-cells and reduced lymph node size 
and leukaemic cell count. Enhanced expression of immune accessory molecules on 
bystander non-infected CLL cells, and increased serum levels of IL-12 and IFN-y was also 
observed, with no dose-limiting toxicity (Wierda et al., 2000).
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1.3.3 Tumour Associated Antigens
Tumour associated antigens (TAA) are divided into two categories. The first category 
consists of antigens selectively expressed on tumour cells and is composed of mutated 
antigens and virus derived tumour antigens, while the second category of antigens are 
present on tumour cells and normal tissues.
1.3.3.1 Tumour restricted antigens
Targeting mutated antigens would be advantageous as there would be minimal cross­
reaction with normal tissue. However, most mutated antigens are unique to each cancer 
patient, requiring the production of patient tailored vaccines. Viral antigens are an 
attractive target as they are often shared between many patients; 95% of human cervical 
carcinomas express HPV-16 E7 antigen (zur Hausen, 2000), and this has been exploited as 
a TAA. Cells transfected with a construct encoding the E7 antigen, or DCs pulsed with 
lysates of such transfected cells, exhibited enhanced MHC I antigen presentation. 
Moreover, vaccination of mice with this construct resulted in a striking increase in E7- 
specific CTLs and significant reduction of tumour development compared to treatment 
with wild-type E7 DNA (Hung et al., 2001). However, only a small minority of cancers are 
associated with viral infection, limiting the application of such a strategy.
1.3.3.2 Shared antigens
The second antigen category is non-mutated antigens, shared with normal tissues, and the 
majority of tumour antigens characterised thus far belong to this group. The potential 
usefulness of these antigens depends on their tissue distribution and pre-existing tolerance. 
Because these antigens are shared with normal tissue, they are also expressed in the
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thymus, so self-tolerance severely impacts on the T-cell repertoire’s capacity to respond 
satisfactorily towards these TAAs. Therefore, the understanding of why certain tissue- 
specific antigens induce tolerance while others do not is vital to the design of tumour 
vaccines (reviewed in de Visser et al., 2003).
Some cancers such as melanoma and renal cell carcinoma express well-defined antigens 
that may elicit a spontaneous immune response (reviewed in Jager et al., 2001). However, 
most TAA do not induce immunity in this manner, but expression by APCs and 
subsequent antigen presentation can provoke immune responses against such TAAs. This 
approach requires identification and sequencing of the TAA gene, which should ideally be 
tumour restricted. The TAA gene is then used to transduce APCs, so the antigen is 
optimally processed and epitopes presented in the context of MHC, inducing T-cell 
responses against tumour cells expressing these antigens. Examples include MUC1, found 
on various human cancer cells, making it a therapeutic target for many types of cancer 
(Maruyama et al’ 2001), or antigens with restricted expression patterns such as prostate- 
specific antigen (Willis et al., 2001).
This approach has shown efficacy in vivo. DC transduced with the murine melanoma 
antigen tyrosinase-related protein-2 demonstrated protective immunity against tumour 
challenge and mediated regression of established tumours (Metharom et al., 2001). In 
another melanoma model, cotransduction of DC with the antigen gplOO and the 
chemokine lymphotactin was able to significantly inhibit tumour growth and increase IL-2 
and IFN-y production more efficiently than either gene alone (Xia et al., 2002). However, 
for many cancers there are no identified TAAs, or the antigen may be up-regulated on 
tumours but also present on other tissues, albeit at lower levels. These TAA are not ideal, 
as there is the danger of generating an autoimmune response.
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1.3.4 Antibody therapy
1.3.4.1 Anti-tumour cell antibodies
Targeted antibodies have become an important approach in the treatment of cancer due to 
their high affinity and specificity towards cells from primary and metastatic lesions, 
resulting in antibody-dependent cell-mediated cytotoxicity and complement-mediated 
cytolysis of tumour cells. By late 2002, six antibodies had been approved for use in the 
United States to treat both solid and haematologic neoplasms (Ross et al,1, 2003). These 
include Rituximab, which targets CD20, found on many B-cell non-Hodgkin’s lymphomas 
(Grillo-Lopez et a I., 2002), and Trastuzumab, which targets the HER-2/neu growth factor 
receptor upregulated in many breast cancers (Ross & Fletcher, 1999). Many others 
antibodies are in stage II/III clinical trials.
1.3.4.2 Conjugated antibodies
Antibodies conjugated to cellular toxins or radioisotopes target the therapy to tumour 
cells, thus minimising damage to surrounding tissues, are also involved in clinical trials, and 
two have been approved in the US. Ibritumomab tiuxetan is the murine version of 
rituximab covalendy linked to a metal chelator, allowing stable binding of yttrium 90 ([90Y]) 
to produce improved targeted cytotoxicity.
Initial trials using murine monoclonal antibodies (mAb) were of limited success due to the 
production of human anti-mouse antibodies, which severely attenuated the half-life of the 
administered mAb and prevented repeat administration. Chimeric antibodies were 
subsequendy developed, containing human IgG constant domains fused to murine 
variable regions, which reduced, but did not eradicate, the production of anti-mouse
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antibodies. Partially humanised antibodies and “primatised” antibodies have enabled long­
term therapy with repeat dosing (Ross et al., 2003) and recently, fully human antibodies 
have been developed using transgenic procedures and murine sources (Reff et al., 2002).
Antibodies targeting NB cells have been conjugated to various molecules to induce 
antitumour responses. GD2-expressing NB cells have been successfully targeted in vitro 
using the catalytic domain of diphtheria toxin (which inhibits protein synthesis) fused to a 
single-chain anti-GD2 Ab, which showed selective toxicity to GD2+ cells only (Thomas et 
al., 2002). Alternatively, GD2-targeted liposomes containing c-myh antisense 
oligodeoxynucleotides reduced NB cellular proliferation by inhibiting gene expression 
(Pagnan et al, 2000). NB has also been targeted in vitro with a single-chain antibody against 
neural cell adhesion molecule (NCAM) conjugated to granulocyte colony-stimulating 
factor (GM-CSF), which could selectively induce growth inhibition of a human NB cell 
line (Dehal et al., 2002).
1.3.4.3 ADEPT
An alternative technique using antibodies for cancer therapy is antibody-directed enzyme 
prodrug therapy, where an antibody-bound enzyme is targeted to tumour cells, permitting 
selective activation of a non-toxic prodrug to a cytotoxic agent at the tumour site. This 
approach has reached clinical trials for colorectal carcinoma using an antibody to 
carcinoembryonic antigen conjugated to a carboxypeptidase, which converts a benzoic 
acid mustard-glutamate prodrug into a cytotoxic molecule (Napier et al., 2000). A variation 
is to exploit an enzyme within the cancer cells; a peptide covalently linked to the 
chemotherapy agent doxorubicin considerably reduces the toxicity of the drug, but is 
hydrolysable by prostate specific antigen (PSA), a serine protease, releasing the highly 
cytotoxic doxorubicin. Therefore, only PSA-expressing cells are exposed to the toxicity of
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the drug, increasing the maximum tolerated dose. Nude mice inoculated with PSA- 
positive cells and treated with the drug-peptide conjugate showed considerable reductions 
in tumour burden (DeFeo-Jones et al., 2000).
1.3.4.4 Antibody therapy for NB
A truly tumour specific antigen has not yet been identified for NB, although the 
disialoganglioside GD2 is highly upregulated on many NBs. Gangliosides are sialic acid- 
containing glycosphyngolipids that are mainly detected in the cell surface membrane and 
GD2 is highly expressed on embryonic tissues. It is down regulated on differentiated 
tissues such as cerebellum and peripheral nerves, but there may still be a basal level of 
expression. Although not all NBs express GD2, preventing it from being used as a 
universal target in all patients, it is currendy the best characterised and widely studied NB 
antigen and has been targeted in many clinical trials.
Patients with GD2 positive tumours were treated in a phase I trial with the anti-GD2 
murine monoclonal antibody 14.G2a in combination with recombinant IL-2 with some 
success (Frost et al’ 1997). The murine antibody was well tolerated and displayed some 
antitumour activity, although some patients developed human antimouse antibodies. A 
different anti-GD2 murine monoclonal IgG3 antibody, 3F8, in conjunction with GM-CSF 
in a phase II trial, showed the treatment was promising for minimal residual disease and 
was well tolerated (Kushner et al., 2001). To reduce antimouse antibody responses, a 
chimeric anti-GD2 antibody, chi 4.18, was used in another trial in conjunction with 
chemotherapy. Limited levels of toxicity were observed, although no survival advantage 
was seen over those patients receiving chemotherapy alone (Kletzel et al., 2002).
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1.3.5 Dendritic Cells in Immunotherapy
Manipulating cells of the immune system to recognise tumour cells and elicit an immune 
response may be another way to combat cancer. As discussed above, the tumour 
environment is often immunosuppressive, resulting in defective immune responses. DC 
are the most potent professional APCs. They act as sentinels of the immune system and 
are unique in their ability to stimulate primary naive T-cells with antigen presented on 
MHC, and also provide the necessary co-stimulation signals to activate the cytotoxicity 
activity of T-cells (Banchereau & Steinman, 1998).
DC exist as a small fraction of the peripheral blood mononuclear cell population (PBMC) 
in an immature form. As immature DC, they have a high endocytic capability, and express 
low levels of activation markers such as CD40, CD80, CD86, MHC II, Dec-205 and are 
CD83-negative. Upon encountering antigens or pathogens, they endocytose and process 
the antigen and present fragments in the peptide-binding groove of MHC class II. During 
antigen-processing, the cell develops a mature phenotype; it loses the ability to endocytose 
further material, and shows a marked increase in the surface expression of CD40, CD80, 
CD86, MHC Class II, Dec-205 and becomes CD83h'8h (Banchereau et al,\ 2000). The cells 
become motile and migrate from the tissues into the circulation and home to lymph nodes, 
where they present their antigen to T-cells. Peptide presented in this way interacts with the 
TCR. Mature DC also secrete high levels of IL-12 (Reis e Sousa et al, 1997).
1.3.5.1 DC and tumour peptide antigens
Exposing DC to peptide in vitro results in the peptide being endocytosed, processed and 
antigen being presented to T-cells in the context of MHC molecules. This approach has 
been used in a clinical trial for stage IV melanoma by pulsing DC with identified individual 
TAA peptides. The majority of patients showed an expansion of antigen-specific CTL
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precursors, regression of metastases was observed in over half the patients, and CTL 
infiltration was demonstrated in lesions in two patients (Thumer et al, 1999). Due to their 
high endocytic capacity, co-culturing DC with whole TAA proteins may allow endocytosis, 
processing and presentation of optimal epitopes, but this approach is limited to only a few 
antigens, as the full sequence of most TAAs is not known.
1.3.5.2 DC and whole tumour lysates
Tumour lysate-pulsing of APC is an alternative strategy that can be used when there are no 
identified TAA. A surgical biopsy is used to make a lysate, and DC are exposed to the 
unfractionated antigen mix (Schott et al., 2001). This approach has the advantage of 
producing a polyclonal effector T-cell population, therefore reducing the possibility of 
tumour escape variants, for example, by antigenic drift (Bai et al, 2003), which can be a 
problem with the single TAA approach. It also requires no prior knowledge of any TAA. 
A comparison of apoptotic and necrotic tumour cells showed that, at least in mice, both 
populations have equivalent capacity to mature DC and both resulted in immune priming 
and anti-tumour immunity in vivo (Kotera et al., 2001).
Success with the lysate-pulsing method has been demonstrated in vitro with pancreatic 
carcinoma cell lines (Schnurr et al., 2001), with in vivo murine models of sarcoma or breast 
carcinoma (Fields et al, 1998), and in melanoma therapy clinical trials (Nestle et al., 1998). 
This approach has also reached clinical trials in the treatment of solid paediatric 
malignancies (Geiger et al., 2001), where cellular immunity against autologous tumour was 
demonstrated in half the patients treated. Systemic administration of cytokines has also 
been shown to augment primary CD8+ responses following vaccination with peptide- 
pulsed DC. In mice, adoptive transfer of antigen-specific T-cells and antigen-pulsed DC
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plus systemic IL-15 demonstrated a significant increase of antigen specific-T-cells 
compared to pulsed DC alone (Rubinstein et al, 2002).
Combining administration of immature DC with targeted y-irradiation of a tumour is 
another antitumour application of DC, where growth of experimental murine sarcoma was 
significandy inhibited and tumour-specific T-cell responses increased by combination 
therapy (Nikitina & Gabrilovich, 2001).
An adaptation of the antigen-pulsing technique that produces anti-tumour responses is 
transfecting DC with RNA encoding whole antigens (Koido et al,\ 2000) or unffactionated 
RNA from tumour cell lysates (reviewed in Mitchell & Nair, 2000). The latter approach 
has been shown to generate antigen-specific T-cells responses that lyse autologous primary 
tumour cells in vitro (Nair et al., 2002).
1.3.5.3 DC and pro-inflammatory cytokines
An alternative application of DC in tumour immunotherapy is expressing cytokine 
transgenes. Two murine lung carcinoma models have been successfully treated with DC 
transduced with IL-7, generating systemic antitumour responses, eradicating established 
tumours, and significandy increasing IFN-y and GM-CSF secretion from splenocytes in 
response to tumour target cells (Miller et al., 2000). Furthermore, complete regression of 
murine NB tumours was observed following treatment with IL-12-transduced DC and 
isolated splenocytes had greater cytolytic activity in vitro compared to controls. Tumour 
infiltration of DC and T-cells was increased, and these cells were protected from tumour- 
induced apoptosis (Shimizu et al., 2001).
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However, DC differentiated from the bone marrow of NB tumour-bearing mice and 
transduced to express IL-12 resulted in reduced anti-tumour responses when adoptively 
transferred into tumour bearing hosts compared to IL-12 transduced DC from naive mice. 
The greater tumour burden of the donor mice, the less therapeutic effect of the transduced 
DCs in the host mice, despite comparable phenotype and effector cell activation in vitro 
with DC from naive mice (Redlinger et al., 2003a). The duration of tumour exposure 
appeared to be related to anti-tumour activity loss, so this feature may be important when 
differentiating DC from tumour bearing individuals for ex vivo modification.
A slightly different approach for the treatment of experimental prostate carcinoma used a 
DC cell line stably transfected with IL-12, then pulsed with tumour lysate. Tumour 
engraftment was delayed, tumour growth reduced by up to 80% compared with controls, 
and tumour-infiltrating mononuclear cells induced tumour cell apoptosis and necrosis. 
This study also showed that route of administration had a marked effect on vaccine 
efficacy, and intramuscular injection was more effective than the intraperitoneal or 
subcutaneous routes (Zhang et al1, 2003a). Vaccines to treat murine tumours have also 
been produced by the fusion of DC with tumour cells. Transgenic mice expressing the 
human MUC1 antigen were unresponsive irradiated carcinoma cells expressing MUC1, but 
immunisation of these cells fused to DC resulted in regression of MUC1-positive 
metastases (Gong et a l 1998). Similarly, mice immunised with DC fused to NB Neuro-2a 
tumour cells, were protected from challenge with wild-type Neuro-2a cells, and T-cells 
responses were induced in vitro and in vivo (Orentas etal., 2001).
1.3.6 Cytokine Therapy
Cytokines are small soluble proteins that affect the behaviour or properties of the secreting 
cell itself (autocrine) or other cells (paracrine). Cytokines can be delivered systemically as a
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bolus injection of protein, elevating the serum concentration, and this has shown efficacy 
in murine models. The major drawback with this method is that many cytokines are toxic 
when delivered at a concentration high enough to elicit antitumour effects (Marshall, 1995; 
Smith, 1997). Thus, other strategies have been developed to reduce the toxicity.
The alternatives include local injection of the cytokine directly into the tumour, but this 
tends to result in only a short period of therapeutic efficacy. Gene therapy vectors allow 
longer-term expression of cytokines, and initially vectors were injected directly in vivo. 
However, anti-viral immune responses, particularly to adenovirus limited this approach 
(Thomas et al, 2003). A more successful approach has been to modify cells ex vivo and 
then return them to the tumour microenvironment. The advantages of this approach are 
that only the target cells are modified to express the transgene, and anti-vector immunity is 
reduced. Many clinical trials of tumour cells modified to express immunostimulatory 
cytokines have shown therapeutic antitumour responses. NB has been treated in clinical 
trials by IFN-y transduced allogeneic tumour cells (Seeger et al., 1998) or autologous NB 
cells adenovirally transduced with IL-2 and the chemokine lymphotactin (Brenner et al., 
2000)
1.3.6.1 Interleukin 2
Interleukin-2 (IL-2) was first identified in 1976 (Morgan et al, 1976) in the supernatant of 
activated peripheral blood lymphocytes as a substance capable of driving lymphocyte 
growth and proliferation. Human IL-2 is a 15.5kDa protein composed of 133 amino 
acids, which can cross-react with mouse cells. The IL-2 gene, located on chromosome 4, 
encodes a globular protein composed of two sets of a-helical domains, positioned 
perpendicular to one another (Brandhuber et al, 1987). Mutations in the IL-2 gene have
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been linked with autoimmune diabetes, and it has been suggested that dysregulation of IL- 
2 signalling has a pathogenic role in adult T-cell leukaemia caused by HTLV-1.
IL-2 is secreted by activated T-lymphocytes, particularly CD4+ T-helper cells, and induces 
T-celi proliferation (Figure 1.1). It also acts as an immune modulator and stimulates T- 
cell activation causing them to secrete the immunostimulatory cytokine IFN-y. IL-2 plays 
a role in maintaining an immune response and activates many cell types in the immune 
system, including CD4+ T-helper cells, CD8+ cytotoxic T-cells, B cells NK cells and 
macrophage-monocyte cells (reviewed in Church, 2003).
The IL-2 receptor (IL-2R) is composed of three subunits, designated IL-2Ra, IL-2RP and 
common y-chain (yc). IL-2Rp is shared with the IL-15R complex, while yc is shared with 
the receptors for IL-4, IL-7, IL-9, IL-15 and IL-21. The IL-2Ra chain (CD25) is unique 
to the IL-2R. This subunit sensitises cells to physiological levels of IL-2, although it does 
not contribute direcdy in IL-2 signalling due to the extremely short cytoplasmic tail. 
Upregulation of IL-2Ra is also important for physiological concentrations of IL-2 to 
induce T-cells to proliferate and become sensitive to activation induced cell death (Nguyen 
et al, 2000). Conversely, both the IL-2Rp and yc chains are required for signalling. IL- 
2RP and yc also compose the signalling fraction of the IL-15R, and therefore IL-2 and IL- 
15 initiate very similar signalling cascades (Gaffen, 2001). The gene for yc is located on 
the X chromosome, and loss of expression of this protein leads to X-linked SCID due to a 
phenotypic loss of all the cytokine receptors listed above.
As with many cytokine receptors, binding of the cytokine induces oligomerisation of the 
IL-2R subunits to initiate signalling. Although the IL-2Ra subunit itself does not signal
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intracellularly, it has been shown that loss of IL-2Ra is functionally equivalent to absence 
of IL-2 (Willerford et al., 1995). IL-2RP and yc monomers have very little affinity for IL-2, 
but as a heterodimer form an “intermediate affinity” receptor, which is able to deliver 
signals. IL-2Ra expression is very tighdy regulated, and has binding affinity for IL-2, 
although the monomer cannot take part in signalling. However, the heterotrimeric 
receptor is the classical, high affinity IL-2R that is able to efficiently transduce signals at 
physiological concentrations of IL-2 (Gaffen, 2001).
The effects of IL-2 are mediated through a series of phosphorylation events. Binding of 
IL-2 induces the subunits to form the IL-2R oligomer. This oligomerisation causes the 
phosphorylation of tyrosine residues on Janus Kinase (JAK)1, which binds to IL-2RP, and 
JAK3 which binds to yc, resulting in a significant increase in their catalytic activity. The 
JAKs phosphorylate tyrosine residues on the cytoplasmic tails of IL-2Rp and yc, which 
subsequendy act as docking sites for signalling molecules containing phosphotyrosine- 
binding domains (reviewed in Gaffen, 2001).
IL-2 has been used clinically to enhance T-cell activity in HIV patients (Jacobsen et al.y
1996) and in the treatment of many cancers. Also, antibodies to IL-2R have been used to 
treat lymphoma and in the prevention of transplant rejection (Waldmann & O’Shea, 1998). 
However, systemic administration of high concentrations of rIL-2 often results in 
detrimental side effects which include high fever, extreme flu-like symptoms, capillary leak 
with hypotension and renal failure (Jacobsen et al.y 1996).
Combination of lower doses of IL-2 with other cytokines or local IL-2 delivery has been 
shown to mediate beneficial effects with much lower toxicity. IL-18 is an IFNy-inducing
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factor that acts on T and NK cells. When used with IL-18, a 100-fold lower concentration 
of IL-2 could induce greater levels of cytolytic activity and proliferation of human 
lymphocytes compared with IL-2 alone (Son et al., 2001). Intratumoural vaccination of 
recombinant IL-18 and IL-2 has been successful in treating established murine sarcoma, 
showing induction of memory responses, enhanced proliferation of NK cells and 
upregulation of CD25, as well as synergistically stimulating NK activity and IFNy 
production (Son et al., 2003). Systemic IL-2 has also been used in combination with 
tumour cells expressing Flt-3 ligand, a key regulator of DC, in a murine colon carcinoma 
model. Mice treated with combination therapy had significandy decreased tumour burden 
and survived significandy longer compared with controls (Sivanandham et al., 2002), while 
IL-2-transduced human melanoma cells have been shown to efficiendy stimulate lysis by 
both MHC-restricted and —unrestricted autologous lymphocytes (Arienti et al., 1994).
1.3.6.2 Interleukin-12
Interleukin-12 (IL-12) is a potent proinflammatory cytokine secreted primarily by activated 
APCs such as DC and macrophages and forms a link between innate resistance and 
adaptive immunity (reviewed in Trinchieri, 2003). IL-12 is a heterodimeric protein of 
70kDa (p70) composed of two covalendy linked glycoprotein chains of 35kDa (p35) and 
40kDa (p40). The human p35 gene is located on chromosome 3pl2-ql3.2, and encodes a 
219aa protein, while the gene for human p40 is located on chromosome 5q31-33 and 
encodes a 328aa protein. Expression of both subunits in the same cell is necessary for 
secretion of biologically active IL-12p70. Human IL-12 has no activity on mouse cells, but 
murine IL-12 is able to elicit effects on both human and mouse cells.
Most cell types express low levels of p35 transcripts, although the protein is not secreted 
in significant amounts. The expression of p40 is much more tighdy regulated than p35
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and is only detected in cells that are able to secrete IL-12. All cells that secrete IL-12p70 
produce a large excess of free p40 (Trinchieri, 1995). p40 homodimers are produced in 
mice, and these can block the in vitro and in vivo functions of IL-12p70. In contrast, human 
cells do not endogenously produce p40 homodimers, and therefore p40 homodimers are 
not physiological antagonists of IL-12p70 in humans (Trinchieri, 2003) and the 
significance of the excess p40 is not clear.
IL-12-mediated innate responses include stimulation of NK cytotoxicity and the ensuing 
activation of neutrophils and macrophages, leading to production of superoxides and nitric 
oxide (NO) which have been shown to contribute to control of tumour growth in animal 
models (Wigginton et al.y 1996). IL-12 also induces proliferation and activation of
lymphokine-activated killer cells and T cells, promoting the differentiation of naive TH0 
cells down the TH1 pathway.
The IL-12 receptor is composed of two subunits, IL-12RP1 and IL-12RP2, both of which 
bind IL-12 with low affinity and are unable to transmit signals as monomers. When these 
subunits form a heterodimer, they constitute the functional receptor and bind IL-12 with 
high affinity. IL-12R is not detected on resting T-cells, but activation through the TCR 
induces expression of both chains, but particularly the p2 chain. IL-12R expression is 
enhanced by TH1 cytokines, including IL-12 itself, and co-stimulation through CD28, but 
inhibited by TH2 cytokines (Gollob et al., 1997, Trinchieri, 2003). The IL-12R activates the 
JAK-STAT signal transduction pathway, causing phosphorylation of JAK2 and TYK2, 
and the specific effects of IL-12 are mainly due to STAT4 activation through 
phosphorylation (Thierfelder et al., 1996).
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Since Brunda et al., (1993) first showed that IL-12 had potent anti-tumour immunity, many 
tumour therapy studies incorporating IL-12 have been undertaken using murine models 
and some have progressed to clinical trials. It is well established that the anti-tumour 
activity of IL-12 is due to IFN-y induction and effector NK and CD8+ T-cell activation 
(reviewed in Colombo & Trinchieri, 2002) (Figure 1.2). However, like IL-2, high systemic 
doses of IL-12 are toxic, and despite the initial promising results of murine tumours 
treated with systemic IL-12, the first clinical trial of IL-12 protein therapy was halted after 
the death of two patients and severe toxic effects in 15 others (Marshall, 1995). Therefore, 
much work has focused on combination cytokine therapy, enabling the use of lower doses 
of IL-12 while still retaining therapeutic efficacy, or local delivery of IL-12 where the 
cytokine level is high in the tumour locale but is not elevated systemically.
IL-12 has been delivered to tumours by a number of mechanisms. Viral delivery, 
including intraperitoneal administration of vaccinia vims or adenovirally-transduced DC 
(Tsung et al., 1997; Redlinger et al., 2003b), or non-viral delivery of IL-12 using a gene gun 
(Rakhmilevich et al., 1997) or a polyvinyl polymeric vector (Mendiratta et al., 1999) have 
been shown to elicit potent anti-tumour effects against many established murine tumours 
including sarcoma, NB, renal carcinoma and colon carcinoma. The antitumour effects are 
mediated by a variety of mechanisms, particularly increased expression of inducible nitric 
oxide synthase (iNOS) in activated macrophages enhancing NO production (Tsung et al.,
1997), NK and CD8+ mechanisms (Redlinger et al., 2003b), augmented CD8+ anti-tumour 
cytolysis and generation of immune memory (Rakhmilevich et al., 1997; Mendiratta et al., 
1999).
Co-transduction of IL-12 with the costimulatory molecule CD80 directly into tumours in 
vivo showed increased efficacy compared to either transgene alone, mediating regression of
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established tumours and induction of immune memory. This vaccine was most effective 
when using one virus encoding both molecules, rather than expressing the genes from 
separate vectors, as high level IL-12 in the vicinity of CD80+ tumour cells was required for 
maximal synergy and separate vectors may not infect the same cell (Piitzer et al., 1997).
Like IL-2, IL-12 stimulates IFN-y production but it also has a potent antiangiogenic effect. 
Studies have shown IL-12 can mediate an angiostatic effect dependent on IFN-y but 
independent of T and NK cells, by the antiangiogenic effect of IL-12 secreting fibroblasts 
on tumours engrafted into NK-depleted SCID mice (Duda et al., 2000). The 
antiangiogenic function of IL-12 does not seem to require recognition of tumour antigens, 
thus it has been suggested that this function should be considered an innate resistance 
mechanism (Colombo & Trinchieri, 2002). This antiangiogenic effect of IL-12 has largely 
been attributed to IP-10 (Coughlin et al., 1998), and experiments using different 
proportions of IP-10-transduced and null-transduced human melanoma cells in nude mice 
showed a direct association between the fraction of IP-10 cells present with tumour 
growth inhibition and microvessel density. Indeed, significant reduction of tumour 
growth was observed when only 50% of melanoma cells expressed IP-10, indicating a 
substantial paracrine effect (Feldman et al., 2002). IP-10 has also been shown to be
essential for IL12-mediated antiangiogenesis, T-cell chemotaxis and the induction of 
tumour-protective CD8+-mediated immune memory in murine NB; depletion of IP-10 
with mAb during immunisation abrogated systemic immunity, but IP-10 depletion in the 
effector phase had litde effect on immune memory (Perd et al., 2001).
IL-12 also enhances IL-2 function by inducing IL-2Ra expression, which is essential for 
high affinity binding of IL-2 at physiological concentrations. This upregulation is 
mediated through a p38 MAP kinase pathway (Nguyen et al., 2000). Furthermore, IL-2 has
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been demonstrated to upregulate both subunits of the IL-12R, and subsequently maintains 
expression of STAT4, a protein critical in IL-12 signalling in NK cells (Wang et al., 2000). 
The synergistic action of combining these two cytokines has been observed in the 
treatment of murine NB. Co-transfecting NB cells to express both IL2 and IL-12 
significantly reduced the growth of established NB tumours (Siapati et al., 2003), while 
vaccinating with IL-12-transfected NB cells together with administration of booster 
injections of an anti-GD2 mAb-IL-2 fusion protein that targets the IL-2 to the site of the 
tumour cells gave lasting protective immunity. The latter treatment also prevented the 
appearance of liver and bone marrow metastases following a lethal challenge of parental 
NB cells and generated CD8+ T-cell activation and MHC I-restricted tumour target lysis in 
vitro (Lode et al, 1999).
IL-12 used in combination with other cytokines can further enhance its effects. The 
combination of IL-12 and IL-18 gready enhances T-cell production of IFN-y, which was 
shown to correlate with the IL-12 mediated upregulation of the IL-18R (Ahn et al., 1997). 
However, excessively increased serum levels of IFN-y as a result of systemic IL-12 and IL- 
18 can result in lethal lymphoproliferation in mice, so the combination of cytokines must 
be carefully considered (Nakamura et al, 2000).
1.3.6.3 Other cytokines
GM-CSF plays an important role in the maturation and functions of specialised APCs 
(Pardoll, 1995). Elevated levels of GM-CSF in the tumour locale results in a 
proinflammatory microenvironment and GM-CSF has been used to modify both 
autologous (Moret et al, 2001; Sandler et al., 2003) and allogeneic tumour cells (Thomas et 
al., 1998), with both approaches demonstrating antitumour efficacy in vivo. Furthermore, 
when linked with diphtheria toxin, GM-CSF has been shown to reduce the number of
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leukaemic colony forming units by monocytes from myelomonocytic leukaemia patients 
(Frankel et al., 1998).
A further related cytokine is macrophage colony-stimulating factor, and the membrane 
form (mM-CSF) has been used to treat a murine model of hepatocellular carcinoma. Mice 
vaccinated with hepatoma cells transduced to express mM-CSF developed protective 
immunity against wild type hepatoma cells that was mediated by macrophages and CD8+ 
CTLs (Dan et al., 2001).
IFN-y is a proinflammatory cytokine that has been widely used in cancer immunotherapy 
and has reached clinical trials for the treatment of malignant melanoma with intratumoural 
adenoviral delivery (Khorana et al., 2003) or intratumoural retroviral transfer, which 
resulted in clinical responses plus significandy elevated levels of anti-melanoma-antigen 
antibodies in patients receiving multiple treatment doses (Fujii et al., 2000). An alternative 
strategy is to increase the level of the IFN-y receptor, which improved the response of 
murine tumours transfected with an adenovirus encoding IFN-yR to recombinant IFN-y 
in vivo (Nishida et al., 2002). Increased IFN-y results in upregulation of further 
downstream mediators such as IP-10, but has also been demonstrated to inhibit the 
expression of many other chemokines (Baggiolini, 1998).
As well as mediating immune effects, IFN-y has also been demonstrated to inhibit the 
growth of murine melanoma by non-immune mechanisms, where IFN-y was shown to 
direcdy inhibit the proliferation of the tumour cells (Yu & Thomas-Tikhonenko, 2001).
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1.3.6.4 Chemokines
Chemokines are small, secreted proteins which mediate leukocyte transport regulation by 
influencing the adhesion of leukocytes to endothelial cells, the initiation of migration 
across the endothelial layer and tissue invasion. They can also affect non-haematopoietic 
cells such as stromal and tumour cells (Homey et al., 2002). GTP-binding protein-coupled 
receptors mediate the effects of chemokines, and the change in cell morphology after just 
a few seconds of adding attractant to leukocytes is their most striking effect. Activation of 
leukocytes by chemokines also results in a rise of intracellular free calcium, production of 
microbicidal oxygen radicals and bioactive lipids and release of cytoplasmic storage granule 
contents, including proteases from neutrophils and monocytes and cytotoxic proteins 
from eosinophils (reviewed in Baggiolini, 1998).
IP-10 is an immunomodulatory chemokine that is a chemoattractant for stimulated T-cells 
combined with potent antiangiogenic activity, which has demonstrated potent reduction of 
tumour growth and microvessel density when expressed by transduced tumour cells in vivo 
(Feldman et al., 2002). This approach has been successful in treating murine NB (Shimizu 
et al., 2001), with regression of primary tumours and lasting memory responses that 
rejected subsequent tumour rechallenge. Co-administration of IP-10 and other 
proinflammatory cytokines has also been successful; adenoviral transfer of IP-10 and IL- 
18 directly into murine myeloma tumours synergistically reduced tumour volume and 
activated tumour specific CTLs (Liu et al, 2002).
Another chemokine that has shown anti-tumour effects is lymphotactin (Lptn), which 
specifically regulates NK and T-cell migration. Experiments in vivo showed that injection 
of Lptn into the peritoneum of mice resulted in large influx of T-cells and NK cells, and
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that activated NK cells also produce Lptn themselves, perhaps suggesting a self-regulatory 
migration mechanism (Hedrick et al., 1997).
Due to its T-cell attracting property, Lptn has been investigated alone and in combination 
with other cytokines. Fibroblasts transduced with Lptn alone mediated little anti-tumour 
activity, but co-vaccination of fibroblasts modified to express IL-2 and Lptn significantly 
suppressed tumourigenicity and growth of established tumours in a murine leukaemia 
model (Dilloo et al., 1996). Another study showed that co-transduction of Lptn+IL-2 or 
Lptn+IL-12 significantly enhanced the anti-tumour effect of both cytokines in murine 
breast cancer models, inducing long lasting protective immunity (Emtage et al\,1999).
Lptn has also been used in combination with TAA; mice vaccinated with DC co­
transduced with Lptn and the melanoma antigen gplOO showed increased resistance to 
tumour challenge and superior regression of established murine melanomas compared to 
singly transduced DC. Production of IL-2 and IFN-y, and CTL and NK cytotoxicity were 
significantly increased, and tumour necrosis and infiltration of lymphocytes was also 
greater in mice receiving co-transduced DC (Xia et al., 2002).
1.3.7 Fibroblasts in Cancer Immunotherapy
The major drawback to modifying tumour cells from surgical biopsies is the difficuldy of 
manipulating primary tumour cells in vitro. This is true for NB (E. Siapati, personal 
communication) and other cancers such as breast cancer (de Zoeten et al., 1999). Model 
systems using transfected cell lines are very effective, and many murine models of disease 
have been successfully treated including fibrosarcoma (Leach & Callahan, 1995), NB 
(Shimizu et al., 1999) and hepatocellular carcinoma (Dan, et al, 2001). However, when the 
system is implemented with clinical samples, the results tend to be poor. The cells often
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do not proliferate and die after fairly short culture periods. Furthermore, some tumours 
may be unresectable, or insufficient tumour may be available in cases of minimal residual 
disease.
One approach to overcome these problems is to use allogeneic tumour cells, with mis­
matched MHC. Murine melanoma has been successfully treated with GM-CSF- 
transduced allogeneic melanoma cells, and this vaccine also induced systemic immunity 
against autologous tumour (Thomas et al., 1998), while NB has been treated in phase I 
trials with allogeneic tumour cells modified to express IFN-y (Seeger et al, 1998).
An alternative strategy is the use of autologous dermal fibroblasts as a vehicle for cytokine 
gene expression. These are relatively easy to establish and expand in culture from skin 
explants, and studies using retroviral transfer of cytokine genes have resulted in high-level 
gene expression. The rationale behind this method is that like transfected tumour cell 
lines, the fibroblasts secrete sustained high levels of cytokines in a localised area. 
However, as primary tumour cells are difficult to culture, the intratumourally injected 
fibroblasts offer an alternative way to provide local sustained cytokine secretion.
An advantage with fibroblasts is that a large culture can be established and transduced, 
then aliquots stored for future doses. IL-12-expressing fibroblasts successfully generated 
protective immunity and were used to treat established murine sarcoma by vaccination at 
the tumour site and a distant site, mediating tumour regression and infiltration of CD4 and 
CD8 T-cells and macrophages. This strategy also significandy reduced lung metastases 
when delivered with low dose systemic IL-2 (Zitvogel et al., 1995). Transduced fibroblasts 
have also successfully treated experimental tumours with IL-2 (Fakhrai et al., 1995).
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Fibroblasts retrovirally transduced to express IL-2 were used in a phase I trial for 
colorectal carcinoma and showed a 5-fold increase in tumour-specific CTL precursors in 
some patients and delayed-type hypersensitivity (DTH) responses were seen at the 
vaccination sites, implying the induction of immune memory (Sobol et al\ 1999). Another 
phase I trial used autologous fibroblasts transduced with IL-12 to treat a variety of solid 
tumours (Kang et al\, 2001) that resulted in clear, although transient reductions in tumours 
in nearly half of patients and CD8+ cells were observed infiltrating tumours. A further 
phase I trial is underway using IL-4 transduced fibroblasts in conjunction with irradiated 
autologous glioma cells and dendritic cells to treat malignant glioma (Okada et al., 2001).
Gene-modified fibroblasts have also been efficacious in treating other conditions, 
including experimental arthritis. Syngeneic fibroblasts transfected with a non-viral vector 
encoding IL-4 were used to treat collagen-induced arthritis and demonstrated significant 
clinical and histological improvement in reducing joint inflammation compared with sham- 
transfected controls or allogeneic IL-4 secreting fibroblasts (Bessis et al., 2002).
Some evidence suggests that cytokine-transfected syngeneic fibroblasts are superior to 
cytokine-transfected allogeneic fibroblasts at priming lymph node cells for in vivo anti­
tumour activity (Aruga et al., 1997). However, other publications report the antitumour 
efficacy of allogeneic tumour cells (Kayaga et al., 1999), and allogeneic cytokine-expressing 
tumour cells have been used in clinical trials (Jaffee et al., 1998; Bowman et al., 1998). 
Thus, the efficacy of autologous compared to allogeneic cells may depend on the tumour 
being studied and the particular functional assays studied as a measure of vaccine efficacy.
Another application of fibroblasts in experimental cancer therapy has been to transfect 
semiallogeneic IL-2-secreting fibroblasts with DNA from breast cancer cells (de Zoeten et
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al., 1999). Tumour bearing mice that received this vaccine, expressing the weakly 
immunogenic breast cancer antigens on the more immunogenic fibroblasts, survived 
significantly longer than controls. It has even been suggested that fibroblasts can act as 
APCs (Kundig et al., 1995) and there is some evidence they express the co-stimulatory 
molecule CD80 (Kim et al., 1995).
1.3.8 Immunotherapy-induced autoimmunity
One question that has been raised is the potential problem of autoimmunity. All the 
immunotherapy strategies described above rely on generating host immune responses to 
previously ignored/tolerated host antigens, either by increasing the proinflammatory 
potential of the tumour environment or directly exposing APCs with tumour peptides or 
lysates, and many of these antigens are also present on normal tissues. However, in the 
clinical trials that have used these approaches, no reactions resulting in morbidity or 
mortality have been observed (Hold et al., 1999) although vitiligo has been reported in 
patients treated for melanoma with lysate pulsed DC (Jager et al., 2001). In this case the 
consequence was not a serious condition, but does demonstrate that induction of an 
immune response is being targeted against a normal cellular protein.
However, in a murine model severe autoimmune disease was observed when peptide- 
pulsed dendritic cells were directed against tumour antigens shared with normal host cells, 
which had previously been immunologically ignored, and CTL activity was maintained for 
a prolonged period of time. Transgenic mice expressing the model tumour antigen in 
pancreatic P cells developed fatal diabetes or mice that expressed the model tumour 
antigen in cardiomyocytes and arterial smooth muscle developed severe myocarditis and 
arteritis and eventually dilated cardiomyopathy where cardiomyocytes had been destroyed 
and replaced by fibrotic tissue (Ludewig et al, 2000). Although an artificial system, this
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study highlights the potential dangers of targeting antigens that are not truly tumour 
specific.
1.4 Gene Therapy Vectors
The process of gene transfer into mammalian cells is generally divided into two groups; 
viral and synthetic methods. Most viral gene delivery is mediated by Herpes simplex virus, 
retroviruses, lentiviruses, adenoviruses or adeno-associated viruses and each has merits for 
use with certain cell types. The amount of transgene that can be delivered is limited and 
varies between viruses (Table 1.3). Other viruses have been investigated, including 
vaccinia virus, but not as widely as the five types above. Influenza viruses have shown 
some promise (Strobel et al., 2000), but generation of recombinant influenza vectors is 
hampered by the virus’s segmented RNA genome.
Synthetic vectors initially consisted of naked DNA, but have become more sophisticated, 
employing DNA-condensing agents and cell-targeting moieties or ligands (Table 1.4). 
Viruses are incredibly effective at entering and delivering nucleic acid to cells, and 
therefore many gene delivery vectors attempt to mimic this process. One of the main 
difficulties is delivering the vector to the target cells, especially in a population of mixed 
cell types, thus much work has been undertaken on the specific targeting of vectors for 
gene therapy.
Vector safety is a crucial issue, and in the case of viruses it is essential that the vectors do 
not recombine and become replication-competent (reviewed in Thomas et a l ,2003). 
Another problem that may limit gene delivery efficiency is the host immune response to 
the vector. Vector immunogenicity results in cellular and humoral immunity, preventing 
repeated administration of the vector and mediating destruction of transduced cells.
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Vector Genetic Packaging Tropism Inflammatory Vector Main Main
Material Capacity Potential Genome Limitations Advantages
Forms
Enveloped
Retrovirus RNA 8kb Dividing Cells 
Only
Low Integrated Only transduces 
dividing cells; 
integration might 
induce oncogenesis 
in some applications
Persistent gene 
transfer in 
dividing cells
Lentivirus RNA 8kb Broad Low Integrated Integration might 
induce oncogenesis 
in some applications
Persistent gene 
transfer in most 
tissues
HSV-1 dsDNA 40kb (replication 
defective)
150kb (amplicon)
Strong for 
neurons, but will 
infect other tissues
High Episomal Inflammatory: 
transient transgene 
expression in cells 
other than neurons
Large packaging 
capacity; strong 
tropism for 
neurons
Non-enveloped
AAV ssDNA <5kb Broad, with the 
possible exception 
of haematopoietic 
cells
Low Episomal (>90%) 
Integrated (<10%)
Small packaging 
capacity
Non­
inflammatory;
non-pathogenic
Adenovirus dsDNA 8kb (replication 
defective)
30kb (helper 
dependent)
Broad High Episomal Capsid mediates a 
potent inflammatory 
response
Extremely 
efficient 
transduction of 
most tissues
Table 1.3 The main groups of viral vectors for gene therapy. Adapted from Thomas et al., 2003.
Vector Constituents Main Limitations Main Advantages
Naked DNA Plasmid DNA Very low gene transfer levels 
Only been shown to work in vivo 
when injected directly into muscle
Gene expression can persist for serveal 
months in muscle
Gene Gun Gold particles coated with 
plasmid DNA transferred 
into cells by high pressure
Difficult to treat internal organs 
Transient in dividing cells
Transfect a wide variety of cells in vivo 
High-level gene transfer
Lipoplex Vectors Plasmid DNA and cationic 
lipids
Short-term gene expression 
No targeting specificity of gene 
transfer
Non-immunogeneic.
Limits the level of endosomal 
degradation of vector
Polyplex Vectors Plasmid DNA and 
condensing agents such as 
poly-L-lysine or PEI
Rapidly cleared from circulation in 
vivo by complement fixing 
No targeting specificity
Positive charge increases contact with 
cells. Biodegradable variants have 
reduced immunogenicity and 
cytotoxicity
Iipopolyplex Vectors Plasmid DNA, cationic lipid 
and condensing agent, often 
with receptor targeting 
capacity
Transient gene expression 
Transfection efficiency decreased 
compared with viral vectors
Target specific cell populations 
Generally higher transfection efficiency 
than non-specific synthetic vectors 
Addition of certain viral proteins can 
increase transfer of vector into the 
nucleus
Table 1.4 The main groups of synthetic vectors for gene therapy.
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1.4.1 Vital Vectors
1.4.1.1 Adenoviral vectors
Adenovirus (Ad) is a non-integrating double stranded DNA virus, which is maintained 
episomally. Most vectors are based on serotype-5, and due to their broad tropism and 
high transduction level, Ad are used extensively in clinical trials (Somia & Verma, 2000). 
Ad vectors have been widely used in the treatment of cancer, delivering cytokine genes 
such as IL-12 or IFN-y, genes encoding TAAs and immunostimulatory molecules such as 
MHC and CD80/CD86. Another application in cancer therapy is the use of selectively 
replicating viruses that only replicate in tumour cells in which the missing function is 
supplied. The conditionally replicating adenovirus ONYX-015 has shown antitumour 
efficacy when used with chemotherapy in phase II trails, and has shown tumour selectivity 
in patients with advanced head and neck cancer (Nemunaitis et al.y 2000).
Ad vectors target the coxsackie-adenovirus receptor (CAR) and interaction of the penton 
base with cell surface integrins enables internalisation into endosomes (Wickham et al.y 
1993), but infection is less efficient in cells that do not express CAR. Pseudotyping Ad-5 
vectors with alternative fibre proteins creates chimeric viruses; this strategy generated a 
virus that could efficiently transduce CD34+ HSCs, by incorporating the Ad-35 fibre into 
an Ad-5 capsid (Shayakhmetov et aiy 2000).
An alternative approach is to genetically modify the fibre protein; replacing the CAR 
binding sequence with an integrin-targeting motif increased gene transfer to CAR-negative 
cells in vitro (Hidaka et al.y 1999). Cell-specific binding peptides can be identified by phage 
panning with specific cell types, then the virus fibre protein engineered to express the 
phage-isolated motifs. This not only increases transduction efficiency, but can also reduce 
non-specific transduction in a mixed cell population.
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One major problem with Ad vectors is their inherent immunogenicity, which can prevent 
repeated dosing of the vector. First generation vectors induced strong CTL responses that 
resulted in elimination of transgene expression. Second and third generation vectors are 
less immunogenic and have reduced toxicity. Ad vectors can induce many components of 
the immune system, including CTL responses against viral gene products or “foreign” 
transgene products. The viral capsid itself induces release of inflammatory cytokines and 
humoral responses, even in the absence of any gene expression. The anti-vector response 
lead to the death of one patient in a phase I clinical trial. An 18 year old, suffering from a 
partial deficiency of ornithine transcarbamylase (OTC) was the first patient whose death 
was directly attributed to the gene therapy vector. He received 3.8xl013 second generation 
recombinant Ad particles via intrahepatic administration, but within hours experienced a 
massive inflammatory response leading to intravascular coagulation, respiratory distress 
and multiorgan failure, and died four days later (Marshall, 1999), underlining how severe 
anti-viral responses can be.
However, helper-dependent vectors with all the viral genes deleted are considerably less 
immunogenic (Morsy & Caskey, 1999). Their increased transgene expression is more 
applicable to long-term gene therapy, and such vectors have shown life-long phenotypic 
correction in murine models of Duchenne muscular dystrophy (DelloRusso et al., 2002).
1.4.1.2 Adeno-Associated Virus Vectors
Adeno-associated virus (AAV) is a small single stranded replication-deficient non­
enveloped DNA parvovirus, which requires adenovirus or herpes simplex virus to 
replicate. AAV is composed of an icosahedral protein capsid and a genome of 4.7kb, 
which encodes rep and cap, flanked at both ends by inverted terminal repeats (ITR)
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(Rabinowitz & Samulski, 2000). Most AAV vectors are based on serotype-2 (AAV-2) and 
are promising for gene therapy, as they are not known to cause any human disease. 
However, only 4.5kb of DNA can be inserted into AAV-2, so small packaging capacity is a 
limitation. Wild-type AAV-2 can integrate into chromosome 19q of the host cell, although 
AAV vectors appear to integrate randomly (Russell et al., 1994). Integration of 
recombinant AAV genomes into host chromatin is associated with chromosomal 
rearrangements, including deletions and translocations (Miller et al., 2002).
AAV-2 has a broad tropism, infecting liver, retina, brain, muscle and heart as it binds to 
ubiquitously expressed heparin sulphate proteoglycans (Summerford & Samulski, 1998). 
However, it does not infect all cells efficiently and pseudotyping AAV-2 with capsids from 
other serotypes with different tissue tropisms is one method of vector retargeting (Buning 
et al., 2003). Alternatively, insertion of ligand coding sequences into the capsid genes 
(Girod et al., 1999) or using an intermediate molecule to interact between the target cell 
and the vector, such as a bispecific antibody (Bartlett et al, 1999) can retarget the vector.
In cancer therapy AAV vectors have delivered the angiostatic molecule angiostatin in a 
murine model of metastatic liver cancer, significantly suppressing angiogenesis and growth 
and increasing survival time (Xu et al., 2003). AAV has also been used in hybrid vectors, 
which combine the best features of different viruses. An Ad/AAV hybrid vector has been 
used to deliver antisense telomerase RNA to breast cancer cells, enhancing apoptosis and 
significantly suppressing their malignant phenotype in vitro (Zhang et al., 2003b).
1.4.1.3 Retroviral Vectors
Retroviral (RV) vectors integrate the transgene stably into the host genome, such that the 
transferred gene is passed on and expressed in all daughter cells. Retroviruses consist of
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two copies of a single stranded RNA genome encoding sequences called gag, which 
encodes structural proteins, pol, which encodes reverse transcriptase (RT) and intergrase, 
and env, which encodes the envelope glycoprotein that binds receptors on the cell surface 
to gain entry and infect the target cell. Once in the cell, the single stranded RNA is 
converted to dsDNA by RT, and intergrase inserts the viral DNA into the host genome 
(reviewed in Kurian et al.,2000; Hu & Pathak, 2000).
The most frequently used RV vectors are based on oncogenic viruses and Moloney Murine 
Leukaemia virus is used most often. Pseudotyping these vectors with surface proteins of 
other viruses has improved the host range and titre. Pseudotyping with VSV-G (the 
glycoprotein of vesicular stomatitis virus), which targets ubiquitously expressed 
phosphatidyl serine residues, has been particularly successful as these vectors have a broad 
host range. VSV-G has also enabled higher viral titres, as it is more stably associated with 
virions than many RV envelope proteins, allowing efficient concentration by 
ultracentrifugation or anion-exchange purification (Yee et al., 1994, Scherr et al., 2002).
Self-inactivating vectors with deletions in the U3 region of the 3’ LTR have further 
improved vector safety. After one round of replication, these deletions are copied into the 
5’ and 3’ LTRs, producing inactive provirus (Yu et al., 1986). The use of tissue-specific 
promoters has also been used to restrict expression to target cell populations.
Severe combined immunodeficiency (SCID)-Xl has been treated with an MLV-based RV 
vector delivering yc to CD34+ stem cells, resulting in functional reconstitution of 
immunity (Cavazzana-Calvo et al., 2000). However, there is concern that the gene could be 
integrated into a proto-oncogene, resulting in malignancy. Indeed, this has resulted in two 
of fourteen patients in the SCID-X1 trial developing T-cell lymphomas. But these are just
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two patients from the hundreds treated with RV vectors for various diseases (Thomas et 
al., 2003). At present, there are no efficient methods for targeted integration. Integrating 
viruses are preferable if stable genetic alteration is to be maintained in dividing cells. 
However, integration does not guarantee stable transcription as transgene expression can 
gradually be silenced over time (Pannell & Ellis, 2001).
RV vectors can also deliver two genes on one plasmid with the use of an internal 
ribosomal entry site (IRES) and this approach has been used in cancer therapy, using one 
vector to deliver CD80 and IFN-y (Qian et al., 2002). This allows the ribosome to bind 
the middle of an mRNA and translate a gene far from the 5’ end of the message, although 
generally the gene expressed with the IRES is translated less efficiendy than the gene at the 
5’ end of the mRNA. RV vectors only transduce dividing cells, making them an attractive 
target for cancer gene therapy as they may target rapidly dividing malignant cells in vivo 
(Roth et al., 1996). However, most RV modification occurs ex vivo, and the requirement 
for mitosis limits their use.
1.4.1.4 Lentiviral Vectors
Lentiviral (LV) vectors are complex retroviruses typically associated with the infection of 
macrophages and lymphocytes. LV vectors are able to infect non-dividing cells by 
interacting with the nuclear import machinery, and the preinegration complex is actively 
transported through the nucleopores (Bukrinsky et al., 1993). Most LV vectors are based 
on HIV-1 although other lentiviruses have been investigated such as HIV-2 and equine 
infectious anaemia. The endogenous HIV-1 envelope protein (gpl20) has a very narrow 
tropism, targeting only CD4 and a co-receptor (CCR5) in vivo, although variants can evolve 
to use CXCR4 as a co-receptor (Clapham & McKnight, 2001), and therefore they are often 
pseudotyped with VSV-G to increase their tropism.
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Many other viral proteins are also deleted, including vif, vpr,; vpu, and nef, which all 
contribute to viral pathogenesis (Naldini & Verma, 1999). LV vectors need to express 
accessory proteins for regulation of their replication so additional or-acting elements are 
incorporated into LV plasmids, including the Rev response element which permits 
transport of viral RNA to the cytoplasm. Addition of the woodchuck hepatitis post- 
transcriptional regulatory element (WPRE) has also been shown to enhance gene 
expression by stabilising mRNA and allowing increased translation (Zufferey et al., 1999). 
Another element that enhances efficient LV transduction is the central polypurine tract, 
which is necessary for second strand DNA synthesis, and is also thought to enhance the 
nuclear transport of the provirus (Zennou et al., 2000).
LV vectors efficiendy transduce non-dividing cells including adult neurons (Naldini et al.,
1996) and human DC and macrophages differentiated from peripheral blood (Schroers et 
al., 2000). LV vectors also integrate into the host genome, although this is not as random 
as previously thought. Analysis of hundreds of HIV integration sites showed that the viral 
genome preferentially integrates into transcriptionally active genes (Schroder et al., 2002).
LV vectors have been used to treat primate models of Parkinson’s disease with the 
delivery of glial derived neurotrophic factor due to their ability to transduce neurons 
(Kordower et al, 2000). They are also effective in cancer therapy, as demonstrated in a 
murine melanoma model, delivering a tumour antigen which resulted in regression of 
established tumours and protective immunity against rechallenge (Metharom et al., 2001).
Another genus of the retrovirus family are the foamy viruses (spumaviruses), which are 
distinct from both RV and LV vectors. They are not known to cause any disease in the
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host, which has prompted interest in their use for gene delivery (Linial, 1999). Preliminary 
work has shown that foamy viruses transduce CD34+ human HSCs with high efficiency, 
equivalent to HIV-1-based LV vectors (Leurs et al.t 2003)
1.4.1.5 Herpes Simplex Vims
Herpes simplex virus (HSV) is a non-integrating, enveloped, double stranded DNA virus 
with a genome of 152kb. Wild-type HSV infects the sensory ganglia of peripheral nerves, 
where it can progress to a latent phase or lytic phase. Many viral genes can be deleted and 
complemented in trans, allowing for their replacement with large or multiple transgenes.
HSV has many advantages as a gene delivery vector, including broad host range, high 
infectivity, the ability to infect non-dividing cells, relatively long-term gene expression and 
low risk of insertional mutagenesis (reviewed in Burton et al.t 2002). However, the vector 
is episomal so it may be diluted out in dividing cells. HSV vectors are divided into two 
categories: recombinant HSV vectors and HSV amplicons.
The recombinant vectors consist of a wild-type HSV genome rendered replication- 
defective by deletion or disruption of essential genes, and can incorporate ~30kb of insert 
DNA. Amplicons are eukaryotic expression plasmids that contain a virus-derived origin 
of replication and the cleavage/packaging sequence. These can be modified to include up 
to ~ 130kb of foreign DNA, enabling the inclusion of promoters, enhancers and 
transgenes, possibly in their genomic form. This was recently achieved using an amplicon 
to deliver and express in vitro the complete genomic human hypoxanthine 
phosphoribosyltransferase locus of 115kb (Wade-Martins etal., 2001).
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HSV has a natural tropism for neural cells where it can establish a latent infection for the 
duration of the host’s lifetime, thus is being considered as a vector for many neurological 
diseases and neurodegeneration, including peripheral neuropathy (Goins et al., 1999; 
Chattopadhyay et al., 2002) and chronic pain management (Goss et al., 2001). HSV vectors 
have also been used to treat cancers of the CNS. Malignant glioma is a fatal, but normally 
localised, CNS tumour and has been treated /// vivo with y-irradiation and a HSV vector 
encoding TNFa and HSV-TK in combination with gancyclovir (Niranjan et a l 2000).
HSV-1 amplicons have also been used in immunotherapy of murine tumours. Cytokine 
therapy of murine melanoma by intratumoural inoculation with a HSV-1 amplicon 
encoding the GM-CSF gene was able to significandy inhibit tumour growth in a dose 
dependent manner (Toda et al1,2000).
1.4.2 Synthetic Gene Therapy Vectors
The first experiments were performed with naked plasmid DNA injected into muscle 
(Wolff et al., 1990). The level of gene transfer was extremely low but gene expression 
persisted for months under certain conditions. Since then non-viral vectors have become 
more sophisticated and more efficient. They are considered a safer alternative to viruses as 
they are less immunogenic, permitting repeated administration (Jenkins et al., 2000) and 
there is no risk of infection. They have fewer size constraints on the amount of DNA they 
can deliver to cells, being able to transfer up to 200kb, thus several genes can be delivered 
at once. However, as they are non-integrating, the transgene is diluted out of rapidly 
dividing cells. This is not necessarily a disadvantage, as some applications may only 
require transient expression.
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Bacterial plasmid DNA incorporated in non-viral vectors is more straightforward to 
construct and produce than the packaging and purification of modified viruses. Immune 
responses triggered against viral proteins can limit the expression from some vectors and 
prevent the re-administration of the vector. Many patients have pre-existing antibodies 
against viral coat proteins due to previous natural exposure to the virus; over 70% of the 
population may carry antibodies to Ad and AAV (Somia & Verma, 2000), which may 
prevent infection and therefore expression of the transgene. Expression of viral proteins 
may stimulate B-cells to generate anti-viral antibodies and CTLs to kill transfected cells.
Plasmids grown in bacteria are associated with innate immune responses to palindromic 
sequences surrounding unmethylated CpG motifs present in bacterial DNA. These 
sequences are down-regulated in vertebrate DNA, and 75% of these dinucleotides are 
methylated. The differences in sequence in bacterial DNA activate components of the 
innate immune system that are an evolutionarily-conserved host defence mechanism that 
recognises conserved molecules restricted to micro-organisms (reviewed in Spack & Sorgi, 
2001) and Toll-like receptor 9 (TLR9) has been shown to be responsible for CpG-DNA- 
mediated signal transduction (Hemmi et al1, 2000). The immunostimulatory properties of 
CpG have been exploited in experimental NB therapy and when CpG oligonucleotides 
were inoculated in conjunction with GM-CSF-secreting irradiated tumour cells, tumour- 
free mice were also resistant to further tumour challenge, indicating development of 
memory responses (Sandler et al^ 2003).
Gene gun technology uses a shock wave generated by high pressure helium to force DNA- 
coated micrometer-sized gold particles to cells or tissues and this method has been used in 
the treatment of experimental cervical cancer, to transfer DNA encoding HPV-16 E7 
antigen (Hung et al., 2001). Murine sarcoma has also been successfully treated by gene
76
Chapter 1
gun-mediated transfer of IL-12 to the area of skin overlying the tumour, eradicating 
established tumours at the site of gene transfer, tumours at distant sites and rejecting later 
rechallenge with unmodified tumour cells, demonstrating systemic effect and immune 
memory (Rakhmilevich et al., 1997).
The main disadvantage of non-viral gene transfer is the low transfection efficiency 
compared to viruses, resulting in much lower transgene expression. Nevertheless, 100% 
transfection efficiency is not necessarily required, as secreted factors can mediate effects 
through paracrine mechanisms (Feldman etal, 2002).
1.4.2.1 Lipoplex Vectors
DNA is negatively charged and when mixed with a cationic lipid, forms a lipoplex due to 
electrostatic interactions. Many reagents have been developed which aim to increase the 
cellular uptake of plasmid DNA. Several of these are cationic lipids that are thought to aid 
entry to the cytoplasm by fusing with the cellular membrane, releasing the DNA into the 
cytoplasm and avoiding degradation via the lysosomal pathway (Feigner et al., 1999). 
Several lipids are regularly used, including DOTMA (dioleoyloxlpropyl- 
trimethylammonium chloride), which had a single positive charge, and DOPE 
(dioleoylphosphatidylethanolamine), which is neutral.
Synthetic vectors have been successful in murine tumour models in treating established 
disease and generating memory responses; intratumoural delivery of IL-12 using a 
polyvinyl non-condensing polymeric vector demonstrated potent antitumour immunity 
against renal and colon carcinoma, and induced protective immune memory. Importantly, 
this formulation did not generate any anti-vector immune responses (Mendiratta et al., 
1999). It has been shown that DNA uptake is quite efficient, but two steps limit
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expression; the routing of DNA through endosomes and lysosomes, and the nuclear 
purging of foreign DNA. Cell lines which are readily transfected demonstrated nuclear 
stability of DNA, while primary cells that show much lower transfection efficiency rapidly 
excluded DNA from the nucleus (Coonrod et al., 1997).
Lipoplexes have been used in experimental cancer models, including murine colon 
carcinoma; a plasmid containing the IFN-y gene complexed with the lipid DC-chol gave a 
greater tumour inhibitory effect than naked plasmid DNA alone, and also generated 
protective immunity against further tumour challenge (Nomura et al., 1999). In another 
murine model, intravenous administration of lipid-DNA complexes encoding IL-2 or IL- 
12 significantly inhibited the growth of advanced lung metastases, and increased numbers 
of NK and CD8+ cells and IFNy production within lung tissues (Dow et al., 1999).
1.4.2.2 Polyplex Vectors
Condensing agents are widely used to package plasmid DNA into smaller particles, such as 
polyethylenimine (PEI) and poly-L-lysine, which can be used alone or in combination with 
lipid formulations. The positive charge of these compounds increases the contact between 
the DNA complex and the negatively charged cell membrane, and cells transfected by 
lipofection show a significant accumulation of DNA at the cell surface (Coonrod et al.,
1997), although this non-specific interaction results in binding to any type of cell.
In vivo, polyplex vectors have shown efficacy, with aerosol delivery of a PEI-p53 gene 
complex in a murine melanoma lung metastasis model inhibiting development of tumour 
foci and metastasis to lymph nodes, and increasing survival time (Gautam et al., 2000). 
However, direct injection of polyplex vectors into the circulation is often ineffective. In 
mice, this is mediated by rapid clearance from the blood due to fixing by complement,
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limited solubility and removal in the liver. In vitro analysis with human blood also showed 
complexes are fixed by complement and IgG. Furthermore, it has also been shown that 
the polycation molecular weight and the type of DNA (circular plasmid or linear) can 
affect the rate at which complexes are cleared from the circulation (Ward et al\, 2001). A 
variant of polylysine, which is biodegradable due the replacement of amide linkages with 
ester linkages, showed efficacy in a murine cancer model. Due to its biodegradable nature, 
it is thought to be nonimmunogenic, and has low cytotoxicity, allowing repeat dosing 
(Maheswari et al., 2000).
PEI-condensed DNA has also been used in combination with a replication-deficient Ad 
vector; the transgene is not encoded by the virus, but the virus aids endosomal release and 
transport of the plasmid DNA to the nucleus (T. Gust, personal communication). A 
variation of this is the use of adenovirus hexon protein in combination with a PEI/DNA 
vector. Covalendy linking hexon protein to PEI demonstrated 10-fold greater transgene 
expression in vitro than PEI/DNA alone, and injection into 'Kenopus oocytes also showed a 
10-fold increase in transgene expression compared to PEI/DNA, without increasing 
vector-uptake. This improved gene expression was due to increased nuclear transfer 
efficiency by means of the nuclear pore complex (Carlisle et al., 2001).
Another cationic peptide, CL22, contains an influenza nucleoprotein sequence and has 
shown increased transfection activity that is thought to result from favourable intracellular 
trafficking, DNA uncoating or expression (Haines et al., 2001). The DNA-binding protein, 
histone H2A, has also been used in transient transfections to increase DNA uptake. Gene 
transfer of IL-2 and IL-12 using histone H2A resulted in antitumour immunity to murine 
neuroblastoma involving both NK and T-cells. Gene transfer was shown to not rely
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merely on positive charge alone, but on other molecular characteristics of H2A, possibly 
including a nuclear localisation signal (Balicki et al., 2000).
One of the main problems with synthetic vectors is the degradation of internalised vector, 
usually in the acidic endosomes. Endosomal buffering agents, such as chloroquine, have 
shown enhanced transgene expression, which is thought to be due to decreased acid 
degradation of complexed DNA after uptake into endosomes. Chloroquine also induces 
osmotic swelling of endosomes, resulting in endosome destabilisation and release of the 
internalised DNA (Wagner et aly 1994).
A novel strategy to aid endosomal escape is the use of bacterial toxin translocation 
domains, such as Pseudomonas aeruginosa exotoxin A domain II (ETA), which facilitates 
translocation of DNA from endosomes/lysosomes to the cytoplasm. Expression of a 
tumour antigen linked to ETA enhanced MHC I presentation of the tumour antigen to 
CD8+ CTLs (Hung et al.y 2001). Similarly, the C-terminal B fragment of diphtheria toxin 
also contains a translocation domain that facilitates endosomal escape, and modular DNA- 
carrier proteins that employ the natural endosome escape mechanism of the toxin are able 
to transport DNA into cells. A chimeric diphtheria toxin molecule constructed by 
replacing the cell recognition function with tumour-specific ligands and replacing the 
enzymatic A fragment with a DNA-binding domain have been used to target gene delivery 
to cancer cells (Uherek et al.y 1998).
Another strategy to enhance uptake of DNA is to complex the plasmid with molecules 
that target cell surface receptors (reviewed in Cotton & Wagner, 1999). Asialoorosomucoid 
covalently linked to polylysine was the first targeting ligand used to target 
asialoglycoprotein receptors on hepatocytes (Wu & Wu, 1987). The transferrin receptor
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was also exploited due to its rapid internalisation and ubiquitous distribution across many 
types of cell (Wagner et al.y 1990). Since this initial work many ligands have been 
integrated into transfection vectors, including antibody fragments, synthetic peptides and 
carbohydrates. Generally, transgene expression is required in only one or a few cell types, 
so targeting of diese complexes is important.
1.4.2.3 LPD Vector
The vector used in this project contains targeting cationic peptides (P) together with a 
cationic lipid formulation (L) and plasmid DNA (D), known as a LPD vector. A panel of 
peptides containing a variety of different binding motifs has been isolated by phage 
panning on different cell types for superior binding ability or transgene expression when 
incorporated into the LPD vector, plus a range of ~10 peptides have been synthesised 
with motifs that target a 5, a 4, or av integrins (Table 2.1, Materials and Methods). 
Integrins are surface molecules involved in adherence that are exploited as a means of 
entering the cell by a variety of viruses. This suggests that they are a good target for gene 
therapy vectors (Hart, 1999). The binding motif is flanked by cysteine residues that form a 
disulphide bond, resulting in a constrained cyclic head group. The targeting head group is 
linked to a 16-residue polylysine tail, resulting in a molecule that targets cell-surface 
molecules at one end and has strong DNA condensing properties at the other end.
At physiological salt and pH, the three reagents spontaneously form a complex through 
electrostatic interactions. It is thought that the DNA and polylysine part of the peptide 
form the core of the complex and the cyclic head groups displayed on the complex surface 
with the lipid forming an outer layer (Figure 1.4). Receptor-mediated endocytosis 
increases the level of cellular uptake and the lipid component aids endosomal escape of the 
DNA once it has entered the cell (Figure 1.5). This vector has been successfully used to
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Plasmid DNA Cationic cyclic 
targeting peptide
45nm
Lipofectin
Figure 1.4: The lipid, peptide and DNA components of the vector spontaneously 
combine to form particles. The DNA condenses with the positively charged 
polylysine tail of the peptide, while the cyclic targeting head group is displayed in 
the outer surface of the vector. Different peptides can be used to target different 
cell surface molecules. The lipid is thought to coat the complex. The size of the 
complex has been determined by atomic force microscopy (Hart et al, 1998).
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Figure 1.5: Proposed mechanism of LID uptake and trafficking though the cell
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treat murine NB in our kb by the transfection of a murine NB cell line with cytokine 
genes (Siapati et al., 2003). However, due to the problems associated with culturing 
primary tumour cells, this model is difficult to transfer to the clinic. In this project, I will 
be developing a more clinically-applicable cellukr vaccine for the treatment of 
experimental murine NB.
1.5 Murine NB
The model of NB used in the project is the A/J mouse and the syngeneic Neuro-2a (N2a) 
neuroblastoma cell line. Originally, C1300-NB appeared spontaneously from the spinal 
cord of strain A mice about 50 years ago. The A/J mouse and N2a cell line is a subclone 
of C l300, is widely used by many researchers working on NB and is considered a good 
model of the disease (Ziegler et al., 1986). The N2a cell line is syngeneic, and therefore is 
used to engraft tumours into A/J mice. Untreated, they form locally invasive, tumours 
which grow progressively until the death of the animal. This allows a variety of 
experiments to be conducted, such as tumourigenicity experiments (preventing 
engraftment of tumours) or eradication experiments (treatment of established tumours). 
For this project, the tumours are engrafted subcutaneously in the flank, making them 
accessible for measurement and treatment. The tumours in this model do not readily 
metastasise, making measurement easier. An alternative syngeneic clone, TBJ-NB, is 
characterised by increased invasive and aggressive growth, and readily forms metastases. 
N-myc mRNA is expressed at much higher levels in the metastatic TBJ-NB clone than in 
the locally-growing Cl 300 and it’s derivatives (Ziegler et al, 1997), consistent with what is 
observed in human NB.
Murine NB dispkys many of the properties of primary human NB tumours. Like human 
NB, the majority of cells in solid primary or metastatic murine tumours are in the resting
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stage (Hayes & Mauer, 1976), and both human and murine cells express only low levels of 
MHC I (Lampson et al,., 1983; Katsanis et al., 1995). Similar to human NB, increased 
concentrations of catecholamine metabolites have been detected in the urine of tumour- 
bearing mice (Pons et al., 1982).
Murine NB also shows differences to the human disease. Primary human NB typically 
shows aggressive growth of primary tumour followed by metastasis to the regional lymph 
nodes and liver, and then in more advanced disease to the bone cortex or bone marrow. 
In the C1300-derived model of NB, regional lymph node metastasis may be seen in the 
later stages of tumour growth, but metastasis to central organs is not observed. The 
spontaneous regression seen in some stage IV-S human NB is very rarely observed in 
murine tumours. Human tumours typically form rosettes of well-oriented neuroblasts, 
which are not observed in murine NB (Ziegler et al., 1997).
NK cell activity against NB can be enhanced in both humans (Alvarado et al., 1989) and 
mice (Reynolds et al., 1989) by administration of recombinant interferon-y or recombinant 
IL-2. Analysing the TCR repertoire of the infiltrating lymphocytes of human tumours has 
demonstrated T-cells with activity against NB, and clonal expansion has also been 
observed (Valteau et al., 1996). CTL activity has also been documented in murine NB, and 
there is some evidence that this activity is augmented by abrogation of the activity of 
suppressor cells (Choi et al., 1989). NB cells engineered to express IL-2 have shown 
reduced tumourigenicity, which was shown principally to be mediated by CD8+ T-cells 
(Katsanis, et al., 1994), and this has also been shown in murine NB (Siapati et al, 2003).
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1.6 Aim
Previous work has shown N2a-derived tumours in the A/J mouse can be effectively 
treated by N2a tumour cells engineered to express IL-2 and IL-12 (Siapati et al., 2003). 
However, due to the difficulty of culturing primary NB cells from patients, this strategy 
may not feasible to transfer to the clinic. The aim of this project was to create an 
alternative immunotherapeutic strategy, developing a cellular vaccine to treat murine NB 
in A/J mice which would be more applicable in a clinical setting.
The two cell types investigated were DC and fibroblasts. The first approach was the 
optimisation of a synthetic gene transfer protocol using the LPD vector to transfect DC. 
DC are the most potent APC of the immune system, activating naive T-cells and being 
essential for the maintenance of memory T-cells. Transfer of genes encoding 
immunostimulatory molecules or model tumour antigens into DC using a synthetic vector 
could be a novel method to treat murine NB tumours. DC transduced with adenoviral 
vectors encoding IL-12 have previously been shown to mediate therapeutic effects against 
murine NB (Redlinger et al., 2003b; Shimizu et al., 2001). However, despite optimisation of 
many parameters, DC appeared refractory to transfection with the LPD vector.
Therefore, an alternative immunotherapeutic strategy was developed using fibroblasts 
transfected with the LPD vector to express IL-2 and IL-12, analogous to the cytokine- 
expressing N2a cells studied previously. Previous studies have shown that cytokine- 
expressing fibroblasts are effective against murine tumours (Lichtor et al., 2002; Zitvogel et 
al., 1995; Fakhrai et al., 1995), and have also been used in clinical trials for the treatment of 
solid tumours (Sobol et al., 1999; Kang et al, 2001). Cytokine-transfected fibroblasts were 
compared with cytokine-transfected N2a cells for their potential to abrogate the 
tumourigenicity of wild-type N2a cells and for therapeutic efficacy against established
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tumours. In vitro assays were performed to investigate the cellular antitumour immune 
response generated against N2a cells in vaccinated mice and tumour sections were 
examined to assess the effect of vaccination on tumour histology, and whether vaccination 
increased the presence of tumour infiltrating leukocytes.
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2.1 Cell Culture
All cell culture media, penicillin/streptomycin, sodium pyruvate and non-essential amino 
acids are manufactured by Life Technologies (Paisley, UK). All foetal calf serum (FCS) 
used in cell culture is manufactured by the Sigma Chemical Company (Dorset, UK) unless 
otherwise stated. All tissue culture plastics were manufactured by Helena Biosciences, 
Sunderland, UK) unless otherwise stated.
2.1.1 Murine DC Culture
Bone marrow was obtained by flushing out the hind tibia and femur from A/J mice and 
resuspended in HEPES-buffered RPMI1640 + Glutamax-1 supplemented with 10% FCS, 
100 IU/ml penicillin, 100 pg/ml streptomycin (complete media) and murine granulocyte- 
macrophage colony-stimulating factor (mGM-CSF - gift from S. de Noronha). Cells were 
maintained at 37°C in 5% C 0 2 for 6 days. The source of GM-CSF was the supernatant 
from a plasmacytoma cell line transfected with an expression vector (Karasuyama et al.y 
1990) containing the PCR-derived mouse GM-CSF gene (Zal et al., 1994). The optimal 
concentration of GM-CSF-containing supernatant had been previously titrated to 5% of 
the final culture volume (S. de Noronha, unpublished).
Total bone marrow from one mouse was cultured in a total of 60 ml media, distributed 
evenly between 2 x 6-well plates. To obtain pure populations of DC for transfection 
experiments, cells were positively selected using MACS mouse C D llc (N418) microbeads 
(Miltenyi Biotech, Surrey, UK). Briefly, cells were washed from 6-well plates, spun down 
at 240 x g and resuspended in 400 pi MACS buffer (0.1% BSA in PBS). 100 pi of MACS 
beads were added and the cells incubated on ice for 15 minutes. Unbound beads were 
diluted out with 10 ml MACS buffer, and the cells spun down and resuspended in 500 pi
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MACS buffer. A MACS MS column was equilibrated with 500 pi MACS buffer and the 
cells applied to the column. The column was washed three times with 500 pi MACS 
buffer, then 1 ml of complete media added and the bound cells were pushed off the 
column with the syringe plunger. This was repeated with another 1 ml of complete media. 
The cells were counted, spun down and resuspended at the appropriate concentration. An 
aliquot of cells was tested for purity by FACS analysis of the % -CDllc+ population.
2.1.2 Human DC Culture
Venous blood was venisected into heparinised tubes and diluted 1:1 in HEPES-buffered 
RPMI1640 + Glutamax-1 before layering onto Lymphoprep (Axis-Shield, Oslo, Norway) 
and spinning at 1100 x g with brake off for 25 minutes. The PBMC layer was aspirated 
from the lymphoprep/serum interface and washed in HEPES-buffered RPMI1640 + 
Glutamax-1 twice to remove platelets, then PBMC were plated into 6-well dishes (Falcon, 
Becton Dickinson, Oxford, UK) in HEPES-buffered RPMI1640 + Glutamax-1, 
antibiotics and 10% low endotoxin FCS (Life Technologies, Paisley, UK) at 3-4x106 
cells/ml, 3 ml per well. Monocytes were allowed to adhere for 2h, after which the floating 
fraction of cells was removed and media replaced. Cytokines were then added; 10 ng/ml 
rhGM-CSF (Leucomax, Novartis, Spain) and 7.5 ng/ml rhIL-4 (Peprotech, London, UK). 
Cells were maintained in 5% C 0 2 at 37°C for 5-6 days before use.
On day 5-6 cells were immunodepleted with CD3 and CD 19 magnetic beads (Dynabeads, 
Dynal Biotech, Wirral, UK) to removing any remaining T and B cells respectively. Briefly, 
the floating fraction of the cells was removed and pelleted. The cells were resuspended in 
2 ml complete media and split between two 1.5 ml tubes. 10 pi each of CD3 and CD19 
beads were added to each tube on ice then transferred to a rotating mixer at 4°C for 20 
minutes. The tubes were then placed on a magnet and B and T cells bound to the beads
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were pulled to the side of the tube. The supernatant was pipetted off and transferred to a 
clean tube and placed back on the magnet to remove any remaining beads. The cells 
remaining in the supernatant were used for experiments. A small aliquot was retained for 
determining cell purity by FACS with anti CDllc-PE (Pharmingen, BD Biosciences, 
Oxford, UK).
2.1.3 Mouse Primary Skin Fibroblasts
Skin was removed from A/J mice, the fur trimmed off and digested in trypsin-EDTA 
overnight at 4°C. The dermis was then peeled away from the epidermis and digested in
1 mg/ml Liberase Cl (Boehringer Mannheim, Lewes, UK) in DMEM (no FCS) at 37°C for
2 h. The Liberase was inactivated by diluting 1:1 with FCS and the suspension passed 
through a cell strainer. Cells were pelleted by centrifugation (240 x g), washed twice with 
DMEM with 50% FCS to inactivate any remaining Liberase and plated out in 6-well plates 
in DMEM with 20% FCS and antibiotics and maintained at 37°C in 5% C 0 2. Cells were 
used at passage 3-5.
2.1.4 Mouse Embryonic Fibroblast culture
MEF cultures were prepared by adaptation of the original 3T3 protocol of Todaro & 
Green (1963) and expertise within the Institute of Child Health (M. Hubank, personal 
communication). Fifteen 13.5dpc A/J embryos were dissected into PBS and the crania 
and red organs removed, leaving the limb buds and spinal region. Each embryo was kept 
as a separate culture. This remaining tissue was minced using scalpels and digested in 
trypsin at 37°C for 30 mins. This was passed through a 16G needle to break up the tissue 
and then passed through a cell strainer. The cells were then counted and plated out into a 
75 cm2 flask in DMEM + 10% FCS and antibiotics. Three days later the cells were 
trypsinised, counted and 50,000 cells put in a 25 cm2 flask, and the process repeated after
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another 3 days. After 2-3 passages most of the cultures became senescent, and at this 
stage, were monitored every few days without passaging of the cells. After ~ 14-20 days, 
ten of the cultures began growing again. Of these ten, two had a fibroblast like 
morphology, and were used in initial transfections. Of these two, one had superior levels 
of transgene expression and the cells grew more rapidly. This culture, hereafter termed 
AJ3.1, was used in all subsequent MEF experiments.
2.1.5 Human Primary Fibroblasts
Human dermal primary fibroblasts (gift from Dr Mike Hubank, Institute of Child Health) 
and maintained in DMEM with 10% FCS and antibiotics and passaged once a week. Two 
cultures of fibroblasts were obtained from skin biopsies from two different normal healthy 
donors. The cells had equivalent morphology and growth characteristics and were used in 
transfections were between passages 13-22.
2.1.6 Cell Line Culture
The mouse fibroblast line NIH-3T3, mouse neuroblastoma line Neuro-2a (N2a), human 
airway epithilia (HAE), human embryonic kidney epithelial line (293) and human cervical 
adenocarcinoma epithelial line (HeLa) were obtained from the ATCC and maintained in 
DMEM with antibiotics, 10% FCS, 1% sodium pyruvate (v/v) and 1% non-essential 
amino acids (v/v). The T-cell CD4+ hybridoma, A18, was a gift from B. Stockinger, 
(NIMR, London, UK) maintained in RPMI + Glutamax-1 with 5% FCS, 50 pM P- 
mercaptoethanol (Sigma Chemical Co, Poole, UK) and antibiotics. All cells were 
maintained at 37°C with 5% C 0 2
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2.2 Plasmid Preparation
Plasmids pCI (Promega, WI, USA) pCI-Luc, pCI-hIL-2, pCI-mIL-12 (gifts from E. 
Siapati, Institute of Child Health, London), pCMV-C5 (gift from B. Stockinger, NIMR, 
London, UK) and pEGFP-Nl (Clontech, CA, USA) were maintained in E.co/i strains 
DH5a or JM109 (Promega, Southampton, UK). See appendix 1 for plasmid maps. All 
plasmids contained the ampicillin resistance gene, except pEGFP-Nl, which contained the 
kanamycin resistance gene. All genes in all plasmids were under the control of the CMV- 
intermediate-early (CMV i.e.) promoter and the plasmids purified with the EndoFree Mega 
Kit (Qiagen, Crawley, UK). Briefly, 500 ml LB broth (Invitrogen, Paisley, UK) containing 
100 pg/ml am picillin or 50 pg/ml kanamycin was inoculated with a 1 ml starter culture 
and grown overnight at 37°C with shaking. The following day the cells were pelleted at 
6000 at 4°C and lysed by alkaline lysis. The lysate was neutralised and passed through a 
filter column using vacuum filtration. Endotoxin removal buffer was added to the filtrate 
and incubated on ice for 30 mins, then the solution passed through an anion-exchange 
resin column. The DNA was eluted by 15% isopropanol in 1.6 M NaCl, pH7 and 
precipitated by the addition of 0.7-volumes 100% isopropanol. The solution was decanted 
into endotoxin-free baked glass Corex centrifuge tubes and spun at 15,000 xg  for 30 mins 
at 4°C. The supernatant was removed and the pellet washed with 70% EtOH in 
endotoxin-free water and spun at 15,000 x g for 15 minutes.
The pellets were resuspended in 1 ml endotoxin-free TE buffer and DNA quantitated by 
absorbence at 260 nm with a GeneQuant spectrophotometer (Pharmacia, Buckingham, 
UK). The ratio of 260 nm / 280nm was used to determine the protein contamination, and 
all plasmid solutions had an absorbance ratio of 1.8 ± 0.1, indicating minimal protein. 
Digestions with restriction enzymes (all Promega, WI, USA) were performed to check
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plasmid integrity. 0.5 pg of plasmid DNA was digested with 1 pi enzyme for one hour at 
37°C in a total volume of 50 pi of lx restriction buffer (Promega) and analysed on 1% 
agarose gels stained with ethidium bromide. Fragment sizes were established by 
comparison with 1 kb ladder (Bioline, London, UK).
2.3 “Helper” Adenovirus Production
Replication-deficient El-deleted adenovirus (Ad) containing the LacZ reporter gene was 
used to infect 293 cells at an MOI of 1. The cells were grown until they were forming 
rounded up plaques and just beginning to detach from the plates, then washed off the 
plates, spun down and resuspended in 10 ml Ad freezing buffer (0.1 M Tris, 5 mM MgCl2, 
pH8). The cells were freeze-thawed three times at —80°C, and the lysate spun at 2750 xg  
for 10 mins to remove cell debris. The density of the supernatant was adjusted to 1.40 
g/ml with CsCl. This was layered onto a 1.5 g/ml CsCl cushion, and the tubes (Ultra 
Clear, Beckman Coulter, High Wycombe, UK) topped up with more 1.4 g/ml CsCl and 
spun at 300,000 x g in an ultracentrifuge (Beckman Coulter) at 15°C for 21-24 hours with 
the brake off.
The virus band was removed by piercing the tube with an 18G needle and carefully 
drawing the virus into a 5 ml syringe. This was resuspended in a total volume of 6 ml 1.4 
g/ml CsCl, layered onto another 1.5 g/ml CsCl cushion, topped up with 1.4 g/ml CsCl 
and spun again at 300,000 x^ 15°C for 21-24 hours. The band of virus was again removed 
and transferred to a Slide-A-Lyser dialysis cassette (Pierce, IL, USA). The CsCl was 
dialysed out overnight in 4 1 Ad dialysis buffer (10 mM Tris, 5 mM MgCl2, 2.3% sucrose, 
pH 8, 4°C). The virus was titred on HeLa cells in 96-well plates, 40,000 cells per well with 
serial dilutions of virus. 1 pi of virus stock was diluted in 1 ml DMEM, and 100 |ll of this
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was added to 900 pi DMEM as the most concentrated sample. 100 |Lll of this was then 
used to make the next dilution and so on, until there was a range of 10-fold serial dilutions 
from 10'3 to 10'9. 50 pi of each dilution was added to the HeLa cells in triplicate and 
incubated for 2-3 h, then another 200 pi DMEM added to each well and incubated for a 
further 48 h. The media was then removed from the cells and the cells fixed with 0.5% 
gluteraldehyde in PBS. The cells were washed then 50 pi 1 mg/ml X-gal added to each 
well and incubated at 37°C, checking regularly for blue cells. The viral titre was 
determined by the limiting dilution that produced blue colonies by X-Gal staining and 
calculating the number of infectious particles per ml. This value is used to calculate the 
multiplicity of infection (MOI) in transfection experiments.
2.4 Phage panning and isolation of binding peptides
Peptides that bound to particular cell types with high affinity were identified by panning 
with phage display libraries (M. Writer, in press and unpublished, A. Kritz, unpublished). 
These peptides were then engineered into the cationic peptide component of the LPD 
vector, by flanking the phage-isolated motif with cysteine residues which cyclise at 
physiological pH, and attaching a chain of 16 lysine residues to the N-terminus.
2.5 LPD Transfections
2.5.1 Calculation of charge ratio of complexes
The charge ratio of the LPD vector was determined from the net charge and molecular 
weight of plasmid DNA and each targeting peptide (see Table 2.1). The charge of DNA 
is calculated from the single negative charge of the phosphate on each DNA base. Thus, 1 
pg of pEGFP-Nl (4700 bp, Mr= 3.11x10®) contains 0.32 pmol of DNA which contributes 
(0.32 pmol x 4700 x 2) = 3.0 nmol of negative charge. As all plasmids contain
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Table 2.1 Peptides used in LPD transfections
Peptide Molecule
targeted
Sequence Net
charge
Mass of peptide 
(pg) for a 7:1 
charge ratio with 
lpg  DNA
Integrin targeting peptides
1 av, a5 [K]16GACRGDMFGCA +16 4
6 a5 [K] 16g a c r r e t a w a c g +17 4
6J Scrambled [K]16GACATRWARECG +17 4
7 <x5 [K]16GAGPEILDVPST +14 4.6
8 a4 [K]16GACQIDSPCA +15 4
10 a4 [K]16GACWLDVCA +16 3.85
11 None [K]16GACRGEMFGCA +16 4.05
12 a5 [K]16XSXGACRRETAWACG +17 4.39
14 a5 [K]16[XSX]3GACRRETAWAC +17 5
K16 None
G
KKKKKKKKKKKKKKKK +16 2.6
Peptides isolated by phage display
VYAR Unknown [K]16GACVYARSMNCG 4
VNLQ Unknown [K]16GACVNLQNPYCG 4
P Unknown [K]16GACLPHKSMPCG 4
E Unknown [K]16GACSERSMNFCG 4
A Unknown [K]16GACSHVKLNSCG 4
B Unknown [K]16GACAPSNSTACG 4
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the same charge per base, 1 pg of any plasmid will contribute 3.0 nmol of negative charge. 
The charge of the peptide depends on the sequence, with glutamic acid (E) and aspartic 
acid (D) each containing a charge of -1 and lysine (K) and arginine (R) each containing a 
charge of +1. Lipofectin contains only one positive charge per molecule (Figure 2.1A), so 
is considered insignificant when calculating LPD vector charge ratios.
2.5.2 DC and Primary Fibroblast Transfections
Cells were seeded into 48-well plates at 50,000 cells per well, and allowed to adhere for 1 h. 
LPD complexes were prepared by combining 1 mg/ml Lipofectin (Invitrogen, Paisley, 
UK) with 100 pg/ml peptide (Zinsser Analytic, Slough, UK), then 10 pg/ml plasmid 
DNA was added to the lipid/peptide mixture. The order in which the vector components 
are added together has previously been shown to be essential to transfection (Hart et al., 
1998). For transfections using an Ad helper virus, the vims was added to the plasmid 
DNA, then the Ad/DNA mix was added to the lipid/peptide combination.
Peptides and DNA were diluted to a working concentration in OptiMEM serum-free 
media (Life Technologies, Paisley, UK), and LPD complexes were also formulated in 
OptiMEM. The ratio of Lipofectin to DNA remained constant at 0.75 pg Lipofectin per 
1 pg DNA, while charge ratio, amount of DNA, targeting peptide (see Table 2.1) and 
length of transfection period were investigated. Total transfection and culture time before 
analysis was 24 h for luciferase assays and up to 14 days for GFP analysis and supernatant 
samples for ELISA, with samples collected over 24 h periods. Each transfection condition 
was performed in triplicate.
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DOPE O
DOTMA
cr
B  DOTMA analogues OR
R=
DOTMA head group 
Cl 8 Unsat
Cl 6 Unsat
C14 Unsat
Cl 2 Unsat
CIO Unsat
R= Cl 8 Sat
Cl 6 Sat
C14 Sat
C12 Sat
CIO Sat
Figure 2.1 Structures of lipids used for transfection (A) Structures of DOPE and 
DOTMA, which are combined at an equimolar ratio to form Lipofectin. DOPE is a 
neutral lipid. DOTMA has a net charge of +1 and is composed of two Cl 8 chains, 
each containing one unsaturated bond, covalently linked to the charged head group.
(B) Structures of DOTMA analogues, which were formulated with and without 
DOPE. The analogues contain the same charged head group as DOTMA, but the 
Cl 8 chains are replaced with lipid chains from the saturated or unsaturated series. 
Each analogue is composed of two identical chains.
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For human fibroblasts, all transfections to test the DOTMA analogues (Figure 2.1B) were 
performed in 96-well plates using peptide 6 at a charge ratio of +7, 0.25 pg DNA per well 
and were transfected for 4 h. Lipofectin was used at a weight ratio of 0.75 pg per 1 pg 
DNA, while the DOTMA analogues were used at weight ratios of 2 pg or 4 pg per 1 pg 
DNA. Each lipid was assayed in six replicates. Transfections to test the peptides isolated 
by phage display, and transfections with cytokine genes were performed in 48-well plates 
using peptides at a charge ratio of +7, 1 pg DNA per well for 4 h. As before, the vector 
components were always added in the order of lipid, then peptide, then DNA.
2.5.3 Cell Line Transfections
Initial transfections were performed in 48-well plates with 25,000 cells per well. Each well 
was transfected in 500 pi OptiMEM containing LPD vector formed with 2 pg DNA at a 
charge ratio of +7 and Lipofectin at a ratio of 0.75 pg per 1 pg of DNA. Cells were 
transfected for 4 h at 37°C, after which the complexes were removed and replaced with 
complete media. Luciferase assays were performed 24 h after transfection and GFP 
transfections were analysed after 48 h. Cells transfected with cytokines for ELISA samples 
were cultured in 1 ml complete medium. Supernatant was collected at 24 h intervals and 
stored at —80°C until analysis by ELISA.
2.6 Retargeted Adenovirus
Retargeted serotype 5 adenovirus a gift from Dr Dan Von Seggem, (The Scripps Research 
Institute, La Jolla, CA, USA). The HI loop of the adenovirus fibre protein, which is 
responsible for binding to CAR (Figure 2.2A) was retargeted with the peptides A and B 
identified by phage display. Briefly, a plasmid containing the gene for the fibre protein, in 
which the wild-type HI loop was deleted and replaced with the coding sequence for
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peptides A or B, was used to transfect 293 cells. The following day, an Ad-5 vector 
mutant that does not express the fibre protein was used to co-infect the same 293 cells 
(Jakubczak et al., 2001). The retargeted fibre assembles in the virions, and the vims 
harvested ~3 days later contains the fibre protein with the retargeted HI loop (Figure 
2.2B).
2.6.1 DC Transduction
GFP-expressing Ad5 vectors encoding containing the fibre protein retargeted with peptide 
A or B were compared with fibre-deleted Ad5 or Ad5 expressing the wild-type fibre 
protein. 50,000 MACS-separated C D llc+ were plated into 24-well plates in 1 ml of 
complete media, and Ad5 vims was added at 100,000 particles per cell (~MOI 100). Cells 
and vims were incubated together for 24 h at 37°C, then cells were fixed in 1% 
paraformaldehyde (PFA) and analysed by flow cytometry. All transductions were 
performed in triplicate.
2.6.2 Stem Cell Transduction
Bone marrow was flushed from the hind tibia and femur of A/J mice and resuspended in 
20 ml RPMI, spun down and washed with 20 ml PBS containing 1% BSA. Cells were 
spun down again and resuspended in 4.5 ml PBS/BSA plus 100 |il of mouse stem cell 
antigen-1 (Sca-1) MACS microbeads (Miltenyi Biotech) and incubated at 4°C for 20 
minutes. 20 ml PBS/BSA was then added to wash off unbound beads, spun down and 
resuspended in 1 ml PBS/BSA. The suspension was applied to a MACS MS column and 
unbound cells allowed to pass through. The bound cells were removed from the column 
with 2 x 1 ml washes of RPMI containing 30% FCS and counted. 50,000 cells were plated 
out in 24-well plates in RPMI with 30% FCS containing 50 ng/ml mSCF, 20 ng/ml IL-6 
and 10 ng/ml Flt-3L (all Peprotech, London, UK). Retargeted, wild type or knock-out
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B
Modified fibre encoded on plasmid Fibre-deleted adenovirus
Infect (day 1)
293 cells
Transfect (day 0)
Isolate retargeted adenoviral 
vector particles (~day 3)
Figure 2.2 Retargeting of adenovirus fibre protein (A) Side and top views of the 
structure of the fibre protein of adenovirus serotype 5 showing the position of the HI 
loop. (Courtesy of D. von Seggern). (B) Overview of production of retargeted 
adenovirus. 293 cells are transfected with a plasmid encoding the modified fibre 
protein, and the following day infected with an Ad5 vector that does not express any 
fibre protein. The new modified fibre assembles on the virus in the 293 cells, and the 
retargeted virus containing the new fibre is isolated around three days later.
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adenovirus expressing GFP was added as above, at 100,000 particles per cell (~MOI 100) 
and incubated overnight at 37°C and analysed by flow cytometry 24 h later.
2.7 Assessment of transfection
2.7.1 Luciferase Assay
Luciferase transfections were assayed using Luciferase Assay System (Promega, WI, USA). 
Media was aspirated from cells, and cells washed once in PBS. 100 pi of Reporter Lysis 
Buffer (RLB) was added per well and the cells lysed by freeze-thawing at -80°C. Each well 
was gently scraped to ensure complete lysis of all the cells and transferred to a V-bottomed 
96-well plate. The lysates were spun at 900 x £  10 minutes, 4°C to pellet the cell debris, 
then 20 pi of the supernatant from each well was transferred to a white 96-well plate. The 
plate was read by an Anthos Lucy-1 luminometer (Labtech) and the relative light units 
emitted by each well was determined 10 seconds after the addition of 100 pi of luciferase 
substrate. The protein concentration of the cell lysate was measured using BioRad Protein 
Assay Reagent (BioRad, Hemel Hempstead, UK) and measuring the absorbance at 590 nm 
and comparing to a standard curve prepared from a range of BSA concentrations. The 
protein values were used to convert the luciferase assay values to relative light units per mg 
of protein (RLU/mg).
2.7.2 Confocal Microscopy
50,000 human DC or HAE cells were plated onto sterile glass cover slips in 24-well plates 
and allowed to adhere. LPD complexes were prepared containing either 1% Oregon 
Green labelled DOTMA, 5% Texas Red labelled peptide 6 (both gifts from Dr. Hailes, 
Department of Chemistry, UCL) or Cy5 labelled pCI-Luc (Mirus LabellT, Panvera, CA, 
USA), then transfected at a 3:1 charge ratio. This ratio was chosen as it minimises the
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amount of free peptide in the transfection complexes and it is vital there is no free peptide 
which could be falsely identified as LPD vector. Cells were fixed with 4% PFA at 
appropriate time points and stained with either Alexa488-phalloidin or Rhodamine- 
phalloidin (both Molecular Probes, OR, USA) as an actdn cytoskeletal counterstain, then 
mounted on microscope slides and visualised with a TCS NT Leica confocal scanning laser 
microscope (Leica Inc., St. Gallen, Switzerland). Images were analysed using Adobe 
PhotoShop (Adobe Systems, CA, USA).
2.7.3 Cytokine ELISA
Sandwich ELISAs were performed to quantitate supernatant concentrations of cytokine 
secreted by transfected cells with hIL-2 Duoset and mIL-12p70 Duoset ELISA kits (R&D 
Systems, Oxford, UK). 96-well Maxisorp plates (Nunc, Roskilde, Denmark) were coated 
overnight with 100 pi 4 pg/ml purified capture antibody in PBS at room temperature. 
The following day the plates were washed four times with wash buffer (0.05% Tween 20 
(Sigma) in PBS) then blocked with blocking buffer (1% BSA, 5% sucrose, 0.05% NaN3in 
PBS) for 1 h. Plates were washed and appropriate dilution of samples and standards 
added in DMEM and incubated for 2 h at room temperature. Samples were removed and 
plates washed four times and 100 pi of biotinylated detection antibody added (50 ng/ml of 
anti-hIL-2 and 400 ng/ml anti-mIL-12p70) and incubated at room temperature for 2 h. 
Plates were then washed, and 100 pi of 1:200 dilution of streptavidin-HRP (horseradish 
peroxidase) in PBS added for 30 mins at room temperature. This was washed off, and 100 
pi of substrate added (Colour Reagent Substrate, R&D Systems) and the colour allowed to 
develop. When the colour had developed sufficiendy, 50 pi of 2N H2S 04 was added to 
halt the reaction and the plates read at 450nm blanked against 570nm. Cytokine secretion 
was calculated as ng/24h/106 cells.
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2.8 ELISpot Assays
All ELISpot assays were performed on 96-well MultiScreen Immobilon-P plates 
(Millipore, MA, USA) coated with 1 pg/ml anti-mouse IL-2 (clone JES6-1A12, 
Pharmingen, Oxford, UK) or 1 pg/ml anti-mouse IFN-y (clone XMG1.2, Bioscience, San 
Diego, USA) and incubated at 37°C for 2 h. Plates were then washed three times with 
RPMI and blocked with 50 pi FCS per well for 30 mins. Following another three washes 
with RPMI, cells were incubated on the plates for 24 h, then plates washed three times 
with wash buffer (PBS + 0.05% Tween-20 (Sigma Chemical Co, Dorset, UK)). 
Biotinylated anti-IL-2 (clone JES6-5H4, Pharmingen) or biotinylated anti-IFN-y (clone 
R4-6A2, Bioscience) was diluted to 2 pg/ml in wash buffer and incubated on plates for 2 
h at 37°C, followed by three washes with wash buffer. A streptavidin-alkaline phosphatase 
(AP) conjugate (ExtrAvidin, Sigma, Dorset, UK) was diluted 1:1000 and incubated on 
wells for 30 mins. After three washes, spots were developed using AP-substrate. The 
reaction was stopped by washing plates in water, and when plates were dry they were read 
on a plate reader (Bioreader, Biosys, Germany).
2.8.1 Antigen presentation ELISpot Assay
DC were transfected for 90 mins with the LPD vector incorporating peptide 1 at a charge 
ratio of +7 with pCMV-C5, which expresses the full-length cDNA for murine 
complement protein 5 (C5), then incubated with complete media overnight at 37°C. The 
T-cells used in this assay were a CD4+ hybridoma, A18, which is derived from a clone 
isolated from an A/J mouse immunised with C5 protein that expresses a TCR specific for 
one epitope of mC5 (residues 106-121: WSKHFSKSKKIPITY) (Zal et al, 1994). The 
following day, ratios of DC to A18 CD4+ hybridoma cells from 1:1 to 1:300 were
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incubated for 24 h on plates previously coated with anti-IL-2 then blocked. Cells were 
washed off and plates developed as above.
2.8.2 Splenocyte ELISpot
Spleens were removed from mice and passed through a cell strainer with RPMI. Cells 
were spun down and resuspended in 1 ml Red Blood Cell Lysing Buffer (Sigma) and 
incubated on ice for 5 mins. Tubes were then topped up to 50 ml with RPMI to dilute out 
the lysis buffer and cells spun down and resuspended in complete media (CM) at 106/ml, 
and 5x10s, 2.5x10s, 1x10s and 5x104 splenocytes were plated out in triplicate for each 
mouse in 96-well U-bottomed tissue culture plates. 5x103 live N2a cells were also added to 
each test well, giving effector:target ratios of 100:1, 50:1, 20:1 and 10:1.. Positive control 
wells contained 50,000 splenocytes in CM + 5 pg/ml Concanavilin A (Sigma), and 
negative control wells contained 50,000 splenocytes in CM only. All wells contained a 
volume of 200 pi and plates were incubated overnight at 37°C then the contents of each 
well was transferred onto ELISpot plates pre-coated with anti-mlFNy or anti-mIL2. 
Plates were incubated for a 24 h then developed the following day.
2.9 Lactate Dehydrogenase Release Assay
Spleens were passed through cell strainers with RPMI to form single cell suspensions, 
spun down, and red cells lysed in 1 ml Red Blood Cell Lysing Buffer (Sigma) on ice for 5 
mins. Tubes were filled to 50 ml to dilute out lysis buffer, cells pelleted and resuspended 
in RPMI-Glutamax-1 with 10% FCS and antibiotics at 106/m l and incubated in the 
presence of 60 IU/ml rhIL-2 (Peprotech, London, UK). Irradiated (2500rads - 25 Gy 
from a cesium-137 source) N2a were added at an effector:target ratio (E:T) of 50:1, and
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cells cocultured for 6 days at 37°C. On day 6 the non-adherent CTL effector fraction was 
removed and resuspended at 107/ml.
LDH is released from lysed cells and is proportional to the number of cells lysed. LDH 
assay (CytoTox96 Non-Radioactive Cytotoxicity Assay, Promega, Southampton, UK) was 
used to determine the percentage cytotoxicity generated against N2a cells by the 
splenocytes. CTL effector cells were co-cultured in quadruplicate in RPMI-Gulatmax-1 
without phenol red containing 5% FCS and antibiotics in U-bottomed 96-well tissue 
culture plates with 5x103 viable N2a cells at E:T ratios between 27:1 to 1:1 in a total 
volume of 200 pi. Controls were also set up in quadruplicate in the plate: culture media 
only background, spontaneous target lysis, maximum target lysis and volume control. 
Spontaneous effector release controls were also set up in quadruplicate for every effector 
concentration cocultured with targets. Plates were incubated for 4 h at 37°C, then 
centrifuged and 50 jul supernatant transferred to a flat-bottomed 96-well plate. 50 pi assay 
substrate was added to each well and plates incubated in the dark for 30 mins before 
halting the reaction with 50 pi stop solution. Plates were then read at 492 nm and % 
cytotoxicity was calculated using the formula:
% cytotoxicity = [(Experimental release -  Effector spontaneous release — Target 
spontaneous release) - 5-  (Target maximum release — Target spontaneous release)] x 100
2.10 Flow Cytometry
All flow cytometry was performed using an EPICS XL cytometer (Beckman Coulter, High 
Wycombe, UK) and data was analysed using Expo 32 software (Beckman Coulter). All 
cells suspended in FACS wash buffer (FWB: 0.1% BSA, 0.005% NaN3 in PBS) and were 
excited with a 488 nm argon laser. Positive events were captured using a band pass filter
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at 525nm (FL1), 575nm (FL2) or 675nm (FL3). Forward and side scatter characteristics 
were used to gate the live cell population, and 10,000 events from the live gate were 
collected.
2.10.1 Phenotype staining of transfected DC
Murine DC were stained for surface markers using the following monoclonal antibodies 
anti-CDllc-biotin or anti-CDllc-PE, anti-CD40-biotin, anti-CD80-FITC, anti-CD86- 
FITC, anti-I-AKa-FITC, anti-I-AKp-FITC, IgGl-FITC isotype, IgG2-FITC isotype and 
streptavidin-Cy (all Pharmingen, BD Biosciences, Oxford, UK). The polyclonal Dec-205 
antibody was a gift from S. De Noronha. All antibodies were used at 1 pg/106 cells, 
except the Dec-205 antibody, which was used at a 1:5 dilution. All antibodies were 
incubated with cells at 4°C for 1 h in a total volume of 100 pi, then unbound antibody was 
removed by two washes of 2 ml FWB, before fixing in 300 pi FWB containing 1% PFA 
and storage at 4°C until analysis.
2.10.2 GFP Analysis
GFP transfections were analysed by flow cytometry. Cells were excited with a 488 nm 
laser and GFP+ events captured with a 525 nm band pass filter. Transfected cells and an 
untransfected negative control were removed from wells, washed in FWB then 
resuspended and fixed in 300 pi 1% PFA in FWB. 10,000 total events were counted and 
the cells gated to include only viable cells.
2.11 Animal procedures
All animal procedures were approved and licensed by the Home Office and performed to 
the standards required by the UKCCCR (Workman et al.y 1998). Male 5-7 week old A/J
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mice, syngeneic with the N2a NB cell line, were purchased from Harlan Laboratories (UK) 
and were housed at the Institute of Child Health according to the Animals (Scientific 
Procedures) Act (1986).
2.11.1 Transfection of cells for injection
Transfections of AJ3.1, NIH-3T3 and N2a cells for injection were carried out in 150 cm2 
flasks. Cells were seeded in flasks at a density of 3xl06 (AJ3.1) or 4xl06 (NIH-3T3 and 
N2a) and cultured overnight. The following day cells were transfected in a volume of 25 
ml with LPD complexes containing a total of 80 pg (40 pg each of pCI-hIL-2 and pCI- 
mIL-12) plasmid DNA with Lipofectin at a ratio of 0.75 pg per 1 pg DNA and at a charge 
ratio of +7. Peptide VYAR was used to transfect AJ3.1 cells, and peptide 6 was used to 
transfect NIH-3T3 and N2a cells. Cells were transfected for 4 h, then replenished with 
complete media and cultured for a further 24 h before being trypsinised, washed three 
times to remove FCS and resuspended in RPMI at 107/m l for injection. All transfected 
cells were assayed for cytokine expression by ELISA in triplicate.
2.11.2 Tumourigenicity Experiments
Tumourigenicity experiments were performed to determine whether cytokine-transfected 
fibroblasts were capable of preventing engraftment of N2a cells. NIH-3T3, AJ3.1 and 
N2a cells were transfected as described above then washed three times and resuspended at 
107/m l in RPMI. Unmodified N2a cells were also trypsinised, washed and resuspended at 
107/m lin  RPMI.
For the experiments using allogeneic fibroblasts, 106 live wild-type N2a alone or in 
combination with 106 NIH-3T3 cells transfected with cytokine genes, empty vector or 
untransfected were mixed together in a total volume of 200 pi. Mice (n=6 per group)
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were then inoculated s.c. in the left posterior flank and tumour growth monitored every 2- 
3 days. Tumour volume was calculated by the formula:
Tumour volume (mm3) = (shortest axis2 x longest axis) x 0.52
In experiments where irradiated cells were required, cells were irradiated with 2500rads (25 
Gy from a cesium-137 source) following transfection.
For experiments with syngeneic fibroblasts, mice (n=6 per group) were inoculated s.c. in 
the left posterior flank with 106 wild-type N2a cells alone or in combination with 106 wild- 
type AJ3.1, 106 AJ3.1-IL2-IL12 or 106 N2a-IL2-IL12 in a volume of 200 pi and tumour 
growth monitored every 2-3 days. In the second tumourigenicity experiment, transfected 
AJ3.1 were irradiated as described above. Mice (n=6 per group) were inoculated s.c. with 
106 wild-type N2a alone or in combination with 106 irradiated AJ3.1-IL2-IL12 or 2xl06 
irradiated AJ3.1-IL2-IL12. Tumour growth was monitored every 2-3 days.
2.11.3 Rechallenge Inoculations
To determine if systemic immunity had been established in tumour-free mice from the 
tumourigenicity experiments with syngeneic fibroblasts, mice were rechallenged at least 7 
weeks later with 106 wild-type N2a cells suspended in a volume of 100 pi RPMI inoculated 
s.c. in the right flank. Tumour development was monitored every 2-3 days.
2.11.4 Eradication Experiments Using AJ3.1
Tumours were engrafted in the left flank of A/J mice with 106 wild-type N2a cells and 
palpable masses were present after 5 days. Mice were allocated to different experimental 
groups such that there was a range of tumour sizes in each group (~ lx l mm to 5x5 mm). 
Another group of six mice was engrafted with a tumour on each flank.
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Transfected cells for vaccinations were prepared as above and DC were cultured and 
purified as described in 2.1.1. Mice (n=6 per group) received either 106 N2a-IL2-IL12 
intratumourally (i.t), 106 AJ3.1-IL2-IL12 i t ,  106 AJ3.1-IL2-IL12 + 106 DC I t ,  or 106 
AJ3.1-IL2-IL12 + 106 irradiated N2a cells in the opposite flank. In the group of mice with 
two tumours, one tumour was treated with 106 AJ3.1-IL2-IL12 i.t., and the other was left 
untreated. Control mice were vaccinated with RPMI i.t and all vaccinations were prepared 
in a volume of 100 jllL Tumour growth was monitored every 2-3 days.
2.11.5 Cytokine Dosing Experiments
A single vaccine was administered to mice (n=6 per group) s.c. in the left flank containing 
106 wild-type N2a cells plus N2a-IL2-IL12 in a range of doses between 106-103 cells in a 
total of 200 pi. A control group of mice received 106 wild-type N2a only. Tumour growth 
was monitored every 2-3 days.
The transfected cells were analysed by ELISA for cytokine expression, and the amount of 
cytokine expressed by each cell dose was calculated from the ELISA data. The number of 
tumour-free mice in each group was used to determine an approximation of the minimum 
dose of cytokine necessary to prevent tumour engraftment.
2.12 Immunohistochemistry
2.12.1 Embedding and sectioning tumour tissue
Tumours were removed from the flank of sacrificed A/J mice, washed in PBS and fixed 
overnight in 4% PFA at 4°C. Tissue was then serially dehydrated in alcohol from 50% 
ethanol in PBS through 70%, 85% and 95% ethanol in water tol00% ethanol, 30 mins per
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dehydration, before 2 x 45 mins incubations in Histoclear (National Diagnostics, 
Yorkshire, UK). Tumours were then incubated in 2 x 45 mins incubations in paraffin wax 
(Raymond Lamb, East Sussex, UK), before finally embedding in paraffin wax and set over 
night. Tissue was then sectioned on a microtome (Microm HM325 Rotary Microtome, 
Raymond Lamb) and subbed onto polyiysine coated glass microscope slides (BDH, Poole, 
UK), air dried overnight at 37°C and stored at 4°C until use.
2.12.2. Histology
Staining with haemotoxylin and eosin was performed to study tumour tissue morphology. 
Wax was removed from sections by 2 x 3 mins washes in Histoclear. Sections were then 
rehydrated by 3 mins washes in 100%, then 95% and 70% ethanol, followed by rinsing in 
dH20. Slides were then stained with Ehrlich’s haemotoxylin (BDH) for 10 minutes 
followed by rinsing in dH20 and rapid immersion in acid alcohol (1% concentrated HC1 in 
70% ethanol (v/v)). Slides were rinsed again in dH20 before staining in a 1% aqueous 
solution of eosin (Raymond Lamb) and finally rinsing in dH20. Sections were then 
dehydrated by washes in 70%, then 95% and 100% ethanol and air-dried. Slides were 
mounted with DPX mountant (BDH) using glass coverslips. Slides were analysed using a 
AxioPhot 2 microscope (Zeiss, Welwyn Garden City, UK) attached to a ProgRes 3012 
digital camera (Kontron Electronic, Chichester, UK) and images were analysed using 
Adobe Photoshop (Adobe Systems, CA, USA).
2.12.3 Immunohistochemical staining
Wax was again removed from sections by 2 x 3 mins incubations in Histoclear, rehydration 
in 3 mins washes in 100%, then 95% and 70% ethanol in dH20, followed by 50% ethanol 
in PBS and rinsing in dH20. Sections were then microwaved for 10 mins in antigen 
unmasking solution (3.75 ml in 400 ml dH20, Vector Laboratories, CA, USA), followed by
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rapid cooling in two washes of dH20. Endogenous peroxidase activity was blocked (0.3% 
H20 2 (v/v), 0.1% NaN3 (w/v) in PBS) for 15 mins, then slides were washed in PBS twice. 
PBS containing 10% rabbit serum (v/v) (Vector Laboratories) was applied to the sections 
to block non-specific antibody binding and incubated at RT°C for 30 mins. Excess block 
was removed from slides, then a 1:20 dilution of unconjugated rat anti-mouse CD45 (pan­
leukocyte marker, Pharmingen) in PBS/1 % BSA was applied. Sections were incubated 
overnight in a humid chamber at 4°C. Control slides were incubated with 10% rabbit 
serum in PBS. Sections were washed in PBS three times, and then the 2° rabbit anti-rat 
biotinylated antibody (Dako, Glostrup, Denmark) was added at a 1:250 dilution in PBS 
and incubated at RT°C for 30 mins. Slides were washed twice then a streptavidin- 
biotinylated peroxidase complex was applied and incubated for 30 mins (ABC Reagent, 
Vector Laboratories). Positively stained cells were identified with 3,3’-Diaminobenzidine 
(Sigma FAST DAB, Sigma Chemical Co.) and the reaction was halted by rinsing in PBS. 
Sections were counterstained in Methyl Green (Vector Laboratories) for 10 mins, washed 
twice in dH20, then dehydrated in butan-l-ol by 2 x 10 immersions Finally, slides were 
washed in fresh butan-l-ol for a further 30 secs, then incubated in Histoclear for 10 mins 
and allowed to air dry. Slides were mounted with glass coverslips using DPX mountant 
and analysed as before.
2.13 Statistical analysis
The two-sample t-test was used to assess the significance between experimental animal 
groups and the paired t-test was used to assess the difference between tumours in the mice 
engrafted with a tumour in each flank.
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2.14 Buffers
Buffers were prepared in dH20 and autoclaved, except antibiotics, which were added to 
solutions <50°C.
LB broth
Ampicillin
Kanamycin
TE Buffer 
TAE (50x)
PBS
10 g/1 tryptone + 5 g/1 yeast extract (both Becton Dickinson) + 10 
g/1 NaCl (BDH) or 20 g/1 LB broth premix (Invitrogen). 15 g/1 
agar was added to LB for solid growth media for culture plates.
4 x 25 mg tablets (Stratagene) per litre autoclaved LB broth, giving 
a working concentration of 100 pg/ml.
Stock solution of 50 mg/ml, diluted in autoclaved LB giving a 
working concentration of 50 pg/ml.
10 mM Tris.Cl, pH 8.0; 1 mM EDTA
242 g Tris base, 57.1 ml Glacial acetic acid, 100 ml 0.5M EDTA 
per litre
Phosphate Buffered Saline tablets (Oxoid, Basingstoke, UK) were 
dissolved in dH20 ,10 tablets/litre
Ad freezing buffer 0.1 M Tris, 5 mM MgC^, pH8
Ad dialysis buffer 10 mM Tris, 5mM MgCl2, 2.3% sucrose, pH8
MACS buffer lxPBS + 0.1% BSA, sterile filtered through 0.22 pm filter.
FACS wash buffer lxPBS + 0.1% BSA + 0.005% (w/v) NaN3
ELISA blocker lxPBS + 1% BSA + 5% sucrose + 0.05% NaN3, sterile filtered
through 0.22 pm filter
ELISA/ ELISpot lxPBS + 0.05% Tween 20 (Sigma) 
wash buffer
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3.1 In t r o d u c t io n
Most applications of gene therapy vectors require the maximal output of transgene 
expression. Therefore, transfection efficiency and total transgene production from the 
transfected cell population are very important, and although not absolutely correlated, 
higher transfection efficiency generally leads to higher total transgene expression.
Previous work with human DC has shown that the tranfection process can activate the 
cells (H. Truman, unpublished), and in the case of a cancer vaccine this is advantageous as 
the cells are in a state to generate proinflammatory immune responses. Activation of DC 
increases the expression of surface molecules involved in antigen presentation and T-cell 
activation, thus their maturation state is critical to their use in immunotherapy. If the cells 
are immature, antigen presentation will not be maximised and the cells will not activate T- 
cells efficiently. However, if the cells are in the late stages of maturity, they will lose their 
migratory capacity and will not travel to lymph nodes.
The lipid and peptide components of the LPD vector components have been shown to 
contribute to activation (H. Truman, unpublished), as well as the CpG oligonucleotides in 
bacterial plasmid DNA. Internalisation and acidification of DNA in endosomes is 
required for CpG-mediated activation of leukocytes and is coupled to the production of 
reactive oxygen species, leading to NF-kB activation and cytokine expression (Yi et aL, 
1998). However, other reports have shown that CpG can bind-cells surface receptors and 
transduce stimulatory signals (Liang et al.t 2000). More recently, CpG-mediated signal 
transduction has been shown to be dependent on Toll-like receptor-9 (TLR9), and the 
presence of CpG contributes to DC activation, inducing IL-12 production and 
upregulation of CD40, CD80, CD86 and MHC II (Hemmi et al., 2000).
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Optimal proportions of each vector component should be determined for murine DCs. 
Incubation time of the complexes with the cells also requires optimisation to maximise 
binding and internalisation. However, incubation for excessive periods may be detrimental 
due to serum-starvation. The following experiments were performed to determine the 
optimal combination of targeting peptide, charge ratio, amount of DNA, duration of 
transfection, and the effect of transfection on the phenotype of the cells.
3.2 Re s u l t s
3.2.1 Optimisation of Targeting Peptide
DC transfections with a luciferase reporter gene were carried out in serum-free OptiMEM 
to optimise the LPD transfection conditions in murine DC. The first experiment 
determined the optimal targeting peptide that gave the highest luciferase expression. A 
range of integrin-targeting peptides were screened, all containing the cationic K16 tail and a 
cyclic head group, held in this conformation by a disulphide bond (Table 2.1, Materials 
and Methods). Only integrin-targeting peptides were available at this stage of the project, 
hence only results with these peptides are shown. Previous work has shown that the 
peptides have strong DNA-condensing properties, but have little transfection ability when 
complexed with DNA alone. The incorporation of Lipofectin into the vector is necessary 
for efficient transfection and a ratio of 0.75|J,g:ljLlg DNA is optimal (Hart et al.y 1998). The 
charge ratios used in this experiment were +7, as this was determined as optimal in other 
cell types, and +3 and +1 to get a better idea of targeting specificity. 50,000 C D llc+ DC 
were transfected for 4 hours in 48-well plates at 37°C then incubated overnight in 
complete media before analysis and this experiment was repeated at least once.
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Pepl was found to consistently result in the highest luciferase expression at all charge 
ratios (Figure 3.1). This peptide contains an RGD motif which is known to bind a5 
integrins on the cell surface. Peptidel 1 also showed good levels of luciferase expression at 
all charge ratios. Peptide 11 has the same charge and sequence as peptide 1 except that the 
RGD motif is changed to a non-specific RGE, suggesting transfection is not mediated 
through a5 integrins in this case.
This result is different to those obtained previously with cell lines and human DC, which 
have generally found superior levels of luciferase expression given by peptide 6 and 
peptide 8 respectively, and this is likely due to different integrin expression on murine DC. 
K16, which contains no targeting group, showed decreased transgene expression as the 
charge ratio was reduced, suggesting the luciferase expression observed at +1 charge ratio 
with peptides 1 and 11 is mediated specifically through surface receptor targeting. 
Peptides 7 and 10 gave minimal levels of transfection, despite their positive charge.
3.2.2 Optimisation of Charge Ratio
The next condition optimised was charge ratio, which was varied by altering the amount of 
cationic peptide, while the amount of DNA and Lipofectin was held constant. As 
Lipofectin only has one positive charge per molecule of DOTMA and DOPE is neutral, it 
is considered insignificant relative to the peptide component of the vector. Charge ratios 
between +1 and +10 were prepared with peptide 1 and cells transfected for 4 hours, 
incubated for 24 hours and analysed by luciferase assay.
The results show that +7 was the optimal charge ratio (Figure 3.2). Reporter gene 
expression is increased by 1.75-fold as the charge ratio increases from +3 up to +7, due 
the increasing attraction between the negatively charged cell membrane and the positively
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Figure 3.1 Optimisation of targeting peptide for LPD vector. Murine bone 
marrow-derived DC were transfected with LPD complexes incorporating different 
targeting peptides at a charge ratio of +7 (A), +3 (B) or +1 (C). Luciferase 
expression was analysed 24 hours after transfection and error bars represent 
standard deviations from triplicate transfections. The experiment was repeated at 
least once and representative data is shown.
118
Chapter 3
1800
tuo^ 1000 
D 
erf
1600 -
□ 0 6
+3 +5 +6 +7 +8 +9 +10
Charge Ratio
Figure 3.2 Optimisation of charge ratio of LPD vector. The charge ratio 
was varied by altering the amount of cationic targeting-peptide (peptide 1) 
whilst keeping the amount of DNA and Lipofectin constant. DC were 
transfected with 2pg DNA per well, and luciferase expression analysed 24 hours 
after transfection. Error bars represent standard deviations of triplicate 
transfections. Experiments were repeated at least once and representative data 
is shown.
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charged complexes. This is consistent with what has been observed in other cell types, 
including human DC and cell lines. Further increase of the charge ratio above +7, up to 
+10 caused a 3-fold drop luciferase expression, so subsequent experiments were 
performed with a +7 charge ratio.
3.2.3 Optimisation of DNA Content of Complexes
The amount of DNA used to transfect each well was varied between lpg to 7(Xg. The 
charge ratio of peptide:DNA, and lipid:DNA ratio was kept constant, so the absolute 
amounts of these components varied, but were kept constant in relation to the amount of 
DNA. Generally, there was an inverse relationship between the amount of DNA used to 
transfect the cells and the level of luciferase expression. Expression peaked at 2|ig/well 
(7990 ±910 RLU/mg) and then dropped in a dose-dependent manner, such that luciferase 
expression with 7pg/well of DNA was nearly 4.5-fold less (1830 ± 550 RLU/mg) (Figure 
3.3A).
This drop in luciferase expression was most likely due to the toxicity of high levels of 
complex on the cells. Morphologically, the cells looked more apoptotic with membrane 
blebbing as the amount of DNA was increased (data not shown). This was also evident 
from the scatter of the cells when analysed by FACS, which appeared very granular when 
transfected with higher amounts of DNA. The gated viable cell population was assessed 
by forward scatter and side scatter characteristics, and decreased with increasing amounts 
of DNA. A dose-dependent decrease in viable cells was observed, from 47.5% viable cells 
in the population transfected with lpg DNA, decreasing to 19.4% of cells transfected with 
7pg DNA. The viable cell population in the untransfected control was 48.7% (Figure 
3.3B).
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Figure 3.3 Optimisation of amount of DNA in LPD vector. Transfection of DC 
with LPD vector with varying amounts of DNA while maintaining the charge ratio at 
+7 and Lipofectin:DNA weight ratio at 0.75:1. (A) Luciferase expression was 
analysed 24 hours after transfection and error bars represent standard deviations of 
triplicate transfections. Experiment was repeated at least once and representative data 
is shown. (B) Transfection efficiency of the viable cell population was assessed by 
GFP expression 24 hours after transfection. Viable cells were determined by forward 
scatter and side scatter characteristics.
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3.2.4 Optimisation of Length of Transfection Period
Finally the transfection incubation period was investigated. Cells were transfected with 
vector complexes containing peptide 1 at a +7 charge ratio with 2pg DNA per well for 
varying amounts of time between 30 mins and 4 h, after which the complexes were 
replaced with complete media. All the cells were incubated at 37°C for a total of 24 h and 
analysed by luciferase assay. Interestingly, the level of luciferase expression rose over 3- 
fold from 30 mins to 90 mins, before dropping slightly then levelling out (Figure 3.4A). 
This is likely to be the optimum balance between the time the complexes had to bind to 
the cell surface and be internalised, and the minimum serum-starvation time and time the 
cells are exposed to the lipofection process. Thus 90 mins was considered the best 
transfection period for all subsequent experiments.
DC were then transfected with the optimised LPD vector using a GFP reporter gene to 
determine transfection efficiency. Cells were analysed by FACS and showed an average of 
<5% GFP positive cells (Figure 3.4B). This is much lower than generally found in cells 
lines, but this level of transfection in DC may still be therapeutic, as one DC is capable of 
activating 100-3000 T-cells (Banchereau & Steinman, 1998). The phenotype of transfected 
and untransfected DC was compared by staining for surface activation markers. This 
confirmed that the transfection process causes murine DC to mature, with increased 
surface expression of activation makers such as Dec205, CD80, CD86 and MHC class II 
(Figure 3.5).
3.2.5 Adenovirus as a Helper Virus
To try improving the transfection efficiency adenovirus (Ad) was added as a “helper 
virus”. This approach has previously been demonstrated to increase the transfection in 
human DC when formulated as an Ad/PEI/DNA complex (Diebold et al.y 1999), or as an
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Figure 3.4 Optimisation of transfection time with the LPD vector
A) Murine DC were transfected with peptide 1 at a charge ratio of +7 with 2pg 
DNA per well for varying times and luciferase expression analysed 24 hours after 
transfection. Error bars represent the standard deviation of triplicate transfections 
and one representative experiment is shown. (B) Murine DC were transfected with 
the optimal LPD vector for the optimal time of 90 minutes with pEGFP-Nl to 
determine maximal transfection efficiency. Cells were analysed by FACS 24 hours 
after transfection and 10,000 events were collected. The scatter plot shows that a few 
of the cells have a high fluorescence intensity, but the percentage of transfected cells 
was very low.
123
Chapter 3
MHC Class II (I-Ak)
DEC-205CD80
Figure 3.5 Analysis of transfected DC phenotype by FACS. The phenotype of 
transfected and untransfected DC was compared by staining for the presence of 
surface activation markers. Blue lines represent untransfected cells, and red lines 
represent transfected cells. Viable cells were gated and 10,000 events from the live 
gate are shown and representative data is shown.
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Ad/PD complex (H. Truman, unpublished) probably by augmenting endosomal escape of 
the complex, reducing DNA degradation. The vims used was an El-deleted replication- 
deficient serotype 5 vims carrying the LacZ reporter gene, which allows virally infected 
cells to be identified and aids titration. The vims was produced as according to materials 
and methods and gave a titre of 5x108 infectious units/ml when titred on HeLa cells.
A range of MOI values were tested with GFP and luciferase. While the addition of vims 
increased the level of luciferase expression in some experiments, this improvement was 
not consistent as expression fluctuated in repeats of the experiment. An experiment using 
Ad/PD (no lipofectin) was performed, as this has been shown to give higher expression in 
human DC, but did not enhance the transfection of murine DC (Figure 3.6). Increasing 
the viral MOI resulted in no increase in transfection efficiency as assessed by GFP 
transfection of DC and analysis by FACS. X-Gal staining showed the level of virally 
infected cells was low (<5%; data not shown), so it was concluded that Ad did not 
enhance the percentage transfection efficiency or the level of transgene expression, as 
assessed by luciferase assay, of murine DC.
3.2.6 Antigen Presentation Assay
Although transfection efficiency was very low, it was still important to investigate whether 
antigen presentation was sufficient to activate T-cells. To test the antigen presentation 
ability of transfected DC an ELISpot assay was performed. DC were transfected with 
pCMV-C5 which encodes full-length murine complement 5 protein (mC5); this protein 
was chosen because A/J mice are C5-negative so mC5 could potentially be used as a 
model antigen in vivo. Also, a CD4+ T-cell hybridoma (A18) was available which 
specifically recognises one epitope of mC5 and these were used as the target cells for 
antigen presentation. These cells lose their CD4 expression in culture fairly quickly, so
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Figure 3.6 Comparison of luciferase expression between the LPD vector, 
Ad/LPD and Ad/PD. Murine DC were transfected with pCI-Luc included in 
either LPD vector alone, LPD vector incorporating Ad-lacZ or PD complexes 
incorporating Ad-lacZ at a range of MOIs and cells were analysed 24 hours after 
transfection. Error bars represent the standard deviation of triplicate transfections 
and one representative experiment is shown.
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freshly sorted cells were used for the assay. Hybridomas do not secrete IFN-y, so an 
ELISpot to measure IL-2 was performed. The assay was performed three times, and no 
IL-2 secretion could be detected on any of the plates (data not shown), suggesting antigen 
was not being presented to the A18 cells.
3.2.7 Confocal Microscopy of Transfected Cells
Confocal microscopy of human DC transfection using labelled components of the LPD 
vector was used to investigate where barriers to transfection were occurring. Human DC 
were used, as these were previously shown to transfect with peptide 6 more efficiendy 
than murine DC, although still at a very low level (~5%) and this was the only labelled 
peptide available. Fluorescendy tagged transfection reagents were used to track the 
progress of the complex through the cell, and to establish which steps were limiting.
These images show that the complexes efficiently adhered to the DC surface within 30 
mins and remained adhered to the cell surface for many hours (Figure 3.7, Figure 3.8). 
Vector internalisation could not be detected by 30 minutes post-transfection (Figure 
3.7C), but a few examples of intracellular vector could be detected after 2 h of transfection 
by examining individual sections taken through cells in the XY plane and Z-axis (Figure
3.8 C&D). If the internalisation had been high, but the complexes had remained in the 
cytoplasm due to low nuclear access, it may have been feasible to try a cytoplasmic 
expression system. However, the internalisation of the complexes was so low, it was 
concluded that this vector system is not optimal for use with these cells.
Confocal imaging of HAE cells was used to investigate the internalisation of LPD by cells 
that transfect with high efficiency. HAE cells transfected with LPD vector containing 
peptide 6 (labelled with Texas Red) and DNA (labelled with Cy5) demonstrated that the
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Figure 3.7 Confocal microscopy of human DC 15-30 minutes after transfection.
Cells were transfected on glass coverslips with LPD vector containing Texas Red-labelled 
peptide 6 (red) and were fixed and counter-stained with Alexa488-phalloidin (green). 
(A&B) DC after 15 minutes of transfection, showing morphological characteristics of 
immature DC. (C) Z-section of DC 30 minutes after transfection, showing labeled 
complexes adhered to the coverslip and cell surface. Between 10-12 sections were taken 
through each cell, and red and green images overlaid. Representative data is shown.
Figure 3.8 Confocal microscopy of human DC 90 minutes - 4h after transfection.
Cells were transfected on glass coverslips with LPD vector containing Texas Red-labelled 
peptide 6 (red) and were fixed and counter-stained with Alexa488-phalloidin (green). 
After 90 minutes (A) 2 hours (C&D) and 4 hours (B) of transfection the morphology of 
the DC has changed to that of a mature phenotype. Podosomes are no longer present 
and the cells have a stellate appearance with many membrane spikes and ruffles. Z- 
sections taken through cells after 2 hours of transfection (C&D) shows some labelled 
vector that appears to be intracellular, indicated by red arrow heads. Between 10-12 
sections were taken through each cell, and red and green images overlaid. Representative 
data is shown
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peptide and DNA remain tighdy complexed, shown by pink staining, until the DNA 
enters the cell (Figure 3.9). Here it appeared that some DNA had separated from the 
peptide, which was shown by diffuse blue staining, and examination of the individual 
sections through the cells confirmed this diffuse DNA staining was intracellular. DNA 
was only observed to separate from the peptide once inside the cell; no separation of 
components was seen with vector bound to the cell surface or adhered to the glass 
coverslip.
Further images with HAE cells, transfected with Cy5-labelled DNA and Oregon Green- 
labelled lipid, showed that the lipid dissociated from the intracellular complexes within 4 h 
(data not shown) and remained perinuclear up to 24 h afterwards (Figure 3.10). Lipid 
staining was shown to be intracellular by analysing individual sections and in some cells 
was quite punctate. This would suggest an endosomal location and is consistent with the 
lipid’s proposed role of aiding the endosomal escape of the complexes. The lipid 
fluorescence was not as strong as the DNA or peptide, and the lipid and DNA stain did 
not appear to co-localise as much as the peptide and DNA stain. However, even the HAE 
cells, which have a high transfection efficiency, showed significant amounts of complex 
adhered to the cell surface which still was not internalised after 24 h. A considerable 
amount of complex also adhered to the glass coverslips due to the electrostatic charge of 
the vector.
The confocal images also showed the effect that LPD transfection had on the morphology 
of the DC, which still displayed the immature characteristics of podosomes (dots of actin 
involved in cell adhesion) and flat, fairly polarised cells 15 mins after transfection (Figure
3.7 A&B). Within 90 mins, podosomes were no longer present and the cells
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Figure 3.9 Confocal microscopy of HAE cells transfected with labeled peptide and 
DNA. (A) HAE cells were transfected on glass coverslips with LPD vector containing Texas 
Red-labeled peptide 6 (red) and Cy5-labelled DNA (blue) and fixed and counter-stained with 
Alexa-488 phalloidin (green) after 15 minutes of transfection. The pink colour shows co­
localisation of peptide and DNA. (B & C) HAE cells were transfected as above and fixed and 
counter-stained 24 hours after transfection. Between 10-12 sections were taken through each 
cell, and red, blue and green images overlaid. The arrows indicate diffuse blue staining where 
the DNA appears to have dissociated from the peptide. Individual sections confirmed this 
staining was intracellular.
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Figure 3.10 Confocal microscopy of HAE cells transfected with labelled lipid 
and labelled DNA. (A-C) HAE cells were transfected on glass coverslips with LPD 
vector containing Oregon Green labelled-lipid (green), Cy5 labelled-DNA (blue) for 4 
hours, then replenished with complete media. Cells were fixed after a further 20 hours 
incubation, then fixed and counter-stained with rhodamine-phalloidin (red). Between 
10-12 sections were taken through each cell, and red, blue and green images overlaid.
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became more rounded, developing a stellate appearance with membrane ruffles and spikes 
that is characteristic of a mature phenotype (Figure 3.8 A-D).
3.2.8 Retargeted Adenovirus Vectors
The previous experiments suggest that DC appear refractory to transfection with the LPD 
vector. An alternative would be to use a viral vector that transfects non-dividing cells, 
such as an adenovirus. Adenoviruses efficiently transfect a variety of cell types and 
binding and internalisation is often mediated by the coxsackie-adenovirus receptor (CAR) 
(Wickham et al., 1993). Cells that do not express CAR are still permissive to transfection, 
albeit at lower levels. Retargeting the Ad vectors to target surface molecules other than 
CAR is one way of increasing transfection efficiency in CAR-negative cell types (Hidaka et 
al., 1999). Alternatively, pseudotyping with fibre proteins from different Ad serotypes may 
also enhance the specificity of vector uptake to certain cell populations (Shayakhmetov et 
al., 2000).
Adenoviral vectors been shown to successfully transfect human (Diao et al.., 1999; 
Lundqvist et al., 2002) and murine DC (Korst et al., 2002; Song et al, 1997), although these 
cells do not express CAR. Advances in vector technology have allowed the genetic 
manipulation of the adenoviral fibre protein, which is responsible for binding to host cells 
and subsequent internalisation. Changes in the fibre protein sequence can result in Ad 
vectors targeted towards specific cell populations, such as DC, mediating increased 
transfection. The increased transfection efficiency may allow lower MOIs to be used, 
which could reduce vector toxicity and anti-vector immune responses, permitting repeated 
administration.
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3.2.8.1 Transfection of murine DC with retargeted adenovirus
The Ad-lacZ vector used in section 3.2.5 did not appear to augment LPD-mediated 
transfection of murine DC, and no expression of Ad vector-encoded lacZ could be 
detected. However, murine DC have been shown to be permissive to transfection with 
Ad vectors (Korst et al., 2002; Xia et al., 2002). Transfection efficiency in murine DC may 
be improved by manipulating the sequence of the fibre protein to a modf that is known to 
bind DC. Phage panning was used to identify two peptide sequences that bound human 
DC with high affinity, and these are designated peptide A and peptide B (M. Writer, 
unpublished) (Table 2.1, Materials and Methods). The HI loop of the fibre protein of a 
GFP-encoding E l and E3 deleted adenoviral vector was engineered to contain the 
sequence of peptide A or peptide B. A knock-out Ad vector was also constructed, 
containing a HI loop with no CAR binding domain. The Ad-peptide A, Ad-peptide B and 
knock-out Ad vectors were compared with a virus containing a wild-type fibre protein for 
their ability to transfect murine C D llc+ DC. GFP+ cells were analysed by flow cytometry.
The knock-out Ad vector mediated only negligible transfection of DC with 1.5% GFP+ 
DC, while the wild-type Ad vector had a transfection efficiency of 15%, which is superior 
to what was achieved with the LPD vector. However, the Ad vectors retargeted with the 
DC binding peptides showed a massive increase in transfection efficiency. Transfection 
with Ad-peptide A resulted in 79% GFP+ DC, and Ad-peptide B resulted in 61% GFP+ 
DC (Figure 3.11), demonstrating the contribution of the fibre protein sequence to vector 
binding and internalisation.
3.2.8.2 Transfection of murine stem cells with retargeted adenovirus
The same Ad vectors were also used to transfect Sca-1+ stem cells isolated by positive 
selection from the bone marrow of A/J mice. Stem cells are an attractive target due to
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Figure 3.11 Improvement of transfection efficiency of murine DC with 
retargeted adenovirus. C D llc+ DCs were transfected with 100,000 Ad-GFP 
particles per cell (~MOI 100) in complete media. 24 hours after transfection cells 
were analysed by FACS. The scatter plot in the top left comer shows the gated 
population of viable cells with the scatter characteristics of DC, and 10,000 events 
were collected from this gate are shown in the histograms. Representative data is 
shown.
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their ability to differentiate into all heamatopoeitic lineages. Transfection of stem cells was 
investigated because there would be many advantages to transferring genes to these cells in 
their quiescent state, without pushing them into the cell cycle, where they start to lose their 
early precursor characteristics. Although current Ad vectors are non-integrating, vectors 
are being developed with the ability to integrate into the cell genome, preventing vector 
loss as the cell divides (Murphy et al., 2002; Mitani & Kubo, 2002).
The knock-out vector mediated negligible transfection that was equivalent to background 
untransfected control. Transfection efficiency of murine stem cells was much lower than 
achieved in murine DC, with only 2.5% GFP+ stem cells following transfection with wild- 
type Ad, and 6% and 5.5% GFP+ stem cells following transfection with Ad-peptide A and 
Ad-peptide B respectively (Figure 3.12). Although the overall level of transfection is low, 
the retargeted vectors still demonstrate increased transfection efficiency compared to the 
wild-type vector.
3.3 D isc u ssio n
The aim of the section of work was to optimise the transfection of murine bone marrow- 
derived DC using the synthetic LPD vector to provide a quick and straightforward 
method of efficient gene transfer to these cells. Transfection of murine DC with the LPD 
vector mediated gene transfer efficiency of ~5%. This is comparable with the transfection 
efficiency achieved in murine primary DC transfected with another cationic peptide, CL22, 
which contains a sequence from influenza nucleoprotein. 1% of DC were transfected 
using CL22, and this was shown to be sufficient for antigen-specific responses (Irvine et 
al., 2000). However, CL22 achieved 17% transfection of human DC, compared to 1% of 
murine primary DC, suggesting murine DC may be intrinsically more difficult to transfect 
than human DC (Irvine et al,1, 2000; Haines et aL, 2001). Other non-viral vectors used to
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Figure 3.12 Transfection of murine Sca-1+ haematopoietic stem cells with 
retargeted adenovirus. Sca-1+ stem cells were transfected with 100,000 Ad-GFP 
particles per cell (~MOI 100) in complete media supplemented with Flt-3 ligand, 
mSCF and IL-6. 24 hours after transfection cells were analysed by FACS. The scatter 
plot in the top left comer shows the gated population of viable cells with the scatter 
characteristics of stem cells, and 10,000 events were collected from this gate are shown 
in the histograms. Representative data is shown.
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transfect DC include PEI/DNA vectors which incorporated an Ad helper virus, which 
were shown to mediate transfection of ~10% (Diebold et al., 1999), while cationic peptides 
composed of ornithine and histidine repeats mediated 3-fold higher transgene expression 
than lysine-based peptides (Chamarthy et al., 2003). The highest level of non-viral 
transfection of DC has been achieved using the recendy developed nucleoporation 
technology, mediating transfection of up to 60%, although loss of cell viability has 
hampered this approach (Lenz et al, 2003).
The LPD vector used here is composed of plasmid DNA, Lipofectin and a receptor 
targeting cationic peptide. Incorporation of the targeting peptide has been shown to 
mediate enhanced transfection in many cell types compared to lipid-DNA complexes or 
untargeted peptide-lipid-DNA complexes (Hart et al, 1998), so was therefore a good 
candidate for transfection of DC. The peptide has two functions; the chain of 16 lysine 
residues has a high positive charge that has DNA condensing properties, while the 
receptor targeting part of the molecule contains a motif that targets cell surface molecules, 
and is held in a cyclic conformation by two cysteine residues flanking the motif, forming a 
disulphide bond. The LPD vectors used here contained integrin-targeting motifs. It is 
proposed that once the vector binds to the cell, it enters the cell through receptor- 
mediated endocytosis. The lipid component of the vector is thought to fuse with the 
endosomal membrane and facilitate release of the peptide/DNA components of the 
vector into the cytoplasm, reducing acidic degradation of the vector. The plasmid 
component of the vector is transported to the nucleus, probably still bound to the peptide, 
although it is not clear how this occurs. Once in the nucleus, the gene is transcribed by 
the host cell’s transcriptional machinery.
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The individual LPD components were optimised for transfection of mouse bone marrow- 
derived DC. The optimal combination was determined of peptide 1 at a charge ratio of 
+ 7 ,2pg DNA in a volume of 500p.l, and a transfection period of 90 minutes.
Peptide 1 contains an RGD motif that targets many integrins including av and a5 (Parkes 
& Hart, 2000), and RGD motifs can be found in proteins involved in cell-cell or cell- 
matrix interactions, such as fibronectin, vitronectin and thrombospondin (Humphries et 
al,1, 2000). Peptide 11 contains the RGE motif so is not integrin-specific, yet both peptide 1 
and peptide 11 resulted in high luciferase expression at all charge ratios tested. Peptide 11 
may mediate internalisation by receptors other than integrins or part of the head group 
other than the RGD/RGE motif may be targeting molecules on the cell surface, as the 
rest of the sequence is identical in both peptides, leading to similar luciferase expression. 
The untargeted K16 peptide also showed comparable levels of transfection with peptide 1 
at a charge ratio of +7, indicating that LPD vector internalisation is not mediated entirely 
by integrin binding, but also by the positive charge of the complexes.
A charge ratio of +7 consistently gave the highest transgene expression in conjunction 
with peptide 1, probably due to maximal binding to the cell surface and internalisation. 
The further the charge ratio was increased above +7, the less luciferase expression was 
observed, which may be due to some peptide not being incorporated into the complexes. 
Free peptide may be competing with the LPD vector for binding to integrins, blocking the 
binding of complexes to the cell and decreasing the amount of internalised vector.
Confocal microscopy with fluorescendy-tagged vector components was performed to 
visualise the complexes in the cells and ascertain where the block to transfection was 
occurring. Potential barriers to efficient transfection were limited internalisation of the
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LPD vector, endosomal degradation of the vector, and prevention of the plasmid DNA 
released into the cytoplasm from translocating to the nucleus. Luciferase transfections 
showed that LPD vector incorporating the labelled peptide mediated comparable 
transfection to unlabelled LPD vector (see appendix 3).
DC transfected with labelled peptide revealed that the LPD complexes adhered to the cell 
surface and remained in contact with the cell for many hours. This has also been observed 
in primary human fibroblasts transfected by lipofection, where substantial amounts of 
complex remained adhered to the cell surface several hours after transfection (Coonrod et 
al[, 1997). However, LPD complexes were only observed inside very few DC.
Human airway epithelial (HAE) cells were used in comparison to DC as these are known 
to transfect with high efficiency, and could therefore demonstrate more clearly the cellular 
trafficking of the LPD vector. Cy-5-labelled DNA was also used for these images, and 
this showed that the peptide and DNA components of the vector remain bound together 
when adhered to the cell surface. HAE cells transfected with labelled lipid and labelled 
DNA showed perinuclear localisation of the lipid after four hours of transfection, with 
punctate staining consistent with an endosomal location, suggesting that the complexes are 
internalised via the endosomal pathway. This is consistent with the model of the lipid 
layer being shed in the endosome and staining with endosomal markers to detect co­
localisation with lipid could confirm this. The only DNA that did not appear to be bound 
to peptide was observed intracellularly, as shown by sections taken through the cell. The 
intracellular DNA may be located in the nucleus, and co-localisation with a nuclear 
counter-stain could determine whether the labelled DNA was intranuclear.
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Comparison of DC and HAE cells showed the main barrier to transfection in DC was 
limited vector internalisation. Many HAE cells showed internalised LPD by the presence 
of lipid in a location consistent with endosomes, and the identification of DNA located 
within the cells. In DC, vector adhered to the cell but very little was shown to internalise.
To further investigate the nature of the receptors for the LPD vector, a panel of antibodies 
targeting different integrins could be used to characterise the surface expression of 
integrins on murine DC. Blocking antibodies against integrins or small soluble peptides 
which compete for binding sites on the integrin molecule with the LPD vector could 
determine the specificity of the integrins targeted. Alternatively, vector internalisation may 
be improved by identifying peptides that bind with a higher affinity, increasing the contact 
time between the vector and the cell surface.
When using DC as a cancer immunotherapy vaccine, ideally the cells should transfect with 
high efficiency and also display high levels of immunostimulatory surface markers. 
Comparison of the phenotype of untransfected and transfected cells showed an increase in 
the level of activation markers following transfection. However, when murine C5 was 
used as a model antigen in an antigen presentation assay no activation of antigen-specific 
CD4 T-cell hybridoma target cells (A18) was observed. The A18 cells recognise only one 
epitope of murine C5 protein (Zal et al., 1994), so it is possible that the DC were 
presenting other epitopes, which were not recognised by the A18 cells. To test the A18 
cells, ConA, PHA and PMA, which non-specifically activate T-cells, were added to the 
positive control wells, but still no IL-2 secretion was seen, suggesting that the A18 cells 
were not responding to stimulation. Therefore, it was it was difficult to assess the antigen 
presenting capacity of the DC due to the low stimulation capability of the A18 cells.
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An alternative method of testing the ability of DC to present transfected antigen C5 as a 
model antigen could be to immunise A/J mice with C5 peptide. The splenocytes from 
these primed mice could be used in an ELISpot with C5-transfected DC to determine the 
ability of the DC to re-stimulate C5-specific splenocytes.
Many publications concerning gene transfer to primary DC use adenoviral vectors, which 
can achieve transfection efficiency of up to 85% or 90% in murine DC (Korst et al, 2002; 
Xia et al.y 2002), and >70% in human DC (Diao et al[, 1999), while HSV-1 amplicons and 
retroviral vectors have achieved a 70% transduction efficiency in human and murine DC 
(Willis et al.y 2001; Specht et al.y 1997; Movassagh et al., 1999). Recently reports using 
lentiviral vectors have been published demonstrating transfection efficiencies of 35% in 
human DC (Schroers et al., 2000) or up to 80% in murine DC (Metharom et al., 2001), 
demonstrating that further work is needed to increase the level of transfection with 
synthetic vectors up to that achieved with viral gene transfer systems.
The addition of Ad-lacZ vector to the LPD vector as a helper virus had little enhancement 
of transfection. However, the adenoviral vectors with fibre proteins retargeted to express 
DC-binding peptides resulted in high-level transfection efficiency and gene expression in 
murine DC. This demonstrates the potential of vector retargeting to augment gene 
transfer into target cells. Ad vectors retargeted to DC could prove very useful in 
mediating high level transgene expression, and transfection with adenoviruses has been 
shown to induce an activated phenotype in both human and murine DC (Korst et al.y  2002; 
Lundqvist et a l.y  2002) which is critical to their antigen presenting capacity. Further work 
would be necessary to characterise the phenotype of murine DC transfected with these 
retargeted viruses, and to confirm the transfected DC are functional.
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In conclusion, the optimal LPD vector formulation was able to mediate only low-level 
transfection of DC, with a transfection efficiency of <5%. An antigen presentation assay 
showed that transfected DC did not appear to be presenting antigen to target cells. 
Confocal work demonstrated that low internalisation of the vector was the major barrier 
to transgene expression in DC, as the cells appear to bind high levels of LPD complex but 
little was taken up into the cell. The studies discussed above have reported that gene 
transfer into DC using synthetic vectors can be achieved, although these levels are lower 
than attained with viral systems. Therefore, further LPD vector development to enhance 
vector uptake should improve the transfection efficiency and transgene expression in 
primary DC.
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4.1 In t r o d u c t io n
Vaccination with DC modified to express tumour antigens (Metharom et al., 2001) or 
tumour lysate-pulsed DC (Fields et al., 1998) is one approach to generating a local pro- 
inflammatory environment. An alternative means of increasing the immunogenicity of the 
tumour microenvironment is to increase the concentration of pro-inflammatory cytokines. 
Proinflammatory cytokines in the tumour locale have been shown to generate cellular and 
humoral adaptive immune responses against established tumours (Son et al., 2003; Fujii et 
al, 2000). Systemic administration of inflammatory cytokines is toxic at the concentrations 
required for tumour regression, and intratumoural injection of recombinant proteins 
results in only short-term cytokine exposure. Transfecting tumour cell lines with cytokine 
genes and injecting them into mice gives localised, high-level cytokine secretion for several 
days, and has been shown to effectively retard tumour growth in vivo in murine tumour 
models (Moret et al., 2001). This approach has reached clinical trial for some malignancies, 
including NB using viral gene transfer methods (Seeger et al., 1998; Brenner etal., 2000).
However, this method is not always appropriate to transfer to a clinical setting due to 
technical difficulties with the culture and manipulation of primary tumour cells from 
surgical specimens (E.Siapati, personal communication; de Zoeten et al, 1999). 
Additionally, there may be insufficient tumour material available from which to culture 
primary cells. Conversely, primary dermal fibroblast are readily cultured from skin 
biopsies and when transfected with cytokine genes, may be used as a cellular vaccine to 
give the same localised cytokine expression.
This approach has already been used in phase I trials for a variety of solid tumours, using 
viral transfer of IL-2 (Sobel et al., 1999) or IL-12 (Kang et al., 2001). Both of these studies 
used autologous fibroblasts and therapeutic effects were seen with these vaccines. These
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phase I clinical trials using autologous cells mentioned above used a retroviral vector to 
transfer the cytokine genes to the fibroblasts. While very efficient, there are potential 
problems associated with retroviral vectors, including the possibility of generating 
replication-competent virus or aberrant integration into the host genome. Synthetic 
vectors are much quicker and simpler to prepare and are considered a safer alternative to 
viral vectors. Provided that therapeutic levels of transgene can be produced, they may 
become an attractive alternative in clinical applications.
The aim of this section of work was to evaluate murine fibroblasts transfected to express 
IL-2 and IL-12 as a tumour vaccine. Therefore transfection of autologous and allogeneic 
murine fibroblasts using the synthetic LPD-vector was optimised for maximal cytokine 
expression.
4.2 Re su l t s  
4.2.1 Optimisation of transfection
4.2.1.1 Transfection of Murine Dermal Fibroblasts
Mouse primary dermal fibroblasts were prepared from skin explants of A/J mice by 
enzyme digestion to produce single cell suspension, and were expanded in vitro. These 
cells were transfected with the LPD vector using the previously optimised transfection 
conditions of a charge ratio of +7, 2pg DNA per well, 0.75jLLg Lipofectin per lpg DNA 
and a transfection time of four hours. Therefore the only condition specifically optimised 
for primary A/J fibroblasts was the targeting peptide and the presence/absence of Ad 
helper virus.
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Experiments using a luciferase reporter gene showed that the LPD vector incorporating 
peptide 6 and Ad helper virus generally had the highest reporter gene expression (Figure 
4.1), although the Ad-mediated enhancement of transfection over LPD vector alone was 
inconsistent, possibly due to differences in cell viability between different cell preps. The 
Ad/PD vector, which has shown superior transfection in human DC (H. Truman, 
unpublished), did not result in superior transfection in murine primary fibroblasts. The 
problems with using these cells were the slow growth and poor viability of these cells, 
which could only be maintained for a few passages. This would be a major limiting factor 
in generating the large numbers of cells required for in vivo procedures with several 
experimental groups of mice.
4.2.1.2 Generation of a syngeneic MEF line
Due to the difficulties of using primary dermal fibroblasts detailed above, a fibroblast cell 
line syngeneic with A/J mice was used to overcome these problems. However, no such 
line is commercially available so a syngeneic fibroblast cell line was developed from 
13.5dpc A/J embryos in a variation of the original method of Todaro and Green (1963) 
and advice available in the institute (Dr M. Hubank, personal communication).
Briefly, the crania and red organs were removed and the remaining tissue digested to form 
a single cell suspension. This suspension was plated in a 75cm3 flask for 2 days, then cells 
were split and plated out at a density of 50,000 per 25cm3 flask and passaged every ~3 days 
until cells reached senescence. This allows the fibroblasts to out-grow any other cell types, 
most of which will not establish in culture. After 10-14 days, a few cells were observed to 
spontaneously immortalise and started growing at an increased rate. Of the 15 embryos 
cultured, 2 gave rise to cells with fibroblast-like morphology. Cells were passaged 5-7 
times to ensure a uniform population of immortalised cells, then used in reporter gene
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Figure 4.1 Reporter gene expression in primary A /J dermal fibroblasts.
Cells were transfected with LPD vector, Ad/LPD or Ad/PD incorporating 
peptide 6, peptide 8 or peptide 12 and analysed by luciferase assay 24 hours after 
transfection. Error bars denote the standard deviation of triplicate transfections 
and representative data is shown.
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transfections. Initial transfections showed one to consistently give higher transgene 
expression levels (see appendix 4) and this culture was used in all subsequent experiments, 
hereafter referred to as AJ3.1 (Figure 4.2A).
4.2.1.3 Optimisation of AJ3.1 transfection
As with the primary dermal fibroblasts, a charge ratio of +7, 2pg DNA per well and a 
transfection time of 4 h was used. At this stage in the project, peptides isolated by phage 
display were available to compare with the integrin-targeting peptides. The two peptides 
with the highest binding on fibroblasts (VNLQNPY and VYARSMN; Table 2.1), the two 
peptides with the highest binding to HAE cells (pep P and E; Table 2.1) and the two 
peptides with the highest binding to human DC (pep A and B; Table 2.1) to the integrin- 
targeting peptide 6.
Both VNLQNPY and VYARSMN gave consistently higher levels of luciferase expression 
than peptide 6 (Figure 4.2B). The DC-binding peptide A and HAE-binding peptide E 
gave consistently elevated luciferase expression compared to peptide 6, but lower than the 
expression mediated by the fibroblast-specific peptides. Peptide B and peptide P did not 
enhance luciferase expression compared to peptide 6. Luciferase expression from 
transfected AJ3.1 was consistently more than 25-fold higher than observed in A/J primary 
dermal fibroblasts.
4.2.1.4 Optimisation of Transfection of Allogeneic NIH-3T3 Fibroblasts
NIH-3T3 fibroblasts were chosen as the allogeneic cells. These cells are derived from 
NIH-Swiss mice, which is an outbred strain and therefore they do not express a defined 
MHC. The phage-isolated peptides were not available at this stage in the project. 50,000 
NIH-3T3 cells were transfected using 2pg DNA per well, with peptide 6 or peptide 1 at
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Figure 4.2 Generation and optimisation o f  transfection o f  AJ3.1 cells. (A) Phase 
contrast microscopy of AJ3.1. These images show passage 12 AJ3.1 cells, 
demonstrating typical fibroblast morphology and a uniform population. Representative 
images are shown of a series of frames captured.
(B) Optimisation of taigeting peptide with AJ3.1. Cells were transfected with pCI-Luc 
using the LPD vector incorporating different targeting peptides at a charge ratio of +7. 
Cells were analysed by luciferase assay 24 hours after transfection and error bars denote 
the standard deviation from triplicate transfections. Representative data is shown.
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+3 or +7 charge ratio for 4 hours at 37°C. Cells were analysed 24 h after transfection by 
luciferase assay (Figure 4.3) which showed either peptide at a charge ratio of +7 to give 
substantially greater luciferase expression than vectors at a charge ratio of +3. Peptide 6 
showed slightly higher expression than peptide 1, so it was decided to use a LPD vector 
containing peptide 6 at a charge ratio of +7 for further work.
Comparison of luciferase expression from the transfected fibroblasts shows that 
transfection of both fibroblast cell lines is far superior to the level of transfection obtained 
in primary dermal fibroblasts. Luciferase expression in AJ3.1 fibroblasts is ~30-fold 
higher than in A/J primary dermal fibroblasts. There is also little difference in luciferase 
expression between either fibroblast cell line and the Neuro-2a (N2a) neuroblastoma cell 
line, which are known to transfect with high efficiency and express high levels of transgene 
using a LPD vector containing peptide 6 (Figure 4.4).
4.2.1.5 Transfection efficiency of fibroblasts with LPD vectors
Transfection with a GFP reporter gene using the optimal LPD vector for each cell type 
was performed to determine transfection efficiency. Primary dermal A/J fibroblasts were 
transfected with peptide 6 and showed very low transfection efficiency of <5% (Figure 
4.5A). AJ3.1 cells transfected with the LPD vector incorporating peptide VYARSMN 
showed the transfection efficiency was consistently >20% (Figure 4.5B) indicating that 
high level reporter gene expression was achieved with the LPD vector incorporating 
VYARSMN. Transfection of NIH-3T3 cells with the LPD vector incorporating peptide 6 
resulted in a transfection efficiency of 45% (Figure 4.5C).
These results suggest the A/J primary dermal fibroblasts are not suited to transfection 
with this vector, and this is probably related to their poor viability in culture. The
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Figure 4.3 Luciferase expression in NIH -3T 3 cells. Cells were transfected with 
pCI-Luc by LPD vector incorporating peptide 6 or peptide 1 at a charge ratio of +3 
or +7 and analysed by luciferase assay 24 hours after transfection. Error bars 
represent standard deviations of triplicate transfections and representative data is 
shown.
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Figure 4.4 Comparison o f  luciferase expression in different fibroblast types.
The luciferase expression mediated by the optimal transfection formulation for A/J 
primary dermal fibroblasts, AJ3.1 fibroblasts and NIH-3T3 fibroblasts was 
compared with transfection o f the A/J derived neuroblastoma cell line (N2a) cells, 
which are known to transfect with high efficiency. Cells were analysed by luciferase 
assay 24 hours after transfection and error bars represent standard deviation of 
triplicate transfections.
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Figure 4.5 Comparison o f  transfection efficiency o f syngeneic and allogeneic 
fibroblasts. Cells were transfected with their respective optimal LPD vector at a 
charge ratio o f +7 incorporating the plasmid pEGFP-Nl and analysed by FACS 48 
hours after transfection. Primary dermal A/J fibroblasts were transfected with peptide 
6 (A), AJ3.1 fibroblasts were transfected with peptide VYARSMN (B) and NIH-3T3 
cells were transfected with peptide 6 (C). Viable cells were gated on the basis of 
forward scatter and side scatter characteristics, and 10,000 events collected from this 
gate are shown in the histograms. Representative data is shown.
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syngeneic AJ3.1 and allogeneic NIH-3T3 fibroblast cell lines both demonstrated a high 
transfection efficiency with their respective optimal LPD vectors. Therefore the level of 
cytokine expression that could be achieved in these cells by transfection with pCI-IL-2 and 
pCI-IL-12 genes using the LPD vector was determined
4.2.2 Cytokine expression of transfected fibroblasts
4.2.2.1 Cytokine expression by primary dermal fibroblasts
Murine primary dermal fibroblasts were transfected with pCI-IL12 using the LPD vector 
and culture supernatant analysed by ELISA (Figure 4.6). This showed the level of 
secreted cytokine was ~ 100-fold lower than typically observed in transfected N2a cells 
(Figure 4.7), and expression rapidly dropped below the level of detection. Transfection 
using Ad/LPD or different targeting peptides did not improve cytokine secretion levels, 
and peak expression was 12ng/24h/106 cells on day 1 using Ad/LPD 12. Cytokine 
expression also decreased rapidly, although very low level IL-12 secretion was detectable 
on day 11. IL-2 secretion by transfected fibroblasts was below the level of detection. 
Repeats of this experiment in primary cells showed this level of secretion to be typical.
It was decided not to progress further with these cells for in vivo work for several reasons. 
Poor cell viability, as mentioned previously, was limiting the number of cells that could be 
maintained in culture, so could subsequendy restrict the in vivo use of these cells. 
Variability between cultures was also a problem, particularly as reproducibility of the 
transfected cell vaccine is vital to its in vivo application. Finally, low level of secreted 
cytokine by transfected primary dermal A/J fibroblasts is unlikely to confer any 
therapeutic benefit, being ~ 100-fold lower than obtained with transfected N2a cells that 
have mediated eradication of established tumours (Siapati et al1, 2003).
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Figure 4.6 Secretion o f mIL-12p70 by transfected primary dermal A /J  
fibroblasts. Cells were transfected with pCI-scIL-12 using LPD or Ad/LPD 
vector incorporating peptides 6 or 12. Supernatant was harvested and 1L-I2p70 
expression determined over a 24-hour period using a sandwich ELISA. 
Representative data is shown.
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4.2.2.2 Cytokine expression by transfected AJ3.1
AJ3.1 cells were transfected individually with pCI-IL2 or pCI-mIL12, or co-transfected 
with both plasmids using peptide VYARSMN and supernatant harvested every 24 hours. 
Cytokine expression was determined by sandwich ELISA and compared to the expression 
from N2a cells co-transfected with both cytokine plasmids. Expression of IL-2 and IL-12 
was very similar between singly transfected and co-transfected cells. In one representative 
experiment, IL-12 expression of transfected AJ3.1 cells peaked two days after transfection 
at 1370ng/24h/106 cells (single transfection) or 1100ng/24h/106 cells (co-transfection) 
compared to 1350ng/24h/106 N2a cells (Figure 4.7A). Five days after transfection, IL- 
12 secretion by AJ3.1 cells was 480ng/24h/106 cells (single transfection) or 
300ng/24h/106 cells (co-transfection), compared with N2a cells at 430ng/24h/106 cells.
Peak expression of IL-2 by AJ3.1 cells was 190ng/24h/106 cells (single transfection) or 
230ng/24h/106 cells (co-transfection), while N2a cells expressed 146ng/24h/106 cells. 
Five days after transfection, AJ3.1 cells expressed 9ng/24h/106 cells (single transfection) 
or 12ng/24h/106 cells (co-transfection), while N2a cells expressed 71ng/24h/106 cells 
(Figure 4.7B). While there was some variation between experimental replicates, AJ3.1 
cells demonstrated expression of both IL-2 and IL-12 that was high and comparable with 
the levels obtained from transfected N2a cells. This level of cytokine secretion was known 
to be in the therapeutic range from previous experiments with N2a cells (Siapati et al.t 
2003), so was suitable for investigation in vivo.
4.2.2.3 Cytokine expression by transfected NIH-3T3 cells
25,000 3T3 cells were transfected with cytokine genes in 24-well plates in triplicate. Cells 
were co-transfected with lpg each of pCI-IL-2 and pCI-scIL-12 using peptide 6 at a
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Figure 4.7 Cytokine production by transfected AJ3.1 cells compared with 
transfected N2a cells. AJ3.1 were transfected with LPD vector containing 
VYARSMN and N2a cells were transfected with LPD vector containing peptide 6. 
AJ3.1 cells were transfected singly with pCI-IL-2 or pCI-scIL-12 (solid lines) or co­
transfected with both plasmids (dotted lines) and cytokine expression was compared 
with co-transfected N2a cells (green lines) or control (GFP) transfected cells (black 
lines). Supernatant was collected at 24-hour intervals and cytokine concentration was 
assayed by sandwich ELISA. Representative data is shown.
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charge ratio of +7. Supernatant samples that were conditioned for 24 hours were collected 
after 1,2 and 7 days and cytokine secretion analysed by ELISA (Figure 4.8).
The levels of IL-2 and IL-12 secreted by transfected 3T3 cells were comparable with those 
secreted by transfected N2a cells, which have been successfully used in our lab for in vivo 
tumour eradication experiments. Expression of IL-12 peaked at 1392ng/24h/106 cells and 
IL-2 expression peaked at 760ng/24h/106 cells. Cytokine expression was still detectable 7 
days after transfection with IL-12 levels of 66ng/24h/106 cells and IL-2 levels of 
45ng/24h/106 cells. This level of cytokine expression was in the therapeutic range 
achieved with N2a cells, so cytokine expression was considered sufficient for in vivo 
experiments. No cytokine expression was observed in GFP-transfected control cells.
4.2.3 Hum an Primary Fibroblasts
Assessment of primary dermal human fibroblasts was performed in vitro. Although these 
cells could not be used with the mouse model, it was still of great interest to optimise 
transfection, as these cells are analogous to what could potentially be used clinically as the 
NB vaccine. Normal human primary dermal fibroblasts were obtained from two healthy 
donors by skin biopsy (Dr Mike Hubank, personal communication), and the following 
experiments were performed on cells below passage 22.
4.2.3.1 Optimisation of Targeting Peptide
25,000 cells were transfected with LPD at a +7 charge ratio, a LipofectinrDNA ratio of 
0.75:1 and 2pg DNA per well for 4 hours. Peptide 6 was again compared to the peptides 
obtained with the phage display libraries (Figure 4.9). As with the AJ3.1 cells, the 
peptides that had been isolated on NIH-3T3 cells, VYARSMN and VNLQNPY, mediated 
the highest luciferase expression, which was ~3-fold higher than achieved with peptide 6.
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Figure 4.8 Cytokine expression o f transfected N IH -3T 3 cells. Cells were co­
transfected with pCI-IL2 and pCI-IL12 using peptide 6 at a charge ratio of +7. 
Conditioned supernatant was collected for 24-hour periods and analysed by 
sandwich ELISA. Representative data is shown.
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Figure 4.9 Optimisation o f targeting peptide on human primary fibroblasts.
Cells were transfected with LPD complexes incorporating different targeting 
peptides. The charge ratio (+7) and amount of DNA (lpg/well) remained 
constant. Cells were analysed 24 hours after transfection. Error bars represent the 
standard deviation from triplicate transfections and representative data is shown.
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There was little difference between VYARSMN and VNLQNPY in many replicates of the 
experiment, but overall VYARSMN mediated slightly superior levels of transgene 
expression. The HAE-binding peptide, E, also gave high levels of luciferase expression. 
Peptides A and P showed a slight improvement of luciferase expression compared to 
peptide 6, while peptide B did not show any enhancement of transgene expression over 
peptide 6.
4.2.3.2 Optimisation of Lipid
A series of DOTMA analogues became available through a collaboration (Chemistry 
Department, UCL) to compare with Lipofectin for improvement of transgene expression. 
The lipid normally used in the LPD vector is Lipofectin, a commercially prepared 
equimolar solution of DOPE, a neutral lipid, and DOTMA, a lipid chain of 18 carbon 
atoms containing one unsaturated bond, with a positively charged head group. The 
analogues consisted of two series of lipids with a tail of 10-18 carbon atoms (C10-C18); 
one series contained a single unsaturated double bond, while the other series was 
composed of different length chains composed entirely of saturated bonds (see Figure 
2.1, Materials and Methods). All lipids contained the same head group as DOTMA and 
each lipid was formulated with and without DOPE. Previous preliminary work had 
shown that these lipids had improved transfection when used at higher weight ratios than 
that used with Lipofectin. Therefore, lipid:DNA weight ratios of 2:1 or 4:1, were 
compared with the standard Lipofectin:DNA weight ratio of 0.75:1.
Luciferase assay revealed that the Cl 6 lipid with the unsaturated bond (C16UN) in 
combination with DOPE had gready superior transfection compared to all other 
formulations (Figure 4.10), and gave ~20-fold better higher transgene expression than 
Lipofectin. In virtually all formulations, the presence of DOPE enhanced transfection.
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Figure 4.10 Screening o f DO TM A analogues on human primary fibroblasts. Cells were transfected with pCI-Luc and peptide 
6 at +7 charge ratio. A series of DOTMA analogues with chain lengths of 10-18 carbon atoms, with or without an unsaturated 
double bond at position X, and with or without the neutral lipid DOPE, were compared with Lipofectin. The Lipofectin:DNA ratio 
was 0.75:1, while the lipid:DNA weight ratio of the analogues was 2:1 or 4:1. Cells were analysed by luciferase assay 24 hours after 
transfection and the error bars represent the standard deviation from six transfection wells. Representative data is shown.
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The unsaturated lipids in the presence of DOPE showed increasing transfection with 
increasing chain length between C l2 to Cl 6, but transgene expression reduced when chain 
length was extended to Cl 8. In the absence of DOPE, the unsaturated lipids still 
mediated some transgene expression, but the presence of DOPE generally further 
enhanced transfection. C16UN plus DOPE at a lipid:DNA ratio of 2:1 repeatedly gave 
the highest luciferase expression.
The series of saturated lipids in the presence of DOPE showed a trend of increasing 
transfection with increasing chain length. In the presence of DOPE, a lipid:DNA ratio of 
2:1 generally gave higher luciferase expression than a lipid:DNA ratio of 4:1. Luciferase 
activity was virtually undetectable using the saturated lipids in the absence of DOPE 
except in the C12SAT lipid.
However, when C16UN + DOPE was compared with Lipofectin some weeks later, the 
same 20-fold increase in luciferase expression could not be observed over several 
experimental replicates, and transgene expression was equivalent to that mediated by 
Lipofectin. This could be due to the lipid oxidising, so new batches of C16UN + DOPE 
were tested. Again, it was not possible to replicate the 20-fold improvement of 
transfection that had been observed previously, and only marginal enhancement of 
luciferase expression was achieved compared to Lipofectin. Due to this inconsistency, it 
was decided to continue using Lipofectin for the following experiments.
4.2.3.3 Maintenance of Transgene Expression
Transfection with synthetic vectors is inherently transient, as the gene is not incorporated 
into the host genome. One factor determining how rapidly transgene expression is lost is 
the rate at which the cells divide, as the amount of plasmid will be shared between each
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daughter cell. Primary human fibroblasts divide more slowly than many immortalised cell 
lines, so it was of interest to investigate the duration of transgene expression, which was 
determined by transfecting the cells with GFP and analysis by FACS.
Human fibroblasts were transfected with pEGFP-Nl using Lipofectin and peptide 
VYARSMN at a charge ratio of +7. Transfected cells were analysed by FACS, which 
showed the transfection efficiency to be 34% 48 hours post-transfection (Figure 4.11A). 
This is high for primary cells transfected with a synthetic vector, when compared with 
<5% for primary A/J DC or primary A/J dermal fibroblasts or 40% for primary human 
umbilical vascular endothelial cells (M. Jacobsen, personal communication). It is also 
higher than the efficiency achieved in some cell lines such as the human SHSY5Y NB cell 
line that demonstrated 25% transfection efficiency (E. Siapati, PhD thesis, 2001). Eight 
days after transfection 28% of human fibroblasts were GFP-positive, and 14 days post­
transfection, 19% were GFP-positive.
4.2.3.4 Cytokine Expression by Transfected Hum an Fibroblasts
To determine if cytokine expression could be maintained, cells were transfected with pCI- 
IL-2 or pCI-IL-12 alone, or co-transfected with both plasmids using peptide VYARSMN 
and Lipofectin at a charge ratio of +7. Conditioned supernatant was harvested over 24- 
hour periods and analysed by ELISA (Figure 4.11B). Expression of both cytokines was 
maximal one day after transfection. The levels of IL-12 expression were similar between 
singly and co-transfected cells. IL-12 expression peaked at ~155ng/24h/106 cells 24 hours 
after transfection, then fell steadily to 11.5ng/24h/106 cells and 9.6ng/24h/106 cells for 
singly and co-transfected cells respectively 14 days after transfection.
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Figure 4.11 Maintenance of transgene expression by primary human dermal 
fibroblasts. (A) Cells were transfected with pEGFP-Nl using peptide VYARSMN 
at a charge ratio of +7 and analysed by FACS 2, 8 and 14 days post-transfection. 
Viable cells were gated on forward and side scatter characteristics and 10,000 live 
events were captured. (B) Cells were transfected with pCI-IL2 or pCI-IL12 alone 
(solid lines), or co-transfected with pCI-IL2 and pCI-IL12 (dotted lines). 
Conditioned supernatant was harvested over 24-hour periods and analysed by 
sandwich ELISA. Representative data is shown.
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Expression of IL-2 from singly transfected cells peaked at 180ng/24h/106 cells, while co­
transfected cells peaked at 56ng/24h/106 cells. Expression levels declined rapidly to 
<3ng/24h/106 cells for either singly or co-transfected cells by 9 days after transfection, 
and trace levels could just be detected 14 days following transfection (1.2ng/24h/106 cells 
for singly transfected cells and 0.52ng/24h/106 cells for co-transfected cells).
4.3 D iscussion
Primary autologous tumour cells from patient biopsies can be difficult to manipulate in 
culture or sufficient tumour cells may not be available, limiting their use as cancer 
vaccines. An alternative approach would be to use fibroblasts transfected to express pro- 
inflammatory cytokines. Therefore, the aims of the work in this chapter were to optimise 
the LPD vector for the transfection of murine and human fibroblasts and determine the 
expression of IL-2 and IL-12 mediated by the optimised vector.
Two syngeneic types of fibroblast were considered for potential use in a NB vaccine; 
primary A/J dermal fibroblasts and a mouse embryonic fibroblast line, AJ3.1, which was 
established from a 13.5dpc A/J embryo. The allogeneic fibroblasts assessed as a vaccine 
were NIH-3T3 fibroblasts, which are derived from out-bred NIH-Swiss mice.
Initially transfection of A/J primary fibroblasts, AJ3.1 and NIH-3T3 cells with the LPD 
vector was optimised and compared with N2a cells. Peptide 6 was the optimal peptide for 
A/J primary fibroblasts and NIH-3T3 cells. For transfection optimisation of AJ3.1 cells, a 
series of targeting peptides identified by phage display was available to compare with the 
integrin-targeting peptide 6. These new peptides were incorporated into the cyclic head 
group of the targeting peptide attached to the |K]16-DNA-condensing tail. A novel
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peptide, VYARSMN, which targets an unknown receptor, mediated optimal transfection 
in AJ3.1 cells, and was used in subsequent transfections.
Transfections with GFP determined the transfection efficiency of the optimal LPD vector 
in each fibroblast population. A/J primary dermal fibroblasts had a transfection efficiency 
of <5%. In comparison the fibroblast cell lines showed consistently much higher 
transfection efficiencies of >20% for AJ3.1 cells and ~45% for NIH-3T3, which is 
consistent for other cell lines transfected with the LPD vector. The human NB lines 
SHSY5Y and IMR-32 showed transfection efficiencies of 25% and 55% respectively, and 
N2a cells transfect with an efficiency of 40% (E. Siapati, PhD thesis, 2001).
An advantage of the LPD vector is that transfection of two genes can be easily achieved 
by one vector. Fibroblasts were co-transfected with the IL-2 and IL-12 genes using their 
respective optimal LPD formulations, and cytokine expression was compared with 
transfected N2a cells, which express quantities of cytokine that mediate antitumour effects 
against established NB tumours (Siapati et al., 2003). Autologous A/J primary dermal 
fibroblasts expressed undetectable levels of IL-2 and very low amounts of IL-12 that were 
substantially below the levels secreted by cytokine-transfected N2a cells. However, the 
AJ3.1 fibroblasts and NIH-3T3 fibroblasts expressed high levels of cytokine when 
transfected with pCI-IL2 and pCI-IL12, which were equivalent to the cytokine-transfected 
N2a cells, and were higher than mediated by other synthetic vectors (Chong et al., 1998; 
Lode et al., 1999; Larchian et al., 2000; Pertl et al., 2001). Furthermore, cytokine expression 
was superior to retroviral and HSV expression systems (Duda et al., 2000; Tahara et al., 
1995; Arienti et al., 1994; Toda et al., 2000) and comparable to the high levels achieved with 
adenoviral vectors (Emtage et al., 1999).
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Transfection of human primary dermal fibroblasts showed that, as with the murine AJ3.1 
fibroblasts, peptide VYARSMN consistently gave the highest luciferase expression. Cell 
surface variation between individuals may affect the targeting and transfection of the LPD 
vector. However, transfection efficiency of primary fibroblasts from two donors was 
similar, suggesting the LPD vector is not specific to individuals and will transfect cells 
from different donors, which is important in the development of autologous vaccines.
The next parameter optimised was the lipid component. At this point in the project, a 
series of DOTMA analogues became available as part of a collaboration (H. Hailes, 
Department of Chemistry, UCL), and these were compared to Lipofectin. The 
C16UN+DOPE formulation at a 2:1 weight ratio with DNA initially showed the highest 
luciferase expression, ~20-fold higher than Lipofectin at the standard 0.75:1 DNA weight 
ratio. Under identical experimental conditions, this result was replicated, although in 
following experiments, results were inconsistent. However, it shows in principle that 
different lipids have the potential to considerably improve transfection and further lipid 
development may further enhance transgene expression by LPD vectors. The 
C16UN+DOPE lipid’s initial improvement of transfection may be mediated by reducing 
endosomal DNA degradation, perhaps by fusing more rapidly with the endosome 
membrane than Lipofectin, releasing the peptide and DNA before it has been degraded.
Transfection efficiency of human primary fibroblasts was assessed by transfection with 
GFP, and peaked at >30% two days after transfection. 19% of cells remained GFP- 
positive 14 days post-transfection, demonstrating that a non-integrating synthetic vector 
can mediate sustained gene expression in human primary fibroblasts.
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IL-2 and IL-12 production by human fibroblasts peaked 24 hours after transfection, and 
encouragingly, expression could still be detected 14 days later. The amount of IL-2 
secreted by these cells compared well with retrovirally transduced autologous dermal 
fibroblasts used in a phase I trial that delivered up to 800 units (up to 30.4ng) of IL-2 
(Sobol et al., 1999). Increases in tumour CTL precursors were observed in some patients 
(Sobol et al., 1999), suggesting that the IL-2 levels achieved by LPD transfection are 
sufficient to mediate immunological responses. The IL-12 levels achieved in human 
fibroblasts with LPD transfection were also equivalent to those observed in primary 
human fibroblasts retrovirally transduced to express IL-12 (Park et al., 1997). The 
subsequent phase I trial by the same group administered fibroblasts expressing doses of 
IL-12 of up to 5000ng /24h by increasing the number of fibroblasts inoculated (Kang et 
al., 2001), a strategy easily applied to LPD-transfected fibroblasts.
Although IL-2 and IL-12 expression could be detected for 14 days in the LPD-transfected 
fibroblasts, after 4 days secretion of IL-2 decreased to around a tenth of peak expression, 
while IL-12 expression decreased by more than 50%. There is evidence that IL-2 can 
switch off some viral promoters, including CMV, (Spack and Sorgi, 2001) and thus highly 
active mammalian promoters such as the chicken P-actin (CBA) promoter may prolong 
expression of the transfected cytokine genes. Alternatively, changes to the cytokine gene 
itself may augment expression. The 3’ UTR of most cytokine genes contain AU-rich 
elements, which confer mRNA instability. Deletion of this region was shown to 
significantly increase expression of several human and murine cytokines in murine cell 
lines, murine skin and serum, and human primary lymphocytes (Yang et al., 2004).
Autologous dermal fibroblasts retrovirally-transduced to express cytokines have been used 
in phase I trials to treat adult solid malignancies (Sobol et al., 1999; Kang et al., 2001) as an
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alternative cytokine delivery “vehicle” to gene-modified primary tumour cells. The 
availability of a population of pure primary tumour cells, together with the difficulty of 
expanding and manipulating these cells in culture limits their use in vaccines. However, 
dermal fibroblasts may overcome the problems associated with primary tumour cells. 
They are straightforward to culture from skin explants, and as shown in these experiments 
are readily transfected with synthetic vectors to co-express two cytokines at levels 
comparable to viral gene transfer systems.
Clinically, it may be advantageous to develop cytokine-expressing bystander allogeneic cell 
lines to treat all patients, removing the need to culture cells from individual patients. 
These bystander lines could be mixed with unmodified autologous tumour, circumventing 
the need to modify autologous cells, while providing pro-inflammatory cytokines in the 
presence of tumour antigen. The allogeneic cells themselves may mediate inflammatory 
reactions, enhancing tumour rejection. A phase I trial of GM-CSF-expressing allogeneic 
pancreatic tumour cells to treat pancreatic adenocarcinoma showed systemic antitumour 
immune responses against autologous tumour and increased disease-free survival time in 
some patients (Jaffee et al., 2001). However, the host adaptive immune response against 
the allogeneic cells may prevent repeated dosing, limiting the use of this method.
In conclusion, human primary dermal fibroblasts can be transfected with high efficiency, 
using the LPD vector and cytokines are expressed at comparable levels to cells transduced 
with retroviral vectors. LPD-transfected syngeneic and allogeneic murine fibroblast lines 
expressed levels of cytokine that have previously been shown to mediate therapeutic 
immunological effects in vivo and cytokine expression was maintained for several days in 
both cell types. Furthermore, these levels are equivalent or superior to those mediated by 
several types of viral vector. Therefore they may provide a suitable alternative to
171
Chapter 4
autologous cytokine-transfected tumour cell vaccines and will be tested in the treatment of 
experimental murine NB tumours in vivo using the A/J mouse model.
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5.1 In t r o d u c t io n
The model of neuroblastoma used in this project is the A/J mouse and syngeneic Neuro- 
2a (N2a) neuroblastoma cell line, and is acknowledged to be a good model of the disease, 
as described in chapter 1 (section 1.7).
The therapeutic effectiveness of IL-2 and IL-12 expressing N2a cells, reducing 
tumourigenicity and mediating regression of established tumours with this model has been 
demonstrated previously (Siapati et al.y 2003). The following experiments were conducted 
to compare the antitumour efficacy of N2a cells and fibroblasts, each co-transfected with 
IL-2 and IL-12. Initially, the amount of IL-2 and IL-12 required to prevent tumour 
engraftment was titrated in vivo using transfected N2a cells. This will also clarify whether 
the cytokine-transfected murine fibroblasts are expressing sufficient IL-2 and IL-12 to 
mediate therapeutic effects.
Tumourigenicity experiments were performed to investigate the ability of cytokine- 
transfected fibroblasts (allogeneic and syngeneic) to inhibit the development of wild-type 
NB tumours, and eradication experiments studied whether cytokine-transfected fibroblasts 
(syngeneic only) were able to mediate regression of established NB tumours. In vitro 
investigation of immune memory responses was also explored.
5.2 Resu lt s
5.2.1 In vivo cytokine dosing
IL-2 and IL-12 transfected N2a cells express levels of cytokine that prevent engraftment 
of N2a tumour cells in A/J mice (Siapati et al.y 2003). However, the actual threshold of IL- 
2 and IL-12 required to prevent tumour engraftment in this model had not been
174
Chapter 5
established. Determination of these levels would confirm whether cytokine production 
from the murine fibroblasts is above the threshold required for stimulation of immune 
responses in vivo.
5.2.1.1 Effect of cytokine dose on N2a tumourigenicity
To determine the cytokine concentration necessary to prevent tumour engraftment, a 
tumourigenicity experiment was performed. Groups of mice were inoculated 
subcutaneously with 106 wild type N2a together with 103-106 cytokine-transfected N2a as a 
single vaccine (n=6 per group). A control group (n=6) received wild type N2a only. The 
maximum amount of cytokine expressed was 2350ng IL-12 + 400ng IL2/24h from 106 
N2a transfectants, down to a minimum of 2.3ng IL-12 + 0.4ng IL-2/24h by a dose of 103 
transfected N2a cells. Mice were monitored every 2-3 days for tumour engraftment.
The mice receiving the highest dose of 106 transfected cells (2350ng IL-12 + 400ng IL- 
2/24h) were fully protected against tumour engraftment for over 30 days. The mice 
receiving 10s cells corresponding to 235ng IL-12 + 40ng IL-2/24h, and therefore only one 
tenth of the amount of each cytokine, remained tumour free for up to 30 days, when one 
of six mice developed a tumour (Figure 5.1A). Mice receiving 5xl04 transfected N2a cells 
corresponding to 118ng IL-12 + 20ng IL-2/24h protected 83% (5 of 6) mice from tumour 
engraftment until day 30, when a second mouse developed a tumour. Even a dose of 
23.5ng IL-12 + 4ng IL-2/24h, which is 100-fold less than the maximum dose, was 
sufficient to prevent tumour engraftment in 50% of mice for over 30 days. All control 
mice had developed tumours within 11 days.
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 235ng YLr\2 + 40ng IL-2
 118ng H^12 + 20ng EL2
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Figure 5.1 In vivo titration of cytokine dose required to inhibit tumour 
engraftment. (A) Mice (n=6 per group) received one vaccination s.c. into the left 
flank containing 106 wild type N2a cells in combination with 106-103 cytokine- 
transfected N2a cells corresponding to different doses of cytokine, as shown in the 
graph legend. Control mice received N2a cells only. Mice were checked for tumour 
engraftment every 2-3 days and a dose-dependent response can be observed.
(B) Five tumour free mice from the two highest cytokine dose groups were 
subsequendy rechallenged with 106 wild type N2a cells in the opposite flank from the 
original vaccination. Control mice received N2a cells only and mice were checked for 
tumour growth every 2-3 days. Mice receiving the highest cytokine dose appeared to 
have slighdy superior systemic antitumour immunity.
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5.2.1.2 Effect of cytokine dose on systemic immunity
Five of six mice in each group that received the two highest doses of IL-2 and IL-12- 
expressing N2a cells remained tumour free seven weeks after inoculation. These tumour- 
free mice were rechallenged with 106 wild type N2a cells in the opposite flank to determine 
if systemic immunity to N2a cells had been established. Two of five mice (40%) which 
initially received the highest cytokine dose remained tumour free. One of five mice (20%) 
receiving the next highest cytokine dose also remained tumour free (Figure 5.1B) 
demonstrating that antitumour immunity had been established in a proportion of the mice. 
These mice remained tumour free for over 35 days. Mice that developed tumours did not 
show any substantial delay in tumour engraftment or growth compared to controls.
5.2.2 Allogeneic Fibroblasts
5.2.2.1 Tumourigenicity experiment using irradiated NIH-3T3 cells
Previous work has shown that injection of 106 wild-type N2a cells consistently results in 
tumour engraftment in 100% of animals in the absence of any therapeutic intervention (E. 
Siapati, PhD thesis, University of London, 2001), and this cell dose was used for all in vivo 
experiments. live N2a cells in RPMI were injected alone or in combination with either 
106 irradiated wild-type NIH-3T3 cells, 106 irradiated NIH-3T3 cells transfected with 
empty vector (pCI) or 106 irradiated NIH-3T3 cells transfected with pCI-IL2 and pCI- 
scIL12 s.c. Cytokine expression of transfected cells is shown in appendix 5A.
It was hypothesised that all the mice except those receiving the NIH-3T3-IL2-IL12 cells 
would develop tumours. However, all the groups of NIH-3T3 cells appeared to exert a 
non-specific antitumour effect whether the NIH-3T3 cells were untransfected, transfected 
with empty vector or transfected with cytokine genes as virtually all the mice receiving
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these cells failed to develop tumours. All control mice receiving only N2a cells developed 
aggressive tumours within 10 days (Figure 5.2).
83% of mice receiving irradiated NIH-3T3 cells and 100% of mice receiving NIH-3T3- 
pCI and NIH-3T3-IL2-IL12 remained tumour-free for over 40 days (Figure 5.3). Any 
mass that was palpable under the skin was investigated by dissection, and appeared to be 
avascular fibrous, scar-like tissue. No tumour tissue was detectable in the mice injected 
with the NIH-3T3 vaccines, with the exception of one mouse in the untransfected NIH- 
3T3 group. The growth of this tumour was delayed by 14 days.
5.2.2.2 Tumourigenicity experiment using live NIH-3T3 cells
To establish if the presence of apoptotic irradiated NIH-3T3 cells caused the failure of 
engraftment of the N2a cells, the experiment was repeated, with live, non-irradiated NIH- 
3T3 cells. Again, all mice were inoculated with 106live wild type N2a cells in combination 
with 106 cytokine-transfected N2a, 106 unmodified NIH-3T3 cells, 106cytokine-transfected 
NIH-3T3 cells. Control mice received N2a only. The cytokine-transfected N2a group 
was included as a control for tumour rejection. The NIH-3T3-pCI group was omitted to 
reduce the number of mice required.
All mice in the control group that received N2a cells only rapidly developed aggressive 
tumours. The mice which received N2a cells plus unmodified NIH-3T3 cells did not 
develop tumours, but had small lumps under the skin at the injection site which were 
revealed by dissection to resemble fibrous scar tissue. This fibrous tissue was also present 
in the mice receiving the cytokine-transfected NIH-3T3 cells, except for one mouse which 
developed a highly-vascularised, wild-type tumour similar to that observed in control mice. 
All of the mice receiving the combination of wild-type N2a plus cytokine-transfected N2a
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Figure 5.2 Tumourigenicity of N2a cells when co-administered with irradiated 
allogeneic NIH-3T3 fibroblasts. (A) Schematic representation of experimental 
protocol. NIH-3T3 cells were transfected in vitro with pCI-IL2 and pCI-IL12 or empty 
pCI vector. The following day animals (n=6 per group) were injected s.c. in the left flank 
with 106 live wild-type N2a plus 106 irradiated transfected or untransfected NIH-3T3 cells. 
Control animals received 106 live N2a only.
(B) Tumour growth curves for each experimental group. Each line represents one 
mouse. Tumours were measured every 2-3 days with calipers and tumour volume 
calculated from two perpendicular axes.
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Figure 5.3 Pooled data of experimental groups in the irradiated allogeneic 
NIH-3T3 tumourigenicity experiment. Percentage of tumour free mice in each 
experimental group (n=6). All control animals developed tumours by day 10, while 
83% of mice receiving irradiated untransfected NIH-3T3 and 100% of mice receiving 
irradiated NIH-3T3 cells transfected with cytokines or empty plasmid remained 
tumour free for over 40 days.
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cells failed to develop any tumours (Figure 5.4). One mouse that received cytokine- 
transfected NIH-3T3 cells developed a tumour on day 13, although the onset of tumour 
engraftment was delayed compared with control mice which had developed tumours by 
day 8 (Figure 5.5). The remaining 83% (5 out of 6) mice in this group, and 100% of mice 
in the untransfected NIH-3T3 group and cytokine-transfected N2a group remained 
tumour free for over 40 days.
The tumour rejection pattern showed many similarities to the previous experiment, with 
virtually all mice vaccinated with NIH-3T3 failing to engraft N2a-derived tumours, 
regardless of whether or not the NIH-3T3 cells were secreting cytokines. This makes the 
use of allogeneic fibroblasts a poor model for therapeutic treatment of murine NB, as it is 
not possible to delineate any effect of the cytokines from the non-specific allogeneic 
effect.
5.2.3 Syngeneic Fibroblasts
5.2.3.1 Tumourigenicity experiment using live transfected AJ3.1
As allogeneic fibroblasts were not suitable for demonstrating a cytokine-mediated anti­
tumour immune effect, it was decided to proceed with syngeneic fibroblasts. For these 
experiments the AJ3.1 cell line derived from A/J embryos was used, which was shown to 
secrete high amounts of cytokine when transfected with the LPD vector. To determine 
whether cytokine-expressing AJ3.1 fibroblasts could prevent engraftment of N2a derived 
tumours, tumourigenicity experiments were performed (Figure 5.6A). Mice (n=6 per 
group) received one subcutaneous injection containing 106 wild-type N2a together with 106 
wild-type AJ3.1,106 AJ3.1-IL2-IL12 or 106 N2a-IL2-IL12. Control mice received 106N2a 
only. The untransfected AJ3.1 group was included to determine whether the fibroblasts 
themselves exerted a protective effect, and the transfected N2a group was included as a
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F igure 5.4 T um ourigen icity  o f  N 2 a  ce lls w h en  co-adm in istered  w ith  live a llogen eic  
N IH -3 T 3  fibroblasts. (A) Schematic representation of experimental protocol. NIH-3T3 
cells or N2a cells were transfected in vitro with pCI-IL2 and pCI-IL12. The following day 
animals (n=6 per group) were injected s.c. in the left flank with 106 live wild-type N2a plus 
106 live cytokine-transfected N2a cells, 106 live cytokine-transfected NIH-3T3 or 106 live 
wild-type NIH-3T3 cells. Control animals received 106 wild-type N2a only.
(B) Tumour growth curves for each experimental group. Each line represents a single 
mouse. Tumours were measured every 2-3 days with calipers and tumour volume 
calculated from two perpendicular axes.
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Figure 5.5 Pooled data of experimental groups from the live allogeneic NIH- 
3T3 tumourigenicity experiment. Percentage of tumour free mice in each 
experimental group (n=6). All control animals had developed tumours by day 8, while 
83% of mice receiving cytokine-transfected NIH-3T3 cells and 100% of mice receiving 
untransfected NIH-3T3 cells or cytokine-transfected N2a cells remained tumour free 
for over 40 days.
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control for prevention of engraftment. Cytokine expression of transfected cells used for 
these vaccinations is shown in appendix 5C.
The vaccines containing cytokine-transfected AJ3.1 or cytokine-transfected N2a cells 
prevented tumour engraftment in 5 of 6 (83%) mice in each group, demonstrating the 
AJ3.1 fibroblast vaccine was as effective as the N2a tumour cell vaccine in inhibiting 
tumour engraftment (Figure 5.6B, Figure 5.7). Aggressive tumours developed rapidly in 
all mice in the N2a-only control group, and all mice in the N2a + wild-type AJ3.1 group 
showed equivalent rapid development of tumours, demonstrating that fibroblasts alone did 
not have a protective effect. Tumour engraftment in the single mouse that developed 
tumour in the AJ3.1-IL2-IL12 group was delayed until day 22, compared with tumour 
engraftment by day 7 in control mice. In the N2a-IL2-IL12 group, a single mouse 
developed a tumour by day 30, compared with day 7 in control mice. The remaining 83% 
of mice in each of these groups remained tumour free for over 40 days.
5.2.3.2 Tumourigenicity experiment using irradiated transfected AJ3.1
Many clinical protocols state that cytokine-transfected cells would be irradiated before 
being administered to the patient. To establish if the tumour protective effect 
accomplished with live cells could be achieved with irradiated cells, the tumourigenicity 
experiment was repeated using irradiated cytokine-transfected AJ3.1 cells. Irradiation with 
2500 rads, has previously been shown to halt the growth of cytokine-transfected N2a cells, 
while cytokine expression is maintained until the cells undergo apoptosis after ~7 days (E. 
Siapati, PhD thesis, University of London, 2001). Therefore, the same dose of y-radiation 
was administered to cytokine-transfected AJ3.1 cells. Preliminary in vitro assay showed that 
irradiated cytokine-transfected AJ3.1 expressed equivalent levels of cytokine to transfected 
live AJ3.1 (appendix 6). Also, as one mouse in each therapeutic group in the previous
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Figure 5.6 Tumourigenicity of N2a cells when co-administered with live 
syngeneic AJ3.1 fibroblasts. (A) Schematic representation of experimental protocol. 
AJ3.1 and N2a cells were transfected in vitro with pCI-EL2 or pCI-IL12. The following 
day animals (n=6 per group) were injected s.c. in the left flank with 106 live wild-type 
N2a plus either 106 cytokine-transfected N2a cells or 106 unmodified or cytokine 
transfected AJ3.1 cells. Control animals received 106 live N2a cells only.
(B) Tumour growth curves for each experimental group. Each line represents one 
mouse. Tumours were measures every 2-3 days with calipers and tumour volumes 
calculated from two perpendicular axes.
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Figure 5.7 Percentage tumour free m ice when wild-type N2a cells are co­
administered with live AJ3.1 syngeneic fibroblasts. Percentage of tumour 
free mice when live N2a cells were co-administered with wild-type AJ3.1, 
cytokine-transfected AJ3.1 or cytokine-transfected N2a cells (n=6 per group).
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experiment using live AJ3.1 cells had succumbed to a growing tumour, a group receiving a 
higher dose of transfected cells was included to see if this could prevent tumour 
engraftment in 100% of vaccinated mice.
In this second tumourigenicity experiment, mice (n=6 per group) received 106 wild type 
N2a together with either 2xl06 irradiated AJ3.1-IL2-IL12 or 106 irradiated AJ3.1-IL2-IL12 
in a single injection inoculated s.c. into the left flank (Figure 5.8A). Control mice received 
106 wild-type N2a only. Cytokine expression by transfected cells is shown in appendix 5D.
Figure 5.8B shows that the mice receiving cytokine-expressing irradiated AJ3.1 cells 
demonstrated a substantial reduction in tumour engraftment compared to control mice, 
which all rapidly developed aggressive tumours. There also appeared to be a dose effect, 
as 4 of 6 mice receiving lx l06 AJ3.1-IL2-IL12 developed tumours, while 2 of 6 mice in the 
group receiving 2xl06 AJ3.1-IL2-IL12 developed tumours. Once established, these 
tumours grew aggressively, with similar kinetics to those in control mice. However, the 
engraftment of tumours in mice receiving cytokine-transfected AJ3.1 cells was delayed 
compared to control mice receiving N2a cells only (Figure 5.9). All mice in the 
therapeutic groups remained tumour-free until 14 days following engraftment, while 5 of 6 
control mice (83%) had developed tumours 14 days after engraftment. On day 14, 2 of 6 
mice in the lxlO6 AJ3.1-IL2-IL12 group, and 1 of 6 mice in the 2xl06 AJ3.1-IL2-IL12 
group developed a tumour, which grew rapidly requiring culling of the animals. No more 
tumours developed until 35 days after engraftment, when another 2 mice in the lxlO6 
AJ3.1-IL2-IL12 group developed tumours, and 41 days after engraftment, one mouse in 
the 2xl06 AJ3.1-IL2-IL12 group developed a tumour. Again, once engrafted, these 
tumours developed aggressively, requiring culling of the animals.
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Figure 5.8 Tumourigenicity of N2a cells when co-administered with irradiated 
syngeneic AJ3.1 fibroblasts. (A) Schematic representation of experimental 
protocol. AJ3.1 cells were transfected in vitro with pCI-IL2- and pCI-IL12. The 
following day the AJ3.1 cells were irradiated with 2500 rads and animals (n=6 per 
group) were injected s.c. in the left: flank with 106 live wild-type N2a cells plus lxlO6 
or 2xl06 irradiated cytokine-transfected AJ3.1 cells. Control animals received 106 live 
N2a cells only.
(B) Tumour growth curves for each experimental group. Each line represents one 
mouse. Tumours were measured every 2-3 days with calipers and tumour volumes 
calculated from two perpendicular axes.
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Figure 5.9 Percentage tumour free mice when wild-type N2a cells are co­
administered with irradiated AJ3.1 syngeneic fibroblasts. Percentage of tumour 
free mice when live N2a cells were co-administered with two different doses of IL-2 
and IL-12 co-transfected AJ3.1 cells. (n=6 animals per group).
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The irradiated vaccine did not appear to be as effective as the live vaccine as 4 of 6 mice 
receiving 106 irradiated AJ3.1-IL2-IL12 developed tumours (Figure 5.8B), compared with 
1 of 6 mice developing a tumour in the group receiving 106 live AJ3.1-IL2-IL12 in the 
previous experiment (Figure 5.6). Moreover, 2 of 6 mice receiving 2x106 irradiated AJ3.1- 
IL2-IL-12 developed tumour, compared with 1 of 6 mice developing a tumour in the 
group receiving 106 live AJ3.1-IL2-IL12 in the previous experiment.
5.2.3.3 Rechallenge with wild-type N2a cells
It was important to determine if long-term systemic immunity to N2a-derived tumours 
had been established in the mice that had rejected N2a cells in the tumourigenicity 
experiments. There is a clinical relevance to the ability of mice to reject tumour cells when 
treatment is no longer being administered, as one goal of immunotherapy is to establish 
systemic protective immunity which can recognise and destroy tumour cells to prevent the 
formation of solid tumours. This experiment is a model for the reoccurrence of malignant 
cells at a site distant to that of the primary tumour.
The five remaining tumour free mice from the N2a-IL2-IL12 and AJ3.1-IL2-IL12 groups 
in the first AJ3.1 tumourigenicity were rechallenged seven weeks after the initial 
vaccination with 106 wild type N2a in the opposite flank to see if immune memory had 
been established. Naive mice (n=5) which had no prior exposure to tumour cells were 
included as a control for the engraftment potential of the wild-type N2a cells.
Two out of five mice (40%) from each of the N2a-IL2-IL12 and AJ3.1-IL2-IL12 groups 
remained tumour free for four weeks after the rechallenge vaccinations (Figure 5.10A), 
suggesting evidence of systemic immune memory. The three mice from each group that 
did develop tumours showed similar kinetics of tumour growth to the naive mice
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Figure 5.10 Effect of cytokine-transfected fibroblasts compared with cytokine- 
transfected N2a cells to generate systemic anti-tumour immunity against wild- 
type N2a cells. (A) Mice that remained tumour free 7 weeks after the vaccination 
with cytokine-transfected AJ3.1 or cytokine-transfected N2a cells were rechallenged 
with 106 wild-type N2a in the opposite flank from the initial vaccination. Control 
naive mice received N2a cells only (n=5 animals per group). Tumour progression 
was monitored.
(B) Tumour growth curves for each experimental group. Each line represents one 
mouse. Tumours were measured every twice per week with calipers and tumour 
volumes were calculated from two perpendicular axes.
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engrafted with wild type N2a cells (Figure 5.10B), suggesting insufficient systemic 
immunity.
5.2.3.4 In vitro evidence of immune memory
To characterise the antitumour immunity in the tumour-free mice, in vitro assays were 
performed to investigate cellular immune responses against wild-type N2a cells. The two 
mice from each group (two from the N2a-IL2-IL12 group and two from the AJ3.1-IL2- 
IL12 group) that remained tumour free four weeks after rechallenge were sacrificed, and 
splenocytes used in ELISpot assays to assess the production of pro-inflammatory 
cytokines in response to N2a cells. Lactate dehydrogenase (LDH) release assays were 
performed to assess cytotoxic responses against wild-type N2a cells. The responses of 
these mice were compared with two mice that had not developed a tumour after the 
primary immunisation, but had succumbed to secondary tumour after rechallenge. Further 
comparisons were made with two mice which developed primary tumours following 
engraftment with wild-type N2a cells and two naive control mice that had no prior 
exposure to N2a cells.
5.2.3.4.1 ELISpot
ELISpot assays to detect IL-2 and IFN-y secreting splenocytes were performed to 
determine if splenocytes produced pro-inflammatory cytokines in response to co-culture 
with syngeneic wild-type N2a cells. Splenocytes were co-cultured with irradiated N2a in 
96-well plates cells at effector (E):target(T) ratios of 100:1, 50:1, 20:1 and 10:1 in triplicate 
where sufficient cells were available. All experimental wells contained 5x103 N2a cells. 
Positive control wells contained splenocytes co-cultured with 5pg/ml Concanavalin A 
(ConA), negative wells contained splenocytes only. Cells were incubated overnight at
192
Chapter 5
37°C before being transferred to ELISpot plates pre-coated with capture antibody and 
incubated for a further 24 h at 37°C. Plates were developed and analysed.
Due to high background staining on the IFN-y plate, quantification using the plate reader 
was not possible. The IL-2 plate had clearer, well-defined staining that was quantified 
using a plate reader. The positive control wells showed very dense spots, confirming the 
splenocytes were functional, and very few spots were present in negative control wells, 
indicating there was litde non-specific splenocyte activation. The E:T ratio of 100:1 gave 
the clearest result for every animal tested, so all results discussed refer to this E:T ratio.
A striking difference was seen between the IL-2 production from naive mice and those 
that had rejected tumour (Figure 5.11A). The number of spots present in the wells 
containing splenocytes from naive mice were ~3-fold lower (32 ± 6.8 spots) than any wells 
that contained splenocytes from mice that had been exposed to tumour cells. The number 
of spots from mice that had developed primary tumours following engraftment with wild- 
type N2a cells (105 ± 11.6 spots) was equivalent to those that had rejected engraftment of 
wild-type N2a cells when co-administered with AJ3.1-IL-2-IL12 but succumbed to 
secondary tumour following rechallenge with wild-type N2a cells only (100 ± 7.2 spots). 
Mice that had rejected the primary challenge of wild-type N2a cells co-administered with 
AJ3.1-IL2-IL12 or N2a-IL2-IL12 and also the subsequent challenge of wild-type N2a cell 
only, also showed equivalent numbers of spots, with 109 ± 11.1 spots from mice receiving 
the N2a-IL2-IL12 vaccine and 109 ± 6.7 spots from mice receiving the AJ3.1-IL2-IL12 
vaccine (Figure 5.11B). All mice exposed to tumour cells had significantly greater IL-2 
expression compared to naive control mice (p<0.001 for all groups).
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Figure 5.11 In vitro evidence o f immune memory in vaccinated m ice with IL-2 
ELISpot. Wild-type N2a cells were co-cultured with splenocytes isolated from naive 
mice, control tumour bearing mice (1° tumour), mice which had developed tumour 
following rechallenge (2° tumour) and tumour-protected mice which rejected 
rechallenge (N2a-2/12 and AJ3.1-2/12). (A) Numbers of spots representing IL-2 
secreting splenocytes were quantified using a plate reader. Wells shown are of an 
effectortarget ratio of 100:1 and are representative for each experimental group.
(B) Average number of spots in each experimental group at the 100:1 effector:target 
ratio. Error bars represent standard deviations of six experimental wells. All mice 
exposed to tumour cells had significandy greater IL-2 expression compared to naive 
control mice (p<0.001 for all groups, calculated by t-test).
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5.2.3.4.2 LDH Release Cytotoxicity Assay
Splenocytes from groups of mice detailed above were co-incubated with irradiated N2a at 
a E:T ratio of 50:1 for 6 days in the presence of 60IU rhIL-2. CTL effectors were then 
harvested and co-incubated with live N2a at ratios of 27:1, 9:1, 3:1 and 1:1 for 5 h and 
LDH release from N2a target cells quantified and used to calculate % cytotoxicity.
Results from the 27:1 and 9:1 E:T ratios gave the clearest and most consistent results and 
are shown in Figure 5.12. Naive mice showed <2% cytotoxicity above background, and 
mice which had developed primary tumours also showed low levels of N2a lysis, with 5 ± 
6% cytotoxicity at a E:T ratio of 9:1 and 6 ± 8% cytotoxicity at a E:T ratio of 27:1. Mice 
which had rejected their first tumour but had developed tumour following rechallenge had 
an increased level of cytotoxicity with 12 ± 13% at a E:T ratio of 9:1 and 14 ± 6% at a E:T 
ratio of 27:1. Mice which rejected two tumour challenges showed the highest level of 
cytotoxicity against N2a cells. Mice vaccinated with N2a-IL2-IL12 showed target cell lysis 
of 36 ± 34% at a 9:1 E:T ratio and 34 ± 47% at a 27:1 E:T ratio. Mice vaccinated with 
AJ3.1-IL2-IL12 showed lysis of target cells 29 ± 30% at a 9:1 E:T ratio and 39 ± 41% at a 
27:1 E:T ratio (Figure 5.12). Due to the large standard deviations, the difference in 
splenocyte cytotoxicity against N2a cells between mice that rejected two tumour challenges 
and those that developed primary tumours (p>0.1) or naive mice (p<0.1 but >0.05) does 
not reach significance.
Encouragingly however, mice vaccinated with cytokine-transfected AJ3.1 fibroblasts 
mediated equivalent levels of cytotoxicity against wild-type N2a cells as the mice that 
received cytokine-transfected N2a tumour cells, demonstrating that syngeneic fibroblasts 
are capable of generating CTL responses against wild-type N2a cells.
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Figure 5.12 LD H  release assay to show in vitro splenocyte-m ediated cytotoxicity 
against N2a target cells. The ability of splenocytes to lyse N2a targets was measured 
by LDH release from N2a cells following co-culture with CTL effectors. Data showing 
average cytotoxicity values of two different effector:target ratios is representative for 
each experimental group. Error bars represent standard deviations of quadruplicate 
samples.
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5.2.3.5 Treatment of established N2a tumours with transfected AJ3.1
The following experiment was performed to investigate the anti-tumour efficacy of 
cytokine-transfected AJ3.1 fibroblasts compared with cytokine-transfected N2a cells when 
multiple doses were administered to mice with established N2a-derived tumours. Due to 
the large numbers of cells required over a three day period for this experiment, large 
batches of transfected cells were prepared to be stored at —80°C. The appropriate number 
of cells was then thawed and cultured overnight before vaccination. Previous preliminary 
assays had shown that cytokine expression was maintained following freezing down and 
subsequent reconstitution in culture (see appendix 7).
Mice (n=30) were engrafted with 106 wild type N2a cells s.c. in the left flank. A further 
group of mice (n=6) was engrafted with 106 wild type N2a cells s.c. in both flanks. 
Tumour engraftment was checked 4 days after inoculation, and transfected cells were 
thawed out from storage at — 80°C. On day 5, tumours were ~3-4 mm in diameter (range 
between lx l mm to 5x5mm) and the 30 mice engrafted with one tumour were divided into 
five groups of six mice, with a range of tumour sizes in each group.
Mice (n=6 per group) received either 106 N2a-IL2-IL12 i.t., 106 AJ3.1-IL2-IL12 i.t., 106 
AJ3.1-IL2-IL12 + 106 DC, or 106 AJ3.1-IL2-IL12 + 106 irradiated N2a. Another group 
was engrafted with a tumour on each flank, of which one was treated with 106 AJ3.1-IL2- 
IL12, to investigate if therapy of one tumour could also mediate a therapeutic effect on a 
tumour at a distant site. One group of mice received syngeneic DC in addition to AJ3.1- 
IL2-IL12 to investigate whether the presence of APCs would increase the immune 
response against the tumour cells. The group treated with AJ3.1-IL2-IL12 + irradiated 
N2a cells on the opposite flank from the tumour was a model for treating metastatic 
lesions, with the irradiated N2a cells included as a pool of tumour antigen at the vaccine
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site. Control mice received 100(4,1 RPMI i.t. Each group received three vaccines, two days 
apart (i.e. days 5, 7 and 9) (Figure 5.13A). Cytokine expression of transfected cells is 
shown in appendix 5E. Two mice from each group were culled 13 days after initial 
engraftment for in vitro analysis of splenocyte responses and tumour histology.
By day 12 post engraftment, average tumour volume of the mice vaccinated with N2a-IL2- 
IL12 i.t. was significandy lower (354 ± 172mm3; p<0.05) than tumours in control mice 
receiving RPMI (1085 ± 695mm3) (Figure 5.13B). Twelve tumours were vaccinated 
intratumourally with AJ3.1-IL2-IL12, which significandy reduced tumour volume after 12 
days (520 ± 434mm3; p<0.05) compared to controls. Of these 12 mice, 6 were engrafted 
with a single tumour that was vaccinated with AJ3.1-IL2-IL12 i.t. and a further 6 were 
engrafted with tumours on each flank, of which one was vaccinated with AJ3.1-IL2-IL12 
i.t. Intratumoural vaccination of AJ3.1-IL2-IL12 + DC also reduced tumour growth 
compared to controls, but this was not significant (802 ± 550mm3; p>0.2). The tumours 
engrafted in animals receiving transfected AJ3.1 cells in the opposite flank from the 
tumour grew at a similar rate to controls, with an average tumour volume of 965 ± 
612mm3 on day 12. However, the tumour growth in individual mice in each group shows 
more clearly the therapeutic effect of intratumoural vaccination.
Tumour growth was effectively retarded by the intratumoural vaccine of cytokine- 
transfected N2a cells, with two of six mice undergoing complete tumour regression. The 
remaining four tumours in this group grew at a reduced rate compared to controls, slowing 
disease progression, thus this vaccine had an effect on 100% of tumour bearing mice 
(Figure 5.14). Two of these four mice were culled for in vitro analysis at 13 days post- 
engraftment, but when the mice were culled, these tumours also were growing more slowly
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Figure 5.13 Average tumour growth o f different experimental groups in 
eradication experim ent. (A) Schematic representation of experimental protocol. 
Mice (n=6 per group) were engrafted with 106 wild-type N2a cells in the left flank plus 
another group (n=6) were engrafted with a tumour on each flank. Three vaccines were 
administered, each two days apart starting on day 5 after engraftment when tumour 
masses were ~3-4 mm in diameter. (B) Mice vaccinated with RPMI or those 
vaccinated with IL-2 and IL-12 expressing AJ3.1 fibroblasts in the opposite flank 
rapidly developed aggressive tumours. Data of the mice engrafted with two tumours, of 
which one was treated i.t., and the mice with a single tumour treated with AJ3.1-IL2- 
IL12 administered i.t. alone were pooled to give a group of n=12. Intratumoural 
vaccination of N2a-IL2-IL12 cells or AJ3.1-IL2-IL12 cell mediated a significant delay in 
tumour growth (p<0.05, calculated by t-test). Arrows indicated vaccine administration.
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Figure 5.14 Effect o f  vaccination with transfected AJ3.1 fibroblasts on established  
N2a-derived tumours. Tumour growth curves for each experimental group. Each line 
represents one mouse. Tumours were measured every 2-3 days with calipers and tumour 
volumes calculated from two perpendicular axes. AJ3.1-IL2-IL12 graph shows pooled 
data from mice engrafted with one tumour that was treated, and data from mice with two 
tumours, of which one was treated. Two mice from each group were culled on day 13 for 
use in in vitro assays. Arrows indicate vaccine administration.
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than controls. In the remaining two mice, tumours developed progressively but this was 
delayed by up to three weeks compared with controls.
Intratumoural cytokine-transfected AJ3.1 fibroblasts retarded tumour growth in eight out 
of twelve mice. Tumour growth was slowed for up to two weeks compared to controls in 
six tumours and a further two tumours were eradicated completely. The two tumours that 
were eradicated were in mice that were also engrafted with untreated tumours on the 
opposite flank. The progressive growth of the contralateral untreated tumour necessitated 
these mice to be culled. The mice receiving DC in addition to cytokine-expressing 
fibroblasts showed severely retarded tumour growth in two of six mice, although by day 27 
post-engraftment a tumour redeveloped at the original vaccination site in one of these 
mice. However, the tumours of the other four mice in the group grew rapidly, so did not 
appear to be responding to the vaccine. The mice receiving transfected AJ3.1 + irradiated 
N2a on the opposite flank did not show a therapeutic anti-tumour effect and tumours 
grew at the same rate as controls (Figure 5.14).
The group of mice with tumour cells engrafted on each flank demonstrated a significant 
difference (p<0.01) between the average growth of the treated tumour (342 ± 326mm3) 
and the untreated tumour (1119 ± 552mm3), clearly showing the efficacy of the AJ3.1-IL2- 
IL12 vaccine (Figure 5.15A). Examination of the tumour growth in individual mice in 
this group shows an interesting feature: in some mice showing a response to the treated 
tumour, there appears to be some level of response in the untreated tumour, although this 
is not significant (Figure 5.15B). The mice represented by the dark blue and burgundy 
lines show a substantial decrease in the growth of the treated tumour, and the untreated 
tumour also appears to develop more slowly than the tumours in control mice. This 
association was not seen in all mice as the mouse represented by the green line shows
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Figure 5.15 Effect of vaccination on tumours at a distant site. Mice (n=6) were 
engrafted with 106 wild type N2a cells on each flank. Tumours were palpable after 5 
days, and mice received three vaccinations, each two days apart, of AJ3.1-IL2-IL12 cells 
into the tumour on the left flank. (A) Comparison of average growth of treated and 
untreated tumours. Tumour volumes on each flank were equivalent at the beginning of 
the vaccination course and tumour mass on day 12 was significandy lower (p< 0.01, 
calculated by paired t-test) in the treated tumour compared to the contralateral 
untreated tumour. Black arrows indicate vaccine administration. (B) Tumour growth of 
individual mice. lines of the same colour between graphs indicate the same mouse. 
Tumours were measured every 2-3 days and volumes calculated from two perpendicular 
axes. Two mice were culled on day 13 for use in in vitro assays. Black arrows indicate 
vaccine administration, and the red arrows highlight the difference between treated and 
untreated tumours in the same mouse.
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eradication of the treated tumour, but aggressive growth of the untreated tumour. 
Nevertheless, this suggests some evidence of antitumour activity at a site distant from the 
vaccination, but the response is too weak to mediate substantial anti-tumour effect.
All the groups of mice treated with the AJ3.1-IL2-IL12 vaccine showed some reduction of 
tumour growth, but it is difficult to interpret the effect of the vaccine on survival due to 
the sacrifice of mice for in vitro assays (Figure 5.16). Larger groups would be required to 
study the effect of the fibroblast vaccine on survival. Nonetheless, one mouse in the 
group receiving AJ3.1-IL2-IL12 + DC and two mice receiving N2a-IL2-IL12 showed 
complete eradication of tumour and remained tumour free for over 70 days.
5.2.3.6 In vitro evidence of anti-tumour activity
Despite some mice in each therapeutic group developing tumours, it was important to 
determine whether immune responses were being generated against N2a cells. Therefore, 
13 days into this experiment, two mice fiom each group were culled and their splenocytes 
used for in vitro assays. Mice with regressing or slow-growing tumours were kept alive to 
determine whether tumours could be eradicated. Consequently, the mice used in the 
ELISpot and LDH release assays had progressing tumours but it was important to 
determine if these mice were raising immune responses against wild-type N2a cells.
5.2.3.6.1 ELISpot
Splenocytes were isolated from two mice per group 13 days into the experiment. ELISpot 
assays were performed to determine if splenocytes produced IL-2 and IFN-y in response 
to co-culture with wild-type N2a cells. Splenocytes were co-cultured with 5x103 irradiated 
N2a cells in 96-well U-bottomed TC plates at effector:target ratios of 100:1, 50:1, 20:1 and 
10:1. Positive control wells contained splenocytes cultured with 5fig/ml ConA, negative
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Figure 5.16 Survival o f  m ice in eradication experiment. Mice (n=6 per group) 
received three vaccinations, as indicated by arrow heads, and tumour growth was 
monitored. Two mice per group were sacrificed on day 13 for in vitro assays, and 
the tumour progression of the remaining four was followed. Two of six mice 
vaccinated with N2a-IL2-IL12 and one mouse vaccinated with AJ3.1-EL2-IL12 + 
DC remained tumour free for over 70 days.
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wells contained splenocytes only. Cells were incubated overnight at 37°C before being 
transferred to ELISpot plates pre-coated with capture antibody and incubated for a further 
24h at 37°C. Plates were developed and analysed.
Very few spots were present in negative control wells, indicating there was little non­
specific splenocyte activation, while the positive control wells showed very dense spots, 
confirming the splenocytes were functional. As in the rechallenge ELISpot assay, the 
100:1 E:T ratio gave the clearest result for every animal tested, so all data discussed refers 
to this E:T ratio and representative wells are shown in Figure 5.17A.
Splenocytes from mice receiving AJ3.1-IL2-IL12 secreted high amounts of IL-2 (123 ±
11.7 spots) and IFN-y (114 ± 15.3 spots) following co-culture with wild-type N2a cells 
(Figure 5.17B). Importantly, this level of cytokine production by splenocytes was 
equivalent to that observed from mice receiving N2a-IL2-IL12, with 128 ± 15.2 IL-2 spots 
and 120 ± 9.5 IFN-y spots. Mice with two tumours receiving AJ3.1-IL2-IL12 in one 
tumour only and mice receiving AJ3.1-IL2-IL12 + DC also showed high IL-2 (136 ± 9.2 
spots and 122 ± 9.2 spots respectively) and IFN-y production (117 ± 11.8 spots and 123 ± 
8.3 spots respectively). Splenocytes from mice receiving AJ3.1-IL2-IL12 in the opposite 
flank showed reduced cytokine production compared to mice which were vaccinated 
intratumourally, with 84 ± 12.3 IL-2 spots per well and 83 ± 9.9 IFN-y spots per well.
Control mice receiving RPMI i.t. secreted IL-2 (85 ± 7.1 spots) and IFN-y (83 ± 9.6) in 
response to co-culture with N2a cells at equivalent levels to the mice vaccinated in the 
opposite flank with AJ3.1-IL2-IL12. All mice vaccinated intratumourally produced 
significantly more IL-2 and IFN-y than RPMI-treated controls (p<0.01 for all groups
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Figure 5.17 In vitro evidence o f immune response against wild-type N2a cells in 
vaccinated m ice by ELISpot. Splenocytes were isolated from two mice in each group 
and co-cultured with N2a cells. Numbers of spots representing IL-2 and IFN-y 
secreting splenocytes were quantified using a plate reader. (A) Wells shown are of an 
effector:target ratio of 100:1 and are representative of each experimental group. (B) 
Average number of spots at the 100:1 E:T ratio from each experimental group. Error 
bars represent the standard deviation from six experimental wells. All groups of mice 
vaccinated intratumourally with cytokine-transfected cells showed significantly increased 
cytokine expression compared to RPMI controls (p<0.01) or mice vaccinated with 
AJ3.1-IL2-IL12 in the opposite flank (p<0.01). Significance was calculated using a t- 
test.
206
Chapter 5
compared to controls) and mice vaccinated in the opposite flank (p<0.01 for all 
intratumoural groups compared with AJ3.1-IL2-IL12 + irradiated N2a).
5.2.3.6.2 LDH release cytotoxicity assay
Splenocytes were co-cultured with irradiated N2a cells at an effectorrtarget ratio of 50:1 in 
the presence of 60IU rhIL-2 for 6 days. CTL effectors were harvested and co-incubated 
with live N2a at ratios of 27:1, 9:1, 3:1 and 1:1 for 5 hours and LDH release from N2a 
target cells quantified and used to calculate % cytotoxicity.
As with the rechallenge LDH assay, results from the 27:1 and 9:1 E:T ratios gave the 
clearest and most consistent results and are shown in Figure 5.18. RPMI treated tumours 
showed cytotoxicity of 3 ± 5% and 6 + 3% at E:T ratios of 9:1 and 27:1 respectively. Mice 
receiving AJ3.1-IL2-IL12 together with irradiated N2a cells in the opposite flank from the 
tumour showed marginally increased cytotoxicity against N2a targets with 6 ± 17% and 13 
± 12% lysis at 9:1 and 27:1 E:T ratios respectively, although this was not significantly 
greater than RPMI-treated controls at either E:T ratio (p>0.2). Mice vaccinated i.t. with 
N2a-IL2-IL12 showed significandy greater cytotoxicity at both 9:1 (14 ± 7%; p<0.05) and 
27:1 E:T ratios (24 ± 9%: p<0.01) compared to RPMI-treated controls. Mice vaccinated 
i.t. with AJ3.1-IL2-IL12 showed significandy greater cytotoxicity against N2a targets 
compared to RPMI-treated controls at a 9:1 E:T ratio (19 ± 11%; p<0.05) but this was not 
significant at the 27:1 E:T ratio due to the large standard deviation (22 ± 14%; p>0.05). 
Mice receiving AJ3.1-IL2-IL12 + DC showed increased cytotoxicity against N2a cells 
compared to RPMI-treated controls, but this was not significant at either E:T ratio (8 ± 
3%; p>0.1 at 9:1 and 10 ± 6%; p>0.2 at 27:1). The mice engrafted with two tumours of
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Figure 5.18 In vitro evidence of cytotoxicity against wild-type N2a cells in 
vaccinated mice. Splenocytes were isolated from two mice in each group of the 
eradication experiment and splenocyte-mediated cytotoxicity against N2a targets was 
determined by LDH assay. The mice used in this assay had developed tumours, but 
tumour burden was lower than the RPMI control group. The data shows average 
cytotoxicity values at two different effectoritarget ratios and is representative of each 
experimental group. Error bars represent standard deviation from quadruplicate 
samples. Significance was calculated using a t-test. Where significance is indicated, this 
refers to experimental vaccinated test groups compared with the RPMI control group 
a the 27:1 E:T ratio.
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which one was treated showed significantly enhanced cytotoxicity compared with RPMI- 
treated controls of 14 ± 5% at 9:1 and 18 ± 3.5% at 27:1 (both p<0.05) (Figure 5.18).
5.2.3.7 Histology of N2a-derived tumours
Tumours were excised from the same mice that were used for the LDH and ELISpot 
assays, fixed in 4% PFA, embedded in paraffin wax and 7pm sections mounted on 
polylysine coated slides. Sections from RPMI-treated control tumours were stained with 
hemotoxylin and eosin, revealing highly vascularised tumours with dense capillary 
networks. Larger vessels were also present around the tumour periphery. As is typical for 
murine NB tumours, no rosettes of neuroblasts could be detected and the majority of cells 
were in the resting stage, with only a few dividing cells observed (Figure 5.19 A&B). 
Staining with an anti-CD45 antibody showed negligible leukocyte infiltration of control 
♦ tumours (Figure 5.19C). Control staining with the secondary layer only showed no 
background staining (Figure 5.19D).
Tumours from mice vaccinated intratumourally with N2a-IL2-IL12 (Figure 5.20 A&B) or 
AJ3.1-IL2-IL12 (Figure 5.20 C&D) were also stained with haemotoxylin and eosin. 
These treated tumours showed decreased presence of capillaries within the tumour 
compared to RPMI-treated controls, with most vasculature confined to the tumour 
periphery. Necrotic areas could be seen in the treated tumours, defined by punctate 
nuclear staining. In some areas the cells also appeared to be aggregating together more 
loosely than in viable tumour tissue, with a complete lack of nuclear staining, suggesting 
areas of dead cells.
Staining of sections with CD45 revealed infiltrating leukocytes (Figure 5.21). Tumours 
vaccinated intratumourally with N2a-IL2-IL12 (Figure 5.21 A&B) or AJ3.1-IL2-IL12
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A
Figure 5.19 H istology and im m unohistochem istry o f tumours from RPMI- 
treated control m ice. (A & B) Haemotoxylin and eosin staining, showing highly 
vascularised tumours. Arrows denote blood vessels and stars denote dividing cells. (C) 
Staining for CD45, showing minimal infiltration of leukocytes. (D ) Control staining 
with secondary layer only. Magnification x 40 (A-D).
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Figure 5.20 Histology of treated tumours. (A&B) Haemotoxylin and eosin staining 
of paraffin-embedded tumours from mice vaccinated intratumourally with N2a-IL2- 
IL12. (C&D) Paraffin-embedded tumours stained with haemotoxylin and eosin from 
mice vaccinated intratumourally with AJ3.1-IL2-IL12. Stars indicate areas of necrosis. 
Magnification x 40.
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Figure 5.21 Immunohistochemistry of treated tumours. (A&B) CD45 staining 
of paraffin-embedded tumours from mice vaccinated intratumourally with N2a-IL2- 
IL12. (C&D) Paraffin-embedded tumours stained for CD45 from mice vaccinated 
intratumourally with AJ3.1-IL2-IL12. Arrows denote examples of CD45+-infiltrating 
leukocytes. Magnification x 40.
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(Figure 5.21 C&D) demonstrated extensive leukocyte infiltration, particularly around the 
tumour periphery, indicated by strong CD45 surface staining of positive cells. This 
contrasts with the absence of CD45 staining in RPMI-treated tumours (Figure 5.19C).
5.2.3.8 Rechallenge of tumour-eradicated mice with wild-type N2a cells
Three mice in the eradication experiment displayed tumour regression after vaccination 
and remained tumour free for over 70 days (two treated with the N2a-IL2-IL12 vaccine, 
one treated with AJ3.1-IL2-IL12 + DC). To determine if these mice had developed 
systemic immunity, they were rechallenged with 106 wild-type N2a cells in the opposite 
flank from the original tumour/vaccination after 11 weeks. While the number of mice is 
too small to provide statistical data, it was an interesting observation that all three mice 
showed no evidence of tumour development at the site of rechallenge or the original 
injection site for over 90 days, suggesting systemic anti-tumour immune memory.
5.3 D isc u ssio n
Fibroblasts transfected to express cytokines are an attractive potential alternative to 
autologous tumour vaccines due to the problems of culturing and manipulating primary 
tumour cells. Transfected fibroblasts provide local sustained cytokine expression in an 
analogous manner to transfected tumour cells, and autologous fibroblasts expressing IL-2 
or IL-12 have already demonstrated therapeutic effects in the treatment of solid tumours 
in phase I trials (Sobel et al.t 1999; Kang etal.> 2001).
Preparing patient-tailored vaccines may take some time, so cytokine-transfected allogeneic 
fibroblast lines that could be rapidly reconstituted from frozen stocks may be 
advantageous. When vaccinated in the tumour locale, the allogeneic cells may mediate
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enhanced inflammatory responses, stimulating antitumour immunity. Therefore, the aim 
of this chapter was to compare the in vivo therapeutic efficacy of syngeneic and allogeneic 
cytokine-expressing fibroblasts with cytokine-expressing N2a cells, which are known to 
have potent antitumour properties in a murine NB model (Siapati et al.y 2003).
The threshold level of cytokine expression required for antitumour responses in this 
model had not been established, so was titrated in vivo. Tumour engraftment was 
prevented in 83% of mice receiving N2a cells expressing 235ng IL-12 + 40ng IL-2. The 
level of cytokine produced by cytokine-transfected AJ3.1 and NIH-3T3 murine fibroblasts, 
as determined in chapter 4, is between the levels administered to the mice in the two 
highest dose groups (between 2350ng IL-12 + 400ng IL-2/24h and 235ng IL-12 + 40ng 
IL-2/24h). This suggests the IL-2 and IL-12 levels expressed by transfected fibroblasts 
exceed the therapeutic threshold required to prevent engraftment and is also within the 
range previously shown to stimulate antitumour responses against established NB tumours 
(Siapati et al.> 2003). Therefore, the therapeutic efficacy of AJ3.1 and NIH-3T3 cells 
expressing IL-2 and IL-12 was compared with cytokine-expressing N2a cells in vivo.
Tumourigenicity experiments compared cytokine-transfected allogeneic and syngeneic 
fibroblasts with cytokine-transfected N2a cells for their ability to prevent engraftment of 
co-injected wild-type N2a cells. Allogeneic NIH-3T3 cells inhibited N2a tumour 
engraftment in virtually all mice, whether the cells were transfected with cytokine genes, 
empty plasmid or untransfected, showing that NIH-3T3 cells alone mediated antitumour 
effects. Cytokine-transfected syngeneic AJ3.1 prevented N2a-derived tumour 
engraftment, while mice receiving untransfected AJ3.1 cells with wild-type N2a cells 
developed tumours at the same rate as N2a-only control mice, showing that unmodified 
AJ3.1 had no inhibitory effect on tumour growth. The cytokine-expressing AJ3.1 were as
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effective as cytokine-expfessing N2a cells at inhibiting N2a tumour engraftment with 83% 
of mice in each group remaining tumour free for over 40 days. This compares well with 
results from a colorectal carcinoma model where live tumour cells mixed with IL-2 
expressing fibroblasts significantly inhibited tumour engraftment compared to wild-type 
fibroblasts (Fakhrai et al.y 1995), while IL-12-expressing syngeneic fibroblasts significantly 
inhibited the development of tumours by co-vaccinated tumour cells in a murine ovarian 
cancer model (Sanches etal.y 2000).
No IL-2 or IL-12 was expressed by untransfected cells or cells transfected with empty 
vector. This suggests inhibition of engraftment by allogeneic fibroblasts was independent 
of cytokine expression, while syngeneic fibroblasts inhibited tumour engraftment in a 
cytokine-dependent manner. However, fibroblasts were being investigated here as an 
alternative to autologous tumour cells to mediate cytokine-dependent tumour regression. 
Therefore, allogeneic NIH-3T3 cells were unsuitable due to their non-specific antitumour 
effect. Previous work has also suggested that autologous cells are more effective than 
allogeneic cells as cancer vaccines (Aruga et al.y 1997; Bowman et al.y 1998a, b). However, 
this contrasts with other reports that indicate that cytokine-expressing allogeneic cell 
vaccines are superior to cytokine-expressing syngeneic cells, and this improved tumour 
regression is cytokine-dependent (Kayaga et al.y 1999).
Many clinical procedures require irradiated cells, so the tumourigenicity experiment was 
repeated with irradiated AJ3.1-IL2-IL12. However, the irradiated cells mediated reduced 
protection against tumour engraftment compared to the live vaccine. Preliminary assays 
had shown irradiation was not detrimental to cytokine production, yet IL-2 and IL-12 
expression by the irradiated AJ3.1 cells used in these vaccinations decreased rapidly 
compared with live AJ3.1 cells. Irradiated AJ3.1 maintained in vitro became apoptotic
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sooner than N2a cells receiving the same radiation dose, indicated by the AJ3.1 becoming 
very granular and non-adherent. This could explain why the higher cell dose did not 
increase the therapeutic effect, as the duration of cytokine expression was reduced. 
Comparing the rate of apoptosis of irradiated AJ3.1 with irradiated N2a cells by staining 
with annexin-V and propidium iodide would allow quantitative measurements of 
apoptosis. Optimisation of the radiation dose for AJ3.1 cells may prolong cytokine 
expression while ensuring the cells are growth-arrested.
The most clinically relevant aspect of any cancer vaccine is to inhibit the progression of 
tumours as most patients present with established disease. Therefore, cytokine-transfected 
AJ3.1 fibroblasts were compared with cytokine-transfected N2a cells in the treatment of 
solid tumours. Intratumoural administration of N2a-IL2-IL12 cells or AJ3.1-IL2-IL12 
fibroblasts mediated a significant reduction in average tumour volume 12 days after 
engraftment compared with RPMI-treated control mice.
N2a-IL2-IL12 cells mediated antitumour responses in all treated mice. Four tumours grew 
more slowly compared to controls, and two tumours regressed completely. The AJ3.1- 
IL2-IL12 i.t. vaccine mediated antitumour effects in 67% (eight of twelve) of treated mice. 
The tumour progression of six mice was slowed by up to two weeks compared with 
controls, and two tumours regressed completely. Six of the twelve mice were engrafted 
with a tumour on each flank but received AJ3.1-IL2-IL12 in only one tumour to 
investigate whether the vaccine would mediate regression of the contralateral tumour. The 
average volume of the treated tumour was significandy reduced compared to the untreated 
tumour, indicating the vaccine is most effective when administered in the tumour locale. 
However, the mice with eradicated tumours were from the group engrafted with tumours 
on both flanks, so it was not possible to follow their progress due to the aggressive growth
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of the untreated tumours. Interestingly, one mouse with an eradicated tumour had slower 
growth and a transient reduction in mass of the contralateral untreated tumour. Other 
work suggests that further vaccinations may be necessary to increase the proportion of 
eradicated tumours. Fibroblasts expressing IL-12 could mediate regression of established 
sarcoma when administered for three weeks (Zitvogel et al.y 1995).
As the most potent APC, it was hypothesised that the addition of DC may enhance 
tumour antigen presentation in the pro-inflammatory environment, increasing antitumour 
responses and augmenting tumour regression. However, the addition of DC to the AJ3.1- 
IL2-IL12 i.t. vaccine did not enhance tumour rejection. Previous work has shown that 
addition of DC in cytokine tumour vaccines has a more marked effect in preventing 
tumour growth after rechallenge, and does not significantly enhance primary tumour 
eradication (Redlinger et al.> 2003).
Cytokine-transfected AJ3.1 fibroblasts induced systemic antitumour immunity as 
effectively as cytokine-transfected N2a cells in the tumourigenicity experiment. Tumour 
free mice initially vaccinated with live AJ3.1-IL2-IL12 or N2a-IL2-IL12 cells were 
rechallenged after 7 weeks with wild type N2a cells on the opposite flank and two of five 
mice in each group (40%) remained tumour free for over 25 days. This is consistent with 
a murine colorectal carcinoma model, which showed that mice injected with cytokine- 
expressing syngeneic fibroblasts or cytokine-expressing tumour cells showed similar levels 
of induced antitumour immunity against rechallenge (Shawler et al1, 1995). Vaccination of 
established tumours mediated tumour eradication in two mice receiving N2a-IL2-IL12 i.t. 
and one receiving AJ3.1-IL2-IL12 + DC i.t. Rechallenge with wild-type N2a cells in these 
mice 11 weeks later revealed evidence of systemic immunity, as they remained tumour free
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for 90 days. Larger groups of animals are required to determine if these results are 
significant and repeated vaccination may increase systemic immunity.
Cellular immune memory responses were investigated in vitro by cytokine production from 
splenocytes and LDH cytotoxicity assay. ELISpot assays with mice from the 
tumourigenicity and rechallenge experiment showed that all mice previously injected with 
N2a cells produced significandy higher numbers of IL-2-expressing splenocytes following 
co-culture with wild-type N2a cells compared with naive control mice. All mice that had 
previously been injected with N2a cells also demonstrated increased lysis of N2a targets in 
the LDH cytotoxicity assay compared with naive mice, suggesting that even wild-type N2a 
cells may stimulate some degree of immune response.
Splenocytes from mice in the tumourigenicity and rechallenge experiment showed 
equivalent levels of IL-2 production ELISpot between mice that had rejected tumour and 
those which developed tumour. This contrasts with the result from the LDH release assay, 
which revealed differences in the level of cytotoxicity against N2a target cells between 
tumour bearing and tumour free mice. Splenocytes from mice that rejected two doses of 
tumour cells had a substantially greater cytotoxic response against N2a cells than mice that 
developed tumours. Mice that had rejected one tumour, but succumbed to rechallenge 
displayed an intermediate level of cytotoxicity against N2a targets.
The initial vaccine of N2a-IL2-IL12 cells or AJ3.1-IL-2-IL12 fibroblasts was administered 
to the mice 7 weeks before tumour free individuals were rechallenged with wild-type N2a 
cells and 11 weeks before the ELISpot and LDH assays were performed. Therefore, the 
responses observed in these assays against wild-type N2a cells suggest evidence of 
induction of cellular immune memory. Importandy, production of IL-2 and the cytotoxic
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response by splenocytes from mice that received AJ3.1-IL-2-IL12 fibroblasts was 
equivalent to mice that received N2a-IL2-IL12 cells.
ELISpot assays from mice with established tumours showed that all vaccinated mice 
responded to N2a cells by increased IL-2 and IFN-y secretion compared with naive mice. 
The splenocytes of all groups of mice vaccinated intratumourally with N2a-IL2-IL-12 or 
AJ3.1-IL2-IL12 produced equivalent numbers of IL-2 and IFN-y spots, and these were 
significandy higher than the number of IL-2 and IFN-y spots from RPMI-vaccinated 
controls or mice vaccinated with AJ3.1-IL2-IL12 in the opposite flank.
In the LDH release assay, mice vaccinated intratumourally with N2a-IL2-IL12 or AJ3.1- 
IL2-IL12 showed significandy higher lysis of N2a cells compared with RPMI-vaccinated 
controls or mice vaccinated with AJ3.1-IL2-IL12 in the opposite flank. Importandy, N2a 
lysis was equivalent between mice receiving AJ3.1-IL2-IL-12 and N2a-IL2-IL12 and 
further supports fibroblasts as a suitable alternative to tumour cells. This level of target 
cell cytolysis also compares well with other reports of IL-12 expressing syngeneic cellular 
vaccines (Perd et ai, 2001). In another report, mice vaccinated with IL-12-expressing 
NSX2 NB cells with an IL-2-anti-GD2 antibody fusion protein mediated significandy 
higher lysis of wild-type NSX2 targets than mice receiving IL-12-expressing NSX2 cells 
with recombinant IL-2 (Lode et al., 1999), suggesting that targeting of cytokines to tumour 
cells may further enhance antitumour responses.
Tumour sections showed extensive leukocyte infiltration in tumours vaccinated with N2a- 
IL2-IL12 or AJ3.1-IL2-IL12 compared to negligible staining of leukocytes in control 
tumours, suggesting the fibroblast vaccine recruits immune effector cells to the tumour 
site as effectively as the tumour cell vaccine. As well as adaptive immune functions, IL-12
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is well documented to elicit angiostatic effects (Duda et al., 2000), largely mediated through 
induction of IP-10 (Coughlin et al.y 1998). Histology suggested that the N2a-IL2-IL12 or 
AJ3.1-IL2-IL12 treated tumours had reduced vascularisation compared with controls. 
Analysis of several sections from each tumour and a larger number of animals would be 
required for quantification of an antiangiogenic effect of the cytokine-expressing vaccines. 
Staining with CD31 or CD34 could also be used to give better definition of blood vessels 
by staining of vessel endothelia.
Haematoxylin and eosin staining revealed necrotic areas of tumour tissue which were more 
prevalent in treated tumours, showing that the vaccine could mediate destruction of 
tumour cells, probably due to a combination of the reduced vascular network, limiting the 
supply of nutrients and oxygen, and extensive infiltration of immune effector cells. To 
quantify the level of cell death within tumours, TUNEL staining (terminal 
deoxynucleotidyl transferase-mediated nick end labelling), which detects apoptotic cells, 
could be used in future experiments. However, this technique is performed on frozen 
sections, so could not be implemented on the paraffin embedded sections studied here.
In conclusion, syngeneic fibroblasts expressing IL-2 and IL-12 prevented engraftment of 
wild-type N2a cells and induced long lasting systemic immune memory that protected 
mice from rechallenge with wild type N2a cells as effectively as cytokine-transfected N2a 
cells. A significant therapeutic antitumour effect was also seen when IL-2 and IL-12- 
expressing syngeneic fibroblasts were vaccinated into established N2a-derived tumours. 
The fibroblast vaccine induced equivalent levels of splenocyte-mediated IL-2 and IFN-y 
release and cytotoxicity against wild type N2a cells as the tumour cell vaccine, and 
extensive leukocyte infiltration was observed in established tumours vaccinated with 
cytokine-transfected fibroblasts. Therefore, a cellular vaccine consisting of syngeneic
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fibroblasts co-transfected with IL-2 and IL-12 is a potential therapy for the treatment of 
neuroblastoma.
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Neuroblastoma is a common paediatric malignancy, with a poor outlook for advanced 
stage patients. The majority of patients with disseminated disease will relapse within three 
years, even after initially successful therapy. Conventional chemotherapy and surgery are 
the main treatments, but do not always eradicate minimal residual disease, so improved 
treatment is necessary to reduce the relapse rate and increase long-term survival. The 
work in this thesis describes the development of a cellular immunotherapeutic vaccine 
using a synthetic gene delivery vector to treat experimental murine NB. Initially DC were 
considered for the vaccine as these are the most potent APC and may augment tumour 
antigen presentation to T cells. Cytokine-expressing fibroblasts were also investigated as 
an alternative means of enhancing pro-inflammatory antitumour immune responses.
The aim of cancer immunotherapy is to educate the immune system to recognise and 
eliminate cancer cells. Tumours exploit many ways to evade immune detection including 
down-regulation of MHC I or tumour antigen expression, reduced expression of death 
receptors, T-cell anergy and secretion of immunosuppressive factors, which all contribute 
to the immune escape of tumours. Immunotherapeutic strategies to treat such tumours 
aim to induce inflammatory responses that mediate destruction or inhibit further growth 
of established tumours. An important goal of immunotherapy is to induce systemic 
immune responses that protect an individual from disease relapse.
6.1 Transfection using the synthetic LPD vector
The synthetic LPD vector system used in this project was composed of plasmid DNA, 
lipid and cationic targeting peptide. One advantage of synthetic vectors is the short 
preparation time. Selection of stable transfectants or retrovirally-transduced clones may 
take weeks to produce, while LPD transfection takes only 24 hours.
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Murine bone marrow-derived DC consistendy showed transfection levels of around 5% 
with the LPD vector and confocal microscopy showed the main barrier to transfection of 
DC was low vector internalisation. Other reports have suggested that this level of gene 
transfer into DC is sufficient to prime T-cells (Irvine et al., 2000), but it was not possible 
here to show antigen-specific immune responses following LPD transfection of a model 
antigen into murine DC.
An alternative approach is to increase the concentration of pro-inflammatory mediators in 
the tumour environment. LPD transfection of IL-2 and IL-12 into N2a tumour cells 
abrogates their tumourigenicity in vivo in syngeneic mice and mediates regression of 
established N2a tumours (Siapati et al.y 2003). However, difficulties with culturing and 
manipulating patient primary NB cells makes this approach difficult to transfer to the 
clinic. Therefore, cytokine-secreting autologous fibroblasts may provide a suitable 
alternative method of supplying sustained, local, high-level cytokine expression.
Transfection of IL-2 and IL-12 into murine fibroblast lines using the LPD vector resulted 
in cytokine expression equivalent to that of LPD-transfected N2a cells which are known to 
mediate antitumour effects in vivo (Siapati et al.y 2003). Moreover, the expression of IL-2 
and IL-12 from LPD-transfected primary human fibroblasts and murine fibroblast lines 
was higher than achieved with many other synthetic vectors and at least equivalent to 
many viral gene transfer systems.
Cytokine-expressing syngeneic fibroblasts prevented the engraftment of N2a-derived 
tumours and, importantly, transfected fibroblasts were as effective as transfected N2a cells 
at inducing systemic antitumour immunity. Furthermore, transfected syngeneic fibroblasts
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significantly inhibited the growth of established N2a-derived tumours when vaccinated 
intratumourally compared to RPMI-vaccinated controls.
Splenocytes from mice vaccinated with AJ3.1-IL2-IL12 demonstrated significandy 
increased cytotoxicity against wild-type N2a target cells and the tumour tissue from these 
mice revealed extensive leukocyte infiltration compared with RPMI-vaccinated controls, 
suggesting induction of cellular antitumour immunity even in tumour bearing mice.
Individual lymphocyte subsets were not investigated in this project, but previous work has 
shown that both CD4+ and CD8+ T-cells are required for tumour rejection in the A/J 
model (Siapati et a l 2003). In another model of murine NB, NXS2 murine NB cells 
expressing IL-12 also induced CD8+-mediated immunity in A/J mice (Lode et al., 1999). 
This IL-12-induced protective immunity was dependent on IP-10 as depletion of IP-10 
abrogated the IL-12-mediated antitumour effects and inhibited tumour cell lysis by CD8+ 
T-cells (Perd et al., 2001). CD8+ T-cells are also essential for antitumour immune 
responses in experimental colon and renal cell carcinoma (Mendiratta et al, 1999).
A combination of IL-2 and IL-12 was used in this project. Previous work with this NB 
model (Siapati et al, 2003) and a Lewis lung carcinoma model (Tanaka et al., 2000) has 
shown the efficacy of IL-2 and IL-12 together is superior to either individual cytokine. 
The combination of IL-12 and tumour-targeted IL-2 in another NB model also enhanced 
CD8+ and memory T-cell responses compared to IL-12 alone (Lode et al., 1999). The 
enhanced response of administering both cytokines may be due to the IL-2-enhanced 
expression of the IL-12 receptor and STAT4 in NK cells. STAT4 is critical in IL-12- 
mediated signalling, leading to increased IFN-y production and killing of target cells (Wang
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et al., 2000). Furthermore, IL-12 can enhance IL-2 function by inducing expression of IL- 
2Ra, the subunit required for the high-affinity IL-2R (Nguyen et al, 2000).
6.2 Fibroblasts as vaccines
Many experimental cancers have been successfully treated with gene-modified syngeneic 
tumours cells. However, then these approaches are transferred to the clinic the vaccines 
tend not to fulfil the potential shown in murine models. This may be due to poor gene 
transfer and viability of the transfected or transduced primary autologous tumour cells, or 
in some cases, there is insufficient tumour material available from which to engineer such 
cellular vaccines. A cellular vaccine composed of fibroblasts could circumvent these 
problems. Fibroblasts are easily cultured from skin explants, so there is no problem with 
availability of cells. Preliminary work in this project also showed that primary dermal 
fibroblasts can be efficiendy transfected with a synthetic LPD vector and the levels of 
cytokines expressed are comparable to those achieved following transduction of primary 
human fibroblasts with retroviral vectors (Sobol et al., 1999; Park et al., 1997).
Syngeneic fibroblasts have also shown promise as gene delivery “vehicles” in a number of 
other experimental systems, such as delivery IL-4 in collagen-induced rheumatoid arthritis 
(Bessis et al., 2002) and production of proteolipid protein to induce T-cell anergy in 
experimental autoimmune encephalomyelitis, the murine model of multiple sclerosis 
(Weiner et al., 2004). Primary fibroblasts have also been used to deliver BDNF and NT-3 
in experimental models of spinal cord injury and this was shown to provide limited 
regeneration (Tobias et al., 2003). Therefore, there are many potential applications for 
gene modified fibroblasts, and LPD-transfection provides a safe, easy and quick method 
of efficiently transferring genes to these cells.
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6.3 Clinical strategies
Results from this project suggest that the vaccine is most effective when administered in 
the tumour locale. Therefore, potential clinical strategies may include intratumoural 
vaccination or peritumoural vaccine administration at the time of surgical resection. The 
vaccine would most likely be administered in addition to other antitumour strategies, 
possibly including antiangiogenic or standard chemotherapeutic treatments. Retrovirally 
transduced autologous dermal fibroblasts have already been used in phase I clinical trials 
to treat adult solid tumour (Sobol et al., 1999; Kang et al., 2001), which showed that the 
treatment was well tolerated and that anti-cancer immune responses were induced in some 
patients. Therefore, this vaccine should also be tolerated by paediatric patients.
Intratumoural vaccination of cytokine-expressing fibroblasts induced antitumour effects, 
but vaccination at a distant site did not inhibit the growth of established tumours. In a 
clinical situation, the tumour may not be accessible for direct treatment, or multiple 
metastases may be present that cannot be treated individually. Therefore the vaccine 
efficacy at sites distant from the tumour requires improvement. One possibility is 
including DC in the vaccine. DC did not enhance the fibroblast vaccine in the mice 
treated intratumourally, but this may be due to the immature phenotype of the DC as 
injection of immature antigen-pulsed DC into humans resulted in inhibition of antigen- 
specific CTL function with reduced IFN-y production and cytolytic activity (Dhodapkar et 
al., 2001). Therefore, mature DC could be used in the vaccination as these may show 
enhanced migration to lymph nodes. Alternatively, pulsing DC with autologous tumour 
lysate to load the DC with tumour antigens may enhance their antitumour response. 
Vaccination of DC co-cultured with live tumour cells also mediated protective immunity 
against tumour rechallenge in murine colon carcinoma (Kim et al., 2001). Furthermore, 
injecting DC intratumourally may not be optimal due to the immunosuppressive effects of
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the tumour environment and NB-derived gangliosides are known to inhibit DC function 
(Shurin et al., 2001).
6.4 Further work
The work presented in this thesis supports the concept that cytokine-transfected 
fibroblasts may offer an effective alternative to transfected autologous tumour cells and 
these initial experiments have demonstrated their antitumour efficacy. However, 
additional work is required to further characterise these antitumour responses.
Extensive infiltration of leukocytes was observed in tumours treated with cytokine- 
expressing fibroblasts or tumour cells, but it was not possible to identify the subsets of 
immune cells present in the tumours. Therefore, an alternative could be to isolate the 
leukocytes from tumour tissue with anti-CD45 magnetic beads, allowing the frequency of 
individual immune cell subsets could be determined from the CD45+ population. Work 
with melanoma-infiltrating T-cells has shown that individual CD4+ and CD8+ cells can be 
clonally expanded and are capable of lysing autologous tumour cells in vitro (Terheyden et 
al., 2000). Therefore, expansion of infiltrating lymphocytes may provide sufficient cells for 
in vitro analysis of antigen specificity. Furthermore, it may even be possible to adoptively- 
transfer the infiltrating cells into naive mice and challenge these hosts with tumour cells.
In vitro assays demonstrated that splenocytes from mice vaccinated with AJ3.1-IL2-IL12 
could lyse N2a target cells. A more comprehensive study of acquired antitumour 
immunity could isolate and investigate tumour-specific CTLs from mice that rejected 
tumour. Co-culture of splenocytes with tumour cells activates the tumour-specific CTL 
population to produce IFN-y, which could then be isolated with magnetic beads. A 
stringent measure of the antitumour capacity of isolated CTLs would be to adoptively
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transfer them into naive hosts, then challenge the hosts with tumour cells. Alternatively 
CTLs could be transferred into tumour-bearing hosts.
Only a combination of IL-2 and IL-12 was considered in this project. Now cytokine 
delivery by transfected syngeneic fibroblasts has demonstrated therapeutic efficacy in this 
NB model, different cytokine combinations could be compared. GM-CSF is a good 
candidate as it has shown antitumour responses in several animal models (Sandler et al'., 
2003; Moret et al.y 2001), and has reached clinical trial for a variety of human cancers 
(Jaffee et al., 2001; Kushner et al., 2001). Lymphotactin is a chemokine that could be 
investigated in this model. It has been shown to enhance antigen specific immunity in 
murine melanoma (Xia et al., 2002), and has also been transduced into autologous tumour 
cells together with IL-2 in a clinical trial for NB (Brenner et al., 2001).
Expression of IL-18 by transduced N2a cells abrogates their tumourigenicity in a T-cell 
mediated manner and induced immunity against wild-type N2a cells (Heuer et al., 1999), 
thus IL-18-transfected fibroblasts may be a good therapy for established tumours. NKT 
cells activated with a combination of IL-12 and IL-18 exhibited antitumour immunity 
when adoptively transferred into syngeneic hosts (Baxevanis et al., 2003), while 
peritumoural injection of IL-2 with IL-18 synergistically mediated the regression of 
established murine NB, although immune memory was not induced (Redlinger et al., 
2003c). However, the same route of administration and dose of IL-2 and IL-18 eradicated 
established murine fibrosarcomas and induced CD4+-dependent memory responses (Son et 
al., 2003), indicating antitumour immune responses are often tumour-specific. 
Furthermore, IL-18 and IL-2 synergistically increase the proliferation, cytotoxicity and 
IFN-y production of human primary lymphocytes (Son et al., 2001).
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Alternatively, fibroblasts could be used for intratumoural delivery of a soluble VEGF-R to 
inhibit tumour angiogenesis by sequestering the pro-angiogenic cytokine VEGF. Such a 
receptor inhibits angiogenesis in a murine model of retinal neovascularisation (Bainbridge 
et al., 2002), and combined with IL-12, could be a potent angiostatic therapy.
The cytokines explored in cancer therapeutics are predominantly pro-inflammatory factors 
or Th1 cytokines to enhance the immunogenicity of the tumour environment. However, 
the Th2 cytokine, IL-4, has also demonstrated potent antitumour properties. IL-4- 
expressing cancer cell lines lose their tumourigenicity in vivo, while T-cell proliferation in 
glioblastoma patients can be improved by IL-4 (reviewed in Mocellin et al., 2001). 
Tumours frequently express IL-10, which is generally acknowledged to act in an 
immunosuppressive manner. However, IL-10 has also demonstrated antitumour 
immunostimulatory properties; murine colon carcinoma transduced with IL-10 showed a 
reduction of their malignant phenotype and induced a systemic tumour-specific TH2 
response (Adris et al., 1999). Murine melanoma and mammary adenocarcinoma cell lines 
also show reduced tumourigenicity when transfected with IL-10, while breast cancer and 
melanoma metastases can regress following IL-10 administration (reviewed in Mocellin et 
al., 2001).
Another method of enhancing vaccine efficacy is blocking the function of CTLA-4. 
Following binding of CD80/86 to CD28, CTLA-4 is expressed on the T-cell, which then 
binds CD80/86 with higher avidity than CD28. Signalling through CTLA-4 limits T-cell 
proliferation and reduces cytokine production (Chambers et al., 2001). The importance of 
CTLA-4 regulation is highlighted by the observation that CTLA-4 knock-out mice develop 
a fatal lymphoproliferation and multi-organ degeneration (Tivol et al., 1995). However, 
transient inhibition of CTLA-4 function enhanced the antitumour effects of GM-CSF-
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expressing vaccines in mouse models and in patients with melanoma or ovarian carcinoma, 
although mild autoimmune reactions were observed (reviewed in Dranoff, 2004). Such 
data demonstrates that carefully controlled, temporary abrogation of CTLA-4 could 
improve the efficacy of cytokine-expressing vaccines.
Further evidence also supports the notion that a vigorous immune response is required for 
successful antitumour responses. Perez-Diez et al. (2002) used a murine colon carcinoma 
line expressing a model antigen to show that strength of the immune response directed 
against the model antigen, rather than its mere presence or absence, strongly correlated 
with the reduction of tumour burden. A clinical trial treating pancreatic cancer with GM- 
CSF-secreting tumour cells showed that the patients with the strongest DTH skin 
reactions against autologous tumour cells also showed the best clinical responses and the 
longest disease-free survival (Jaffee et al., 2001). This requirement for strong immune 
responses is particularly important considering the immunosuppressed state of most 
tumour microenvironments.
One potential major advantage of transfected fibroblasts over transfected tumour cells is 
that they may be effective against multiple tumour types. Cytokine-expressing autologous 
tumour cells have generally only been used against the parental tumour, and allogeneic 
tumour cells are only used to treat tumours of the same type. However, autologous 
dermal primary fibroblasts expressing IL-2 or IL-12 have already been used in clinical trials 
to treat many types of tumour (Sobol et al., 1999; Kang et al., 2001), and IL-2 engineered 
syngeneic fibroblasts have also been injected intracerebrally to treat experimental glioma 
(Lichtor et al., 2002). Therefore, transfected AJ3.1 fibroblasts may be effective against 
other syngeneic tumours. Firstly, treatment of other syngeneic NB cell lines such as NSX2 
or the aggressive metastatic TBJ could be compared with N2a-derived tumours. It is also
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important to investigate the effectiveness of transfected AJ3.1 cells against different 
tumour types, such as the SCK murine mammary carcinoma, which is syngeneic with A/J 
mice and has previously been shown to be sensitive to IL-12 (Coughlin et al., 1998).
The complexity of the human disease plus the polymorphisms present in the human 
population compared with the inbred strain of mice used here means that caution is 
necessary when extrapolating the results obtained in this project to what could potentially 
be attained clinically. Furthermore, possible toxicity issues related to cytokine dose would 
also need to be addressed. Nonetheless, cytokine-transfected syngeneic fibroblasts 
demonstrated therapeutic efficacy in this murine NB model. The syngeneic fibroblast 
vaccine compared extremely well with the tumour cell vaccine in every experiment, 
abrogating the tumourigenicity of wild-type N2a cells, inducing systemic protective 
antitumour immunity and mediating significant regression of established tumours. In vitro 
assays demonstrated cellular responses to wild-type N2a cells, while vaccinated tumours 
revealed necrosis and extensive leukocyte infiltration. In conclusion, syngeneic fibroblasts 
expressing IL-2 and IL-12 present a viable alternative to autologous tumour vaccines and 
warrant further investigation for the treatment of neuroblastoma and other solid 
neoplasms.
Re f e r e n c e s  a n d
A p p e n d ix
'References
Adris SK, Klein S, Jasnis MA, Chuluyan E, Ledda MF, Bravo Al, Carbone C, 
Chemajovsky Y, IL-10 Expression by CT2 Colon Carcinoma Cells Inhibits Their 
Malignant Phenotype and Induces a T Cell-Mediated Tumour Rejection in the Context of 
a Systemic Th2 Response (1999) 6,1705-1712
Ahn HJ, Maruo S, Tomura M, Mu J, Hamaoka T, Nakanishi K, Clark S, Kurimoto M, 
Okamura H, Fujiwara H, A Mechanism Underlying Synergy Between IL-12 and IFN- 
gamma-inducing Factor in Enhanced Production of IFN-gamma (1997) J Immunol 159, 
2125-2131
Airoldi I, Lualdi S, Bruno S, Raffaghello L, Occhino M, Gambini C, Pistoia V, Corrias 
MV, Expression of Costimulatory Molecules in Human Neuroblastoma. Evidence that 
CD40+ Neuroblastoma Cells Undergo Apoptosis Following Interaction with CD40L 
(2003) Br J Cancer 88,1527-1536
Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich 
DI, Clinical Significance of Defective Dendritic Cell Differentiation in Cancer (2000) Clin 
Cancer Res 6,1755-1766
Altucci L, Gronemeyer, The Promise of Retinoids to the Fight Against Cancer (2001) Nat 
Rev Cancer 1,181-193
Alvarado CS, Findley HW, Chan WC, Hnath RS, Abdel-Mageed A, Pais RC, Kutner MH, 
Ragab AH, Natural Killer Cells in Children with Malignant Solid Tumours: Effect of 
Recombinant Interferon-2 and Interleukin-2 on Natural Killer Cell Function Against 
Tumour Cell lines (1989) Cancer 63, 83-89
Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, Friberg M, 
Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W, Phase I Trial of a B7-1 (CD80) 
Gene Modified Autologous Tumour Cell Vaccine in Combination with Systemic IL-2 in 
Patients with Metastatic Renal Cell Carcinoma (2002) J Urol 167,1995-2000
Atienti F, Sule-Suso J, Melani C, Maccalli C, Belli F, Illeni MT, Anichini A, Cascinelli N, 
Colombo MP, Parmiani G, IL-2 Gene-Transduced Human Melanoma Cells Efficiently 
Stimulate MHC-Unrestricted and MHC-Restricted Autologous Lymphocytes (1994) 
Human Gene Therapy 5,1139-1150
Armstrong TD, Clements VK, Ostrand-Rosenberg S, MHC Class II-Transfected Tumour 
Cells Direcdy Present Antigen to Tumour-Specific CD4+ T Lymphocytes (1998) J 
Immunol 160, 661-666
Aruga A, Aruga E, Chang AE, Reduced Efficacy of Allogeneic Versus Syngeneic 
Fibroblasts Modified to Secrete Cytokines as a Tumour Vaccine Adjuvant (1997) Cancer 
Res 57, 3230-3237
Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F, An Essential Role For 
Interleukin 10 in the Function of Regulatory T Cells That Inhibit Intestinal Inflammation
(1999) J Exp Med 190, 995-1004
Baggiolini M, Chemokines and Leukocyte Traffic (1998) Nature 392, 565-568
234
References
Bai XF, Liu J, Li O, Zheng P, Liu Y, Antigenic Drift as a Mechanism for Tumour Evasion 
of Destruction by Cytolytic T Lymphocytes (2003) J Clin Invest 111, 1487-1496
Bainbridge JWB, Mistry A, De Alwis M, Paleolog E, Baker A, Thrasher AJ, Ali RR, 
Inhibition of Retinal Neovascularisation by Gene transfer of soluble VEGF Receptor sFlt- 
1 (2002) Gene Ther 9, 320-326
Balicki D, Reisfeld RA, Pertl U, Beutler E, Lode HN, Histone H2A-Mediated Transient 
Cytokine Gene Delivery Induces Efficient Antitumour Responses in Murine 
Neuroblastoma (2000) PNAS 97,11500-11504
Banchereau J, Steinman RM, Dendritic Cells and the Control of Immunity (1998) Nature 
392,245-252
Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K, 
Immunobiology of Dendritic Cells (2000) Ann Rev Immunol 18, 767-811
Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ, Targeted Adeno-Associated Virus 
Vector transduction of Nonpermissive Cells Mediated by a Bispecific F(ab’gamma)2 
Antibody (1999) Nat Biotechnol 17,181-186
Baxevanis CN, Gritapis AD, Papamichail M., In Vivo Antitumour Activity of NKT Cells 
Activated by the Combination of IL-12 and IL-18 (2003) J Immunol 171,2953-2959
Beierle EA, Strande LF, Chen MK, VEGF Upregulates BCL-2 Expression and Is 
Associated With Decreased Apoptosis in Neuroblastoma Cells (2002) J Pediatr Surg 37, 
467-471
Bergers G, Benjamin LE, Tumourigenesis and the Angiogenic Switch (2003) Nat Rev 
Cancer 3, 401-410
Bessis N, Cottard V, Saidenberg-Kermanach N, Lemeiter D, Fournier C, Boissier MC, 
Syngeneic Fibroblasts Transfected with a Plasmid Encoding Interleukin-4 as Non-Viral 
Vectors for Anti-Inflammatory Gene Therapy in Collagen-Induced Arthritis (2002) T Gene 
Med 4, 300-307
Beverly B, Kang SM, Lenardo MJ, Schwartz RH, Reversal of In Vitro T Cell Clonal Anergy 
By IL-2 Stimulation (1992) Int Immunol 4, 661-671
Bin Q, Johnson BD, Schauer DW, Casper JT, Orentas RJ, Production of Macrophage 
Migration Inhibitory Factor by Human and Murine Neuroblastoma (2002) 23,123-129
Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J, 
TRAIL Receptor-2 Signals Apoptosis Through FADD and Caspase-8 (2000) Nat Cell Biol 
2,241-243
Bowman L, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, Leimig T, 
Coustan-Smith E, Campana D, Jenkins J, Woods D, Kitchingman G, Vanin E, Brenner M, 
IL-2 Adenovector-Transduced Autologous Tumour Cells Induce Antitumour Immune 
Responses in Patients with Neuroblastoma (1998a) Blood 92,1941-1949
235
References
Bowman L, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, Leimig T, 
Coustan-Smith E, Campana D, Jenkins J, Woods D, Brenner M, Interleukin-2 Gene- 
Modified Allogeneic Tumour Cells for the Treatment of Relapsed Neuroblastoma (1998b) 
Hum Gene Ther 9,1303-1311
Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson ADJ, Plantaz D, Meddeb M, 
Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F, Gain of 
Chromosome Arm 17q and Adverse Outcome in Patients with Neuroblastoma (1999) N 
Engl J Med 340,1954-1561
Brandhuber BJ, Boone T, Kenney WC, McKay DB, Three-Dimensional Structure of 
Interleukin-2 (1987) Science 238,1707-1709
Brenner MK, Heslop H, Krance R, Horowitz M, Strother D, Nuchtem J, Grilley B, 
Martingano E, Cooper K, Phase I Study of Chemokine and Cytokine Gene-Modified 
Autologous Neuroblastoma Cells for Treatment of relapsed/Refractory Neuroblastoma 
using an Adenoviral Vector (2000) Human Gene Ther 11,1477-1488
Brewster MA, Berry DH, Serial Studies of Serum Dopamine-B-hydroxylase and Urinary 
Vanillylmandelic Homovanillic acids in Neuroblastoma (1979) Med Paed Oncol 6, 93-99
Brodeur GM, Sekhon G, Goldstein MN, Chromosomal Aberrations in Human 
Neuroblastomas (1977) Cancer 40,2256-2263
Brodeur GM, Hayes FA, Green AA, Casper JT, Wasson J, Wallach S, Seeger RC, 
Consistent N-myc Copy Number in Simultaneous or Consecutive Neuroblastoma Samples 
from Sixty Individual Patients (1987) Cancer Res 47,4248-4253
Brunda MJ, Luistro L, Warner RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately 
MK, Antitumour and Antimetastatic Activity of Interleukin-12 Against Murine Tumours
(1993) J Exp Med 178,1223-1230
Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, Spitz L, Lewis P, 
Goldfarb D, Emerman M, Stevenson M, A Nuclear Localisation Signal Within HIV-1 
Matrix Protein that Governs Infection of Non-Dividing Cells (1993) Nature 365, 666-669
Buning H, Ried MU, Perabo L, Gemer FM, Huttner NA, Enssle J, Hallek M, Receptor 
Targeting of Adeno-Associated Virus Vectors (2003) Gene Ther 10,1142-1151
Burton EA, Fink DJ, Glorioso JC, Gene Delivery Using Herpes Simplex Virus Vectors
(2002) DNA Cell Biol 21, 915-936
Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F, Total Loss of 
MHC Class I in Colorectal Tumours Can Be Explained By Two Molecular Pathways: 
Beta2-Microglobulin Inactivation in MSI-Positive Tumours and LMP7/TAP2 
Downreguladon in MSI-Negative Tumours (2003) Tissue Antigens 61, 211-219
Cabrera T, Angustias Fernandez M, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra 
A, Garrido F, High Frequency of Altered HLA Class I Phenotypes in Invasive Breast 
Carcinomas (1996) Human Immunol 50,127-134
236
References
Carlisle RC, Bettinger T, Ogris M, Hale, Mautner V, Seymour LW, Adenovirus Hexon 
Protein Enhances Nuclear Delivery and Increases Transgene Expression of 
Polyethylenimine/Plasmid DNA Vectors (2001) Mol Ther 4,473-483
Caron HN, Allelic loss of Chromosome 1 and Additional Chromosome 17 Material are 
both Unfavourable Prognostic Markers in Neuroblastoma (1995) Med Pediat Oncol 24, 
215-221
Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G, Slater R, Westerveld 
A, Voute PA, Versteeg R, Allelic Loss of Chromosome lp  as a Predictor of Unfavourable 
Outcome in Patients with Neuroblastoma (1996) NEJM 334, 225-230
Cascino I, Papoff G, De Maria R, Testi R, Ruberti G, Fas/Apo-1 (CD95) Receptor 
Lacking the Intracytoplasmic Signalling Domain Protects Tumour Cells from Fas- 
mediated Apoptosis (1996) J Immunol 156,13-17
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz 
F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A, Gene Therapy of 
Human Severe Combined Immunodeficiency (SCID)-X1 Disease (2000) Science 288, 669- 
672
Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW, 
Irradiation of Tumour Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL 
Adoptive Immunotherapy (2003) J Immunol 170, 6338-6347
Chamarthy SP, Kovacs JR, McClelland E, Gattens D, Meng WS, A Cationic Peptide 
Consists of Ornithine and Histidine Repeats Augments Gene Transfer in Dendritic Cells 
(2003) Mol Immunol 40, 483-490
Chambers CA, Kuhns MS, Egen JG, Allison JP, CTLA-4-Mediated Inhibition in 
Regulation of T Cell Responses: Mechanisms and Manipulation in Tumour
Immunotherapy (2001) Ann Rev Immunol 19, 565-594
Chattopadhyay M, Wolfe D, Huang S, Goss J, Glorioso JC, Mata M, Fink DJ, In Vivo 
Gene Therapy For Pyridoxine-Induced Neuropathy By Herpes Simplex Virus-Mediated 
Gene Transfer of Neurotrophin-3 (2002) Ann Neurol 51,19-27
Choi SH, Reynolds JV, Ziegler MM, Systematic Analysis of the Immunoregulation of 
Murine Neuroblastoma (1989) J Pediatr Surg 24,15-20
Chong H, Todryk S, Hutchinson G, Hart IR, Vile RG, Tumour Cell Expression of B7 
Costimulatory Molecules and Interleukin-12 or Granulocyte-Macrophage Colony- 
Stimulating Factor Induces a Local Antitumour Response and May Generate Systemic 
Protective Immunity (1998) Gene Ther 5,223-232
Church AC, Clinical Advances in Therapies Targeting the Interleukin-2 Receptor (2003) 
QJM 96,91-102
Clapham PR, McKnight A, HIV-1 Receptors and Cell Tropism (2001) Br Med Bull 58, 43- 
59
237
References
Colombo MP, Tiinchieri G, Interleukin-12 in Anti-Tumour Immunity and 
Immunotherapy (2002) Cytokine Growth Fact Rev 13,155-168
Combaret V, Gross N, Lasset C, Frappaz D, Peruisseau G, Philip T, Beck D, Favrot MC, 
Clinical Relevance of CD44 Cell Surface Expression and N-myc Gene Amplification in a 
multicentric analysis of 121 Paediatric Neuroblastomas (1996) J Clin Oncol 14, 25-34
Coonrod A, Li FQ, Horwitz M, On the Mechanism of DNA Transfection: Efficient Gene 
Transfer Without Viruses (1997) Gene Ther 4,1313-1321
Comas MV, Occhino M, Croce M, De Ambrosis A, Pistillo MP, Bocca P, Pistoia V, ferrini 
S, Lack of HLA-Class I Antigens in Human Neuroblastoma Cells: Analysis of its 
Relationship to TAP and Tapasin Expression (2001) Tissue Antigens 57,110-117
Corvi R, Savelyeva L, Schwab M, Patterns of Oncogene Activation in Human 
Neuroblastoma Cells (1997) J Neurooncol 31,25-31
Cotton M, Wagner E, “Receptor-mediated Gene Delivery Strategies” Chapter 11, The 
Development of Human Gene Therapy (1999) Published by Cold Spring Harbour 
Laboratory Press
Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma XJ, Gri G, Wysocka 
M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G, Lee WFM, Tumour Cell 
Responses to IFN-gamma Affect Tumourigenicity and Response to IL-12 Therapy and 
Antiangiogenesis (1998) Immunity 9,25-34
Cuenca A, Cheng F, Wang H, Brayer J, Homa P, Gu L, Bien H, Borrello IM, Levitsky HI, 
Sotomayor EM, Extra-Lymphatic Solid Tumour Growth Is Not Immunologically Ignored 
and Results in Early Induction of Antigen-Specific T-Cell Anergy: Dominant Role of 
Cross-Tolerance to Tumour Antigens (2003) Cancer Res 63,9007-9015
Dan Q, Sanchez R, Delgado C, Wepsic HT, Morgan K, Chen Y, Jeffes EW, Lowell CA, 
Morgan TR, Jadus MR, Non-Immunogenic Murine Hepatocellular Carcinoma Hepal-6 
Cells Expressing the Membrane Form of Macrophage Colony Stimulating Factor are 
Rejected In Vivo and Lead to CD8+ T-cell Immunity Against the Parental Tumour (2001) 
Mol Ther 4, 427-437
DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, 
Leander K, McAvoy E, Lumma P, Wai J, Senderak ET, Motzel SL, Keenan K, van 
Zwieten M, Lin JH, Freidinger R, Huff J, Oliff A, Jones RE, A Peptide-Doxorubicin 
“Prodrug” Activated by Prostate-Specific Antigen Selectively Kills Prostate Tumour Cells 
Positive for Prostate-Specific Antigen In Vivo (2000) Nat Med 6,1248-1252
Dehal PK, Embleton MJ, Kemshead JT Hawkins RE, Targeted Cytokine Delivery to 
Neuroblastoma (2002) Biochem Soc Trans 30, 518-520
DelloRusso C, Scott JM, Hartigan-O'Connor D, Salvatori G, Barjot C, Robinson AS, 
Crawford RW, Brooks SV, Chamberlain JS, Functional Correction of Adult mdx Mouse 
Muscle Using Gutted Adenoviral Vectors Expressing Full-Length Dystrophin (2002) 
PNAS 99,12979-12984
238
References
De Visser KE, Schumacher TNM, Kruisbeek AM, CD8+ T Cell Tolerance and Cancer 
Immunotherapy (2003) J Immunother 26,1-11
de Zoeten E, Carr-Brendel V, Markovic D, Taylor-Papadimitriou J, Cohen EP, Treatment 
of Breast Cancer with Fibroblasts Transfected with DNA from Breast Cancer Cells (1999) 
J Immunol 162, 6934-6941
Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N, Antigen-Specific 
Inhibition of Effector T Cell Function in Human After Injection of Immature Dendritic 
Cells (2001) J Exp Med 193, 233-238
Diao J, Smythe JA, Smyth C, Rowe PB, Alexander IE, Human PBMC-Derived Dendritic 
Cells Transduced With an Adenovirus Vector Induce Cytotoxic T-Lymphocyte Responses 
Against a Vector-Encoded Antigen In Vitro (1999) Gene Ther 6, 845-853
Diebold SS, Lehrmann H, Kursa M, Wagner E, Cotten M, Zenke M, Efficient Gene 
Delivery into Human Dendritic Cells by Adenovirus Polyethylenimine and Mannose 
Polyethylenimine Transfection (1999) Hum Gene Ther 10, 775-786
Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A, Brenner M, Combined 
Chemokine and Cytokine Gene Transfer Enhances Antitumour Immunity (1996) Nat Med 
2,1090-1095
Doran T, Stuhlmiller H, Kim JA, Martin EW, Triozzi PL, Oncogene and Cytokine 
Expression of Human Colorectal Tumours Responding to Immunotherapy (1997) J 
Immunother 20, 372-376
Dow SW, Elmslie RE, Fradkin LG, Liggitt DH, Heath TD, Willson AP, Potter TA, 
Intravenous Cytokine Gene Delivery by Lipid-DNA Complexes Controls the Growth of 
Established Lung Metastases (1999) Hum Gene Ther 10,2961-2972
Dranoff G, Cytokines in Cancer Pathogenesis and Cancer Therapy (2004) Nat Rev Cancer 
4,11-22
Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa SI, Matsumoto G, Shimamura 
H, Shibuya K, Takeda K, Matsuno S, Direct In Vitro Evidence and In Vivo Analysis of 
the Antiangiogenesis Effects of Interleukin 12 (2000) Cancer Res 60,1111-1116
Dumontet C, Rebbaa A, Bienvenu J, Portoukalian J, Inhibition of Immune Cell 
Proliferation and Cytokine Production by Lipoprotein-Bound Gangliosides (1994) Cancer 
Immunol Immunother 38, 311-316
DVries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN, 
Heterogeneous Expression of Immunotherapy Candidate Proteins gplOO, MART-1 and 
Tyrosinase in Human Melanoma Cell Lines and In Human metastatic Lesions (1997) 
Cancer Res 57, 3223-3229
El-Deiry WS, Insights Into Cancer Therapeutic Design Based on p53 and TRAIL 
Receptor Signalling (2001) Cell Death Differ 8,1066-1075
239
References
Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, Gauldie J, Adenoviral 
Vectors Expressing Lymphotactin And Interleukin-2 or Lymphotactin and Interleukin-12 
Synergise to Facilitate Tumour Regression in Murine Breast Cancer Models (1999) Hum 
Gene Ther 10, 697-709
Enomoto A, Kato K, Yagita H, Okumura K., Adoptive transfer of cytotoxic T 
lymphocytes induced by CD86-transfected tumour cells suppresses multi-organ metastases 
of Cl 300 neuroblastoma in mice (1997) Cancer Immunol Immunother 44,204-210
Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW, Prognostic Factors in 
Neuroblastoma (1987) Cancer 59,1853-1859
Facchini LM, Penn LZ, The Molecular Role of Myc in Growth and Transformation: 
Recent Discoveries Lead to New Insights (1998) FASEB J 12, 633-651
Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE, Cytokine 
Gene Therapy with Interleukin-2 Transduced Fibroblasts: Effects of IL-2 Dose on Anti- 
Tumour Immunity (1995) Hum Gene Ther 6, 591-601
Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS, Turner EM, Hewitt SM, 
Alexander HR, Retroviral Gene Transfer of Interferon-inducible Protein-10 Inhibits 
Growth of Human Melanoma Xenografts (2002) Int J Cancer 99,149-153
Feigner PL, Zelphati O, Liang X, “Advances in Synthetic Gene Delivery System 
Technology” Chapter 10, The Development of Human Gene Therapy (1999) Published by 
Cold Spring Harbour Laboratory Press
Fields RC, Shimizu K, Mule JJ, Murine Dendritic Cells Pulsed with Whole Tumour 
Lysates Mediate Potent Anti-Tumour Responses In Vitro and In Vivo (1998) PNAS 95, 
9482-9487
Fitzgibbon MC, Tormey WP, Paediatric Reference Ranges for Urinary 
Catecholamines/Metabolites and Their Reference in Neuroblastoma Diagnosis (1994) 
Ann Clin Biochem 31,1-11
Fontana A, Frei K, Bodmer S, Hofer E, Schreier MH, Palladino MA, Zinkemagel RM, 
Transforming Growth Factor-Beta Inhibits the Generation of Cytotoxic T Cells in Vims 
Infected Mice (1989) J Immunol 143, 3230-3234
Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, 
McLain C, Hall P, Tagge E, Berger M, Eaves C, Diphtheria Toxin Fused to Granulocyte- 
Macrophage Colony-Stimulating Factor is Toxic to Blasts From Patients with Juvenile 
Myelomonocytic Leukaemia and Chronic Myelomonocytic Leukaemia (1998) Blood 92, 
4279-4286
French LE, Tschopp J, Inhibition of Death Receptor Signalling by FLICE-Inhibitory 
Protein as a Mechanism for Immune Escape of Tumours (1999) J Exp Med 190, 891-893
Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettdnger 
LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM, A Phase I/IB
240
References
Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a plus Interleukin-2 in Children 
with Refractory Neuroblastoma (1997) Cancer 80, 317-333
Fujii S, Huang S, Fong TC, Ando D, Burrows F, Jolly DJ, Nemunaitis J, Hoon DS, 
Induction of Melanoma-Associated Antigen Systemic Immunity Upon Intratumoural 
Delivery of Interferon-gamma Retroviral Vector in Melanoma Patients (2000) Cancer 
Gene Ther 7,1220-1230
Fukuzawa M, Sugiura H, Koshinaga T, Ikeda T, Hagiwara N, Sawada T, Expression of 
Vascular Endothelial Growth Factor and Its Receptor Flk-1 in Human Neuroblastoma 
Using In Situ Hybridization (2002) J Pediatr Surg 37,1747-1750
Gaffen SL, Signalling Domains of the Interleukin-2 Receptor (2001) Cytokine 14, 63-77
Gallimore A, Sakaguchi S, Regulation of Tumour Immunity by CD25+ T Cells (2002) 
Immunology 107, 5-9
Garrido F, Algarra I, MHC Antigens and Tumour Escape from Immune Surveillance
(2001) Adv Cancer Res 83,117-158
Gautam A, Densmore CL, Waldrep JC, Inhibition of Experimental Lung Metastasis by 
Aerosol Delivery of PEI-p53 Complexes (2000) Mol Ther 2, 318-323
Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang 
AE, Braun TM, Mule JJ, Vaccination of Paediatric Solid Tumours Patients with Tumour 
Lysate-Pulsed Dendritic Cells Can Expand Specific T Cells and Mediate Tumour 
Regression (2001) Cancer Res 61, 8513-8519
Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G, Reciprocal 
Activating Interaction Between Natural Killer Cells and Dendritic Cells (2002) J Exp Med 
195,327-333
Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deleage G, Hallek M, 
Genetic Capsid Modifications Allow Efficient Retargeting of Adeno-Associated Virus 
Type 2 (1999) Nat Med 5,1052-1056
Goins WF, Lee KA, Cavalcoli JD, O'Malley ME, DeKosky ST, Fink DJ, Glorioso JC, 
Herpes Simplex Virus Type-1 Vector-Mediated Expression of Nerve Growth Factor 
Protects Dorsal Root Ganglion Neurons form Peroxide Toxicity (1999) J Virol 73, 519- 
532
Gollob JA, Kawasaki H, Ritz J, Interferon-gamma and Interleukin-4 Regulate T-Cell 
Interleukin-12 Responsiveness Through the Differential Modulation of High-Affinity 
Interleukin-12 Receptor Expression (1997) Eur J Immunol 27, 647-652
Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, 
Kufe D, Reversal of Tolerance to Human MUC1 Antigen in MUC1 Transgenic Mice 
Immunised with Fusions of Dendritic and Carcinoma Cells (1998) PNAS 95, 6279-6283
241
References
Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA, Immunohistochemical Staining 
For Transforming Growth Factor Beta 1 Associates with Disease Progression in Human 
Breast Cancer (1992) Cancer Res 52, 6949-6952
Goss JR, Mata M, Goins WF, Wu HH, Glorioso JC, Fink DJ, Antinociceptive Effect of a 
Genomic Herpes Simplex Virus-Based Vector Expressing Human Proenkephalin in Rat 
Dorsal Root Ganglion (2001) Gene Ther 8, 551-556
Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG, 
Overexpression of Multidrug Resistance-associated Protein Increases Resistance to 
Natural Product Drugs (1994) Cancer Res 54, 357-361
Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M, Rituximab: Ongoing and Future 
Clinical Development (2002) Semin Oncol 29 (1 supplement 2), 105-112
Grohmann U, Bianchi R, Ayroldi E, Belladonna ML, Surace D, Fioretti MC, Puccetti P, A 
Tumour-Associated and Self Antigen Peptide Presented By Dendritic Cells May Induce T- 
cell Anergy In Vivo, But IL-12 Can Prevent or Revert the Anergic State (1997) J Immunol 
158, 3593-3602
Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, 
Bomand T, Fontana A, Lienard D, Cerottini J, Tschopp J, Melanoma Cell Expression of 
Fas (Apo-l/CD95) Ligand: Implications for Tumour Immune Escape (1996) Science 274, 
1363-1366
Haines AMR, Irvine AS, Mountain A, Charlesworth J, Farrow NA, Husain RD, Hyde H, 
Ketteringham H, McDermott RH, Mulcahy AF, Mustoe TL, Reid SCH, Rouquette M, 
Shaw JC, Thatcher DR, Welsh JH, Williams DE, Zauner W, Phillips RO, CL22 - A Novel 
Cationic Peptide For Efficient Transfection of Mammalian Cells (2001) Gene Ther 8, 99- 
110
Hart SL, Integrin-mediated Vectors for Gene Transfer and Therapy (1999) Curr Op Mol 
Ther 1,197-203
Hart SL, Arancibia-Carcamo CV, Wolfert MA, Mailhos C, O'Reilly NJ, Ali RR, Coutelle C, 
George AJ, Harbottle RP, Knight AM, Larkin DF, Levinsky RJ, Seymour LW, Thrasher 
AJ, Kinnon C, Lipid-mediated Enhancement of Transfection by a Non-viral Integrin 
Targeting Vector (1998) Hum Gene Ther 9, 575-585
Hatzi E, Murphy C, Zoephel A, Rasmussen H, Morbidelli L, Ahom H, Kunisada K, 
Tontsch U, Klenk M, Yamauchi-Takihara K, Ziche M, Rofstad EK, Schweigerer L, Fotsis 
T, N-myc Oncogene Overexpression Down-regulates IL-6; Evidence that IL-6 Inhibits 
Angiogenesis and Suppresses Neuroblastoma Tumour Growth (2002a) Oncogene 21, 
3552-3561
Hatzi E, Murphy C, Zoephel A, Ahom H, Tontsch U, Bamberger AM, Yamauchi- 
Takihara K, Schweigerer L, Fotsis T, N-myc Oncogene Overexpression Down-regulates 
Leukaemia Inhibitory Factor in Neuroblastoma (2002b) Eur J Biochem 269, 3732-3741
Hayes FA, Mauer AM, Cell Kinetics and Chemotherapy in Neuroblastoma (1976) J Nad 
Cancer Inst 57, 697-699
242
References
Hedrick JA, Saylor V, Figueroa D, Mizoue L, Xu Y, Menon S, Abrams J, Handel T, 
Zlotnik A, Lymphotactin is Produced by NK Cells and Attracts Both NK Cells and T 
Cells In Vivo (1997) J Immunol 158,1533-1540
Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, 
Wagner H, Takeda K, Akira S, A Toll-Like Receptor Recognises Bacterial DNA (2000) 
Nature 408, 740-745
Hersey P, Zhang XD, How Melanoma Cells Evade TRAIL-Induced Apoptosis (2001) Nat 
Rev Cancer 1,142-150
Heuer JG, Tucker-McClung C, Hock RA, Neuroblastoma Cells Expressing Mature IL-18 
But Not proIL-18 Induce Strong and Immediate Antitumour Immune Response (1999) J 
Immunother 22, 324-335
Heuer JG, Tucker-McClung C, Gonin R, Hock RA, Retrovirus-Mediated Gene Transfer 
of B7-1 and MHC Class II Converts a Poorly Immunogenic Neuroblastoma into a Highly 
Immunogenic One (1996) Human Gene Therapy 7,2059-2068
Hidaka C, Milano E, Leopold PL, Bergelson JM, Hackett NR, Finberg RW, Wickham TJ, 
Kovesdi I, Roelvink P, Crystal RG, CAR-Dependent and CAR-Independent Pathways of 
Adenovirus Vector-Mediated Gene Transfer and Expression in Human Fibroblasts (1999) 
J Clin Invest 103, 579-587
Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek AM, Shay JW, Correlating 
Telomerase Activity Levels with Human Neuroblastoma Outcomes (1995) Nat Med 1, 
249-255
Hold L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, 
Bartsch G, Thumher M, Cellular and Humoral Responses in Patients with Metastatic 
Renal Cell Carcinoma After Vaccination with Antigen Pulsed Dendritic Cells (1999) J Urol 
161, 777-782
Homey B, Muller A, Zlotnik A., Chemokines: Agents For The immunotherapy of Cancer? 
Nat Rev Immunol 2,175-184
Hu WS, Pathak VK, Design of Retroviral Vectors and Helper Cells for Gene Therapy 
(2000) Pharmacol Rev 52,493-511
Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, 
Dubinett SM, Non-Small Cell Lung Cancer Cyclooxygenase-2-Dependent Regulation of 
Cytokine Balance in Lymphocytes and Macrophages: Up-Regulation of Interleukin 10 and 
Down-Regulation of Interleukin 12 Production (1998) Cancer Res 58,1208-1216
Humphries JD, Askari JA, Zhang XP, Takada Y, Humphries MJ, Mould AP, Molecular 
Basis of Ligand Recognition by Integrin (2000) J Biol Chem 275, 20337-20345
Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC, Cancer Immunotherapy 
Using a DNA Vaccine Encoding the Translocation Domain of a Bacterial Toxin Linked to 
a Tumour Antigen (2001) Cancer Res 61, 3698-3703
243
References
Ikematsu S, Nakagawara A, Nakamura Y, Sakuma S, Wakai K, Muramatsu T, Kadomatsu 
K, Correlation of Elevated Level of Blood Midkine with Poor Prognostic Factors of 
Human Neuroblastomas (2003) Br J Cancer 88,1522-1526
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter 
M, Bums K, Mattmann C, Rimoldi D, French LE, Tschopp J, Inhibition of Death 
Receptor Signals by Cellular FLIP (1997) Nature 388,190-195
Irvine AS, Trinder PKE, Laughton DL, Ketteringham H, McDermott RH, Reid SCH, 
Haines AMR, Amir A, Husain R, Doshi R, Young LS, Mountain A, Efficient Nonviral 
Transfection of Dendritic Cells and Their Use for In Vivo Immunisation (2000) Nat 
Biotech 18,1273-1278
Iwakami SI, Setoguchi Y, Saijo Y, Azuma M, Fukuchi Y, Replication-deficient Adenovirus- 
mediated Transfer of B7-1 (CD80) cDNA Induces Anti-tumour Immunity in Isolated 
Human Lung Cancer (2001) Respirology 6,135-144
Jacobson EL, Pilaro F, Smith KA, Rational Interleukin-2 Therapy for HIV Positive 
Individuals: Daily Low Doses Enhance Immune Function Without Toxicity (1996) PNAS 
93,10405-10410
Jaffee EM, Abrams R, Cameron J, Donehower R, Duerr M, Gossett J, Greten TF, 
Grochow L, Hruban R, Kem S, Lillemoe KD, O’Reilly S, Pardoll D, Pitt FIA, Sauter P, 
Weber C, Yeo C, A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic 
Tumour Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic 
Adenocarcinoma (1998) Hum Gene Ther 9,1951-1971
Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, 
Coleman J, Grochow L, Donehower RC, Lillemoe KD, O’Reilly S, Abrams RA, Pardoll 
DM, Cameron JL, Yeo CJ, Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating 
Factor-Secreting Tumour Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and 
Immune Activation (2001) J Clin Oncol 19,145-156
Jager D, Jager E, Knuth A, Immune Responses to Tumour Antigens: Implications for 
Antigen Specific Immunotherapy of Cancer (2001) J Clin Pathol 54, 669-674
Jakubczak JL, Rollence ML, Stewart DA, Jafari JD, Von Seggem DJ, Nemerow GR, 
Stevenson SC, Hallenbeck PL, Adenovirus Type 5 Viral Particles Pseudotyped With 
Mutagenized Fiber Proteins Show Diminished Infectivity of Coxsackie B-Adenovirus 
Receptor-Bearing Cells (2001) J Virol 75,2972-2981
Jenkins RG, Herrick SE, Meng QH, Kinnon C, Laurent GJ, McAnulty RJ, Hart SL, An 
Integrin-Targeted Non-viral Vector for Pulmonary Gene Therapy (2000) Gene Ther 7, 
393-400
Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H, Pahlman S, 
Hypoxia Alters Gene Expression in Human Neuroblastoma Cells Toward an Immature 
and Neural Crest-Like Phenotype (2002) PNAS 99, 7021-7026
244
References
Kanayama H, Matrix Metalloproteinases and Bladder Cancer (2001) J Med Invest 48, 31- 
43
Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, Park K, Kim K, Jeong WS, 
Kim AK, Nam SJ, Yang JH, Son YI, Baek AH, Han J, Ree HJ, Lee ES, Kim SH, Kim 
DW, Ahn YC, Huh AJ, Choe YH, Lee JH, Park MH, Kong GS, Park EY, Kang YK, Bang 
YJ, PaikNS, Lee SN, Kim AH, Kim Y, Robbins PD, Tahara H, Lotze MT Park CH, 
Interleukin-12 Gene Therapy of Cancer by Peritumoural Injection of Transduced 
Autologous Fibroblasts: Outcome of a Phase I Study (2001) Hum Gene Ther 12, 671-684
Karasuyama H, Kudo A, Melchers F, The Proteins Encoded by the VpreB and lambda 5 
pre-B Cell-Specific Genes can Associate with Each Other and with mu Heavy Chain 
(1990) J Exp Med 172, 969-972
Katsanis E, Orchard PJ, Bausero MA, Gorden KB, Mclvor RS, Blazar BR, Interleukin-2 
Gene Transfer Into Murine Neuroblastoma Decreases Tumourigenicity and Enhances 
Systemic Immunity Causing Regression of Pre-established Retroperitoneal Tumours
(1994) J Immunother Emphasis Tumour Immunol 15, 81-90
Katsanis E, Xu Z, Bausero MA, Dancisak BB, Gorden KB, Davis G, Gray GS, Orchard 
PJ, Blazar BR, B7-1 Expression Decreases Tumourigenicity and Induces Partial Systemic 
Immunity to Murine Neuroblastoma Deficient in Major Histocompatibility Complex and 
Co-stimulatory Molecules (1995) Cancer Gene Ther 2, 39-46
Kayaga J, Souberbielle BE, Sheikh N, Morrow WJW, Scott-Taylor T, Vile R, Dalgleish 
AG, Anti-Tumour Activity Against B16-F10 Melanoma with GM-CSF Secreting 
Allogeneic Tumour Cell Vaccine (1999) Gene Ther 6,1475-1481
Kelly T, Borset M, Abe E, Gaddy-Kurten D, Sanderson RD. Matrix Metalloproteinases in 
Multiple Myeloma (2000) Leuk Lymphoma 37,273-281
Keshelava N, Seeger RC, Reynolds CP, Drug Resistance in Human Neuroblastoma Cell 
Lines Correlates with Clinical Therapy (1997) Eur J Cancer 33,2002-2006
Khong HT, Restifo NP, Natural Selection of Tumour Variants in the Generation of 
“Tumour Escape” Phenotypes (2002) Nature Immunol 3, 999-1005
Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, Rosell 
K, Whiteside T, Phillippe S, Acres B, Slos P, Squiban P, Ross M, Kendra K, A Phase I 
Trial of Immunotherapy With Intratumoural Adenovirus-Interferon-gamma (TGI 041) in 
Patients with Malignant Melanoma (2003) Cancer Gene Ther 10, 251-259
Kim ES, Soffer SZ, Huang J, McCmdden KW, Yokoi A, Manley CA, Middlesworth W, 
Kandel JJ, Yamashiro DJ, Distinct Response of Experimental Neuroblastoma to 
Combination Antiangiogenic Strategies (2002) J Pediatr Surg 37, 518-522
Kim KD, Choi SC, Kim A, Choe YK, Choe IS, Lim JS, Dendritic Cell-Tumour Co- 
culturing Vaccine can Induce Antitumour Immunity Through Both NK and CTL 
Interaction (2001) Int Immunopharmacol 1, 2117-2129
245
References
Kim TS, Xu WS, Sun T, Cohen EP, Immunisation with Interleukin-2/Interferon-y 
Double Cytokine-Secreting Allogeneic Fibroblasts Prolongs the Survival of Mice with 
Melanoma (1995) Melanoma Res 5,217-227
Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, Geissler G, 
Marymount MH, Liu D, Kalapurakal JA, Shore RM, Bardo DME, Schmoldt J, Rademaker 
AW, Cohn SL, Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose 
Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study (2002) J Clin Oncol 
20,2284-2292
Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J, Induction of Antitumour 
Immunity by Vaccination of Dendritic Cells Transfected with MUC1 RNA (2000) J 
Immunol 165, 5713-5719
Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, 
Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, 
Trono D, Hantraye P, Deglon N, Aebischer P, Neurodegeneration Prevented By 
Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson’s Disease (2000) 
Science 290, 767-773
Korst RJ, Mahtabifard A, Yamada R, Crystal RG, Effect of Adenovirus Gene Transfer 
Vectors on the Immunologic Functions of Mouse Dendritic Cells (2002) Mol Ther 5, 307- 
315
Kotera Y, Shimizu K, Mule JJ, Comparative Analysis of Necrotic and Apoptotic Tumour 
Cells as a Source of Antigen(s) in Dendritic Cells-Based Immunization (2001) Cancer Res 
61, 8105-8109
Krona C, Ejeskar K, Abel F, Kogner P, Bjelke J, Bjork E, Sjoberg RM, Martinsson T, 
Screening for Gene Mutations in a 500kb Neuroblastoma Tumour Suppressor Candidate 
Region in Chromosome lp; Mutation and Stage-Specific Expression in UBE4B/UFD2
(2003) Oncogene 22,2343-2351
Kundig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A, 
Kuhlcke K, Ohashi PS, Hengartner H, et aly Fibroblasts as Efficient Antigen-Presenting 
Cells in Lymphoid Organs (1995) Science 268,1343-1347
Kurian KM, Watson CJ, Wyllie AH, Retroviral Vectors (2000) J Clin Pathol: Mol Pathol 
53,173-176
Kushner BH, Kramer K, Cheung NK, Phase II Trial of the Anti-GD2 Monoclonal 
Antibody 3F8 and Granulocyte-Macrophage Colony Stimulating Factor for 
Neuroblastoma (2001) J Clin Oncol 19,4189-4194
Lampson LA, Fisher CA, Whelan JP, Striking Paucity of HLA-A, B, C and B2 
Microglobulin on Human Neuroblastoma Cell Lines (1983) J Immunol 130,2471-2478
Larchian WA, Hotiguchi Y, Nair SK, Fair WR, Heston WDW, Gilboa E, Effectiveness of 
Combined Interleukin 2 and B7.1 Vaccination Strategy is Dependent on the Sequence and 
Order: A Liposome-mediated Gene Therapy Treatment for Bladder Cancer (2000) Clin 
Cancer Res 6,2913-2920
246
References
Leach DR, Callahan GN, Fibrosarcoma Cells Expressing Allogeneic MHC Class II 
Antigens Induce Protective Anti-Tumour Immunity (1995) J Immunol 154, 738-745
Leurs C, Jansen M, Pollok KE, Heinkelein M, Schmidt M, Wissler M, Lindemann D, Von 
Kalle C, Rethwilm A, Williams DA, Hanenberg H, Comparison of Three Retroviral 
Vector Systems For Transduction of Nonobese Diabetic/Severe Combined 
Immunodeficiency Mice Repopulating Human CD34+ Cord Blood Cells (2003) Hum 
Gene Ther 14, 509-519
Lenz P, Bacot SM, Frazier-Jessen MR, Feldman GM, Nucleoporation of Dendritic Cells: 
Efficient Gene Transfer by Electroporation into Human Monocyte-Derived Dendritic 
Cells (2003) FEBS Lett 538,149-154
Liang H, Reich CF, Pisetsky DS, Lipsky PE, The Role of Cell Surface Receptors in the 
Activation of Human B Cells by Phosphorothioate Oligonucleotides (2000) J Immunol 
165,1438-1445
Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP, Application of 
Interleukin-2-secreting Syngeneic/Allogeneic Fibroblasts for the Treatment of Primary 
and Metastatic Brain Tumours (2002) Cancer Gene Ther 9, 464-469
Linial ML, Foamy Viruses are Unconventional Retroviruses (1999) J Virol 73,1747-1744
Liu Y, Huang H, Saxena A, Xiang J, Intratumoural Coinjection of Two Adenoviral 
Vectors Expressing Functional Interleukin-18 and Inducible Protein-10, Respectively, 
Synergises to Facilitate Regression of Established Tumours (2002) Cancer Gene Ther 9, 
533-542
Lode HL, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA, Tumour- 
Targeted IL-2 Amplifies T Cell-Mediated Immune Response Induced by Gene therapy 
with Single-Chain IL-12 (1999) PNAS 96, 8591-8596
Loskog A, Riemensberger J, Malmstrom PU, Bohle A, Brandau S, Totterman TH, 
AdCD40L Transduced Tumour Cells Induce Potent Anti-tumour Immunity in 
Experimental Bladder Cancer (2001) Abstract, ISCGT London Conference July 2001
Lovat PE, Irving H, Annicchiarico-Petruzzelli M, Bemassola F, Malcolm AJ, Pearson 
ADJ, Melino G, Redfem CPF, Retinoids in Neuroblastoma Therapy: Distinct Biological 
Properties of 9-cis- and All-trans-Retinoic Acid (1997) Eur J Cancer 33, 2075-2080
Ludewig B, Graf D, Gelderblom HR, Becker Y, Kroczek RA, Pauli G, Spontaneous 
Apoptosis of Dendritic Cells is Efficiendy Inhibited by TRAP (CD40-ligand) and TNF-a 
But Strongly Enhanced by Interleukin-10 (1995) Eur J Immunol 25,1943-1950
Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkemagel RM, 
Immunotherapy With Dendritic Cells Directed Against Tumour Antigens Shared with 
Normal Host Cells Results in Severe Autoimmune Disease (2000) J Exp Med 191, 795-803
Lundqvist A, Choudhury A, Nagata T, Andersson T, Quinn G, Fong T, Maitland N, 
Pettersson S, Paulie S, Pisa P, Recombinant Adenovirus Vector Activates and Protects
247
References
Human Monocyte-Derived Dendritic Cells from Apoptosis (2002) Hum Gene Ther 13, 
1541-1549
Maheshwari A, Mahato RI, McGregor J, Han SO, Samlowski WE, Park JS, Kim SW, 
Soluble Biodegradable Polymer-Based Cytokine Gene Delivery for Cancer Treatment 
(2000) Mol Ther 2,121-130
Mandelboim O, Vadai E, Feldman M, Eisenbach L, Expression of Two H-2K Genes, 
Syngeneic and Allogeneic, as a Strategy for Potentiating Immune Recognition of Tumour 
Cells (1995) Gene Therapy 2, 757-65
Marshall E, Gene Therapy Death Prompts Review of Adenovirus Vector (1999) Science 
286, 2244-2245
Marshall E, Cancer Trial of Interleukin-12 Halted (1995) Science 268,1555
Mamyama K, Akiyama Y, Nara-Ashizawa N, Hojo T, Cheng JY, Mizuguchi H, Hayakawa 
T, Yamaguchi K, Adenovirus-Mediated MUC1 Gene Transduction into Human Blood- 
Derived Dendritic Cells (2001) J Immunother 24, 345-353
Medema JP, de Jong J, van Hall T, Melief CJM, Offringa R, Immune Escape of Tumours 
In Vivo by Expression of Cellular FLICE-Inhibitory Protein (1999) J Exp Med 190,1033- 
1038
Mendiratta SK, Quezada A, Matar M, Wang J, Hebei HL, Long S, Nordstrom JL, Pericle 
F, Intratumoural Delivery of IL-12 Gene by Polyvinyl Polymeric Vector System to Murine 
Renal and Colon Carcinoma Results in Potent Antitumour Immunity (1999) Gene Ther 6, 
833-839
Metharom P, Ellem KAO, Schmidt C, Wei MQ, Lentiviral Vector-Mediated Tyrosinase- 
Related Protein 2 Gene Transfer to Dendritic Cells for The Therapy of Melanoma (2001) 
Hum Gene Ther 12, 2203-2213
Miller DG, Rudedge EA, Russell DW, Chromosomal Effects of Adeno-Associated Vims 
Vector Integration (2002) Nat Genet 30,147-148
Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, Lin Y, Dohadwala M, Batra RK, 
Wu L, Economou JS, Dubinett SM, Intratumoural Administration of Adenoviral 
Interleukin 7 Gene-Modified Dendritic Cells Augments Specific Antitumour Immunity 
and Achieves Tumour Eradication (2000) Hum Gene Ther 11, 53-65
Mitani K & Kubo S, Adenovirus as an Integrating Vector (2002) Curr Gene Ther 2,135- 
144
Mitchell DA, Nair SK, RNA-transfected Dendritic Cells in Cancer Immunotherapy (2000) 
J Clin Invest 106,1065-1069
Mocellin S, Wang E, Marincola FM, Cytokines and Immune Response in the Tumour 
Microenvironment (2001) J Immunother 24, 392-407
248
References
Moll UM, La Quaglia M, Benard J, Riou G. Wild-type p53 Protein Undergoes Cytoplasmic 
Sequestration in Undifferentiated Neuroblastomas But Not in Differentiated Tumours 
(1995) PNAS 92,4407-4111
Monsaingeon M, Perel Y, Simonnet G, Corcuff JB, Comparative Values of 
Catecholamines and Metabolites for the Diagnosis of Neuroblastoma (2003) Eur J Pediatr 
162, 397-402
Moret I, Algas R, Revert F, Guillem V, Crespo A, Diaz J, Alino SF, Melanoma Tumour 
Growth Prevention by Vaccination with Genetically Modified B16 Tumour Cells (2001) 
Abstract, ISCGT London Conference July 2001
Morgan DA, Ruscetti FW, Gallo R, Selective In Vitro Growth of T Lymphocytes from 
Normal Human Bone Marrows (1976) Science 193,1007-1008
Morsy MA, Caskey CT, Expanded-Capacity Adenoviral Vectors — The Helper Dependent 
Vectors (1999) Mol Med Today 5,18-24
Movassagh M, Baillou C, Cosset FL, Klatzmann D, Guigon M, Lemoine FM, High Level 
of Retrovirus-Mediated Gene Transfer into Dendritic Cells Derived from Cord Blood and 
Mobilised Peripheral Blood CD34+ Cells (1999) Hum Gene Ther 10,175-187
Murphy SJ, Chong H, Bell S, Diaz RM, Vile RG, Novel Integrating Adenoviral/Retroviral 
Hybrid Vector for Gene Therapy (2002) Hum Gene Ther 13, 745-760
Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK, 
Induction of Tumour-Specific Cytotoxic T Lymphocytes in Cancer Patients by 
Autologous Tumour RNA-transfected Dendritic Cells (2002) Ann Surg 235, 540-549
Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM, Expression and Function of TRK-B 
and BDNF in Human Neuroblastomas (1994) Mol Cell Biol 14, 759-767
Nakamura S, Otani T, Ijiri Y, Motoda R, Kurimoto M, Orita K, IFN-gamma-Dependent 
and—Independent Mechanisms in Adverse Effects Caused by Concomitant Administration 
of IL-18 and IL-12 (2000) J Immunol 164, 3330-3336
Nakano Y. et al., Serum and Urinary Chatecholamines and their Metabolites (1973) Jap J 
Clin Med 31,1645-1656
Naldini L, Verma IM, Lentiviral Vectors, pp47-60, The Development of Human Gene 
Therapy, (1999) Cold Spring Harbour Press
Naldini L, Blomer U, Gage FH, Trono D, Verma IM, Efficient Transfer, Integration and 
Sustained Long-Term Expression of the Transgene in Adult Rat Brains Injected with a 
Lentiviral Vector (1996) PNAS 93,11382-11388
Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, Beer DG, Lack of Cell 
Surface Fas/APO-1 Expression in Pulmonary Adenocarcinomas (1998) J Clin Invest 101, 
1102-1110
249
References
Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, 
Cushen N, O’Malley D, Begent RHJ, Antibody-Directed Enzyme Prodrug Therapy: 
Efficacy and Mechanism of Action in Colorectal Carcinoma (2000) Clin Cancer Res 6, 
765-772
Neithammer D, Handgretinger R, Clinical Strategies for the Treatment of Neuroblastoma
(1995) EurJ Cancer 4, 568-571
Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, 
Romel L, Randlev B, Reid T, Kaye S, Kim D, Selective Replication and Oncolysis in p53 
Mutant Tumours with ONYX-015, an ElB-55kd Gene-Deleted Adenovirus, In Patients 
With Advanced Head and Neck Cancer: A Phase II Trial (2000) Cancer Res 60, 6359-6366
Nesde FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D, 
Vaccination of Melanoma Patients with Peptide- or Tumour Lysate-Pulsed Dendritic Cells 
(1998) Nat Med 4, 328-332
Nguyen T, Wang R, Russell JH, IL-12 Enhances IL-2 Function By Inducing CD25 
Expression Through a p38 Mitogen-Activated Protein Kinase Pathway (2000) Eur J 
Immunol 30,1445-1452
Nikitina EY, Gabrilovich DI, Combination of y-Irradiation and Dendritic Cell 
Administration Induces a Potent Antitumour Response in Tumour-Bearing Mice: 
Approach to Treatment of Advanced Stage Cancer (2001) Int J Cancer 94, 825-833
Ninane J, Pearson ADJ, (1997) Paediatric Oncology, Chapterl7, 2nd edition. Edited by C. 
R. Pinkerton and P. N. Plowman. Published by Chapman & Hall, London.
Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, Fellows W, 
Rajendiran S, Tamura M, Cohen JB, Glorioso JC, Effective Treatment of Experimental 
Glioblastoma by HSV Vector-Mediated TNF-alpha and HSV-tk Gene Transfer in 
Combination With Radiosurgery and Gancyclovir Administration (2000) Mol Ther 2,114- 
120
Nishida Y, Maeda Y, Hara A, Arima T, Kimura E, Yamashita S, Uyama E, Mita S, Uchino 
M, Adenovirus-Mediated Murine Interferon-gamma Receptor Transfer Enhances the 
Efficacy of IFN-gamma In Vivo (2002) Biochem Biophys Res Commun 290,1042-1047
Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Horio Y, Sekido Y, Hara T, 
Hashimoto N, Takahashi M, Shimokata K, Hasegawa Y, Induction of Antitumour 
Immunity by Transduction of CD40 Ligand Gene and Interferon-gamma Gene into Lung 
Cancer Cells (2001) Cancer Gene Ther 8, 421-429
Nomura T, Yasuda K, Yamada T, Okamoto S, Mahoto RI, Watanabe Y, Takakura Y, 
Hashida M, Gene Expression and Antitumour Effects Following Direct Interferon (IFN)- 
gamma Gene Transfer with Naked Plasmid DNA and DC-chol Liposome Complexes in 
Mice (1999) Gene Ther 6,121-129
Noujaim D, van Golen CM, van Golen KL, Grauman A, Feldman EL, N-Myc and Bcl-2 
Coexpression Induces MMP-2 Secretion and Activation in Human Neuroblastoma Cells
(2002) Oncogene 21,4549-4557
250
References
Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, 
Zinkemagel RM, Immune Surveillance Against a Solid Tumour Fails Because of 
Immunological Ignorance (1999) PNAS 96, 2233-2238
Okada H, Pollack IF, Lieberman F, Lunsford LD, Kondziolka D, Schiff D, Attanucci J, 
Edington H, Chambers W, Kalinski P, Kinzler D, Whiteside T, Elder E, Potter D, Gene 
Therapy of Malignant Gliomas: A Pilot Study of Vaccination with Irradiated Autologous 
Glioma and Dendritic Cells Admixed with IL-4 Transduced Fibroblasts to Elicit an 
Immune Response (2001) Hum Gene Ther 12, 575-595
Orentas RJ, Schauer D, Bin Q, Johnson BD, Electrofusion of a Weakly Immunogenic 
Neuroblastoma With Dendritic Cells Produces a Tumour Vaccine (2001) Cell Immnol 213, 
4-13
O’Shea JJ, Ma A, Lipsky P, Cytokines and Autoimmunity (2002) Nat Rev Immunol 2, 37- 
45
Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI, Vascular 
Endothelial Growth Factor Affects Dendritic Cell Maturation Through the Inhibition of 
Nuclear Factor-icB Activation in Haematopoietic Progenitor Cells (1998) J Immunol 160, 
1224-1232
Pagnan G, Stuart DD, Pastotino F, Raffaghello L, Montaldo PG, Allen TM, Calabretta B, 
Ponzoni M, Delivery of c-myb Antisense Oligodeoxynucleotides to Human 
Neuroblastoma Cells Via Diasialoganglioside GD(2)-Targeted Immunoliposomes: 
Antitumour Effects (2000) J Nat Cancer Inst 92, 253-261
Pannell D, Ellis J, Silencing of Gene Expression: Implications For Design of Retrovirus 
Vectors (2001) Rev Med Virol 11, 205-217
Pardoll DM, Paracrine Cytokine Adjuvants in Cancer Immunotherapy (1995) Ann Rev 
Immunol 13, 399-415
Park C, Kang WK, Oh M, Kim WS, Yang JH, Lotze MT, Kim S, Park K, Chan H, 
Production of IL-12 From Gene Modified Human Dermal Fibroblasts (A Preclinical 
Study for IL-12 Cancer Gene Therapy) (1997) Exp Mol Med 31, 65-69
Parkes RJ & Hart SL, Adhesion Molecules and Gene Transfer (2000) Adv Drug Del Rev 
44,135-152
Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, 
Schadendorf D, Compete Loss of HLA Class I Antigen Expression on Melanoma Cells: A 
Result of Successive Mutational Events (2003) Int J Cancer 103, 759-767
Perez-Diez A, Spiess PJ, Restifo NP, Matzinger P, Marincola FM, Intensity of the 
Vaccine-Elicited Immune Response Determines Tumour Clearance (2002) J Immunol 168, 
338-347
Pertl U, Luster AD, Varki NM, Homann D, Gaedicke G, Reisfeld RA, Lode HN, IFN-y- 
Inducible Protein-10 is Essential for the Generation of a Protective Tumour-Specific CD8
251
References
T Cell Response Induced by Single-Chain IL-12 Gene Therapy (2001) J Immunol 166, 
6944-6951
Pons G, O’Dea RF, Mirkin BL, Biological Characterisation of the Cl 300 Murine 
Neuroblastoma: An In Vivo Neural Crest Tumour Model (1982) Cancer Res 42, 3719-3723
Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL, A Critical Role for Transforming 
Growth Factor-Beta But Not Interleukin-4 in the Suppression of T Helper Type 1- 
Mediated Colitis by CD45RB (low) CD4+ T Cells (1996) J Exp Med 183, 2669-2674
Prezioso JA, Heating VJ, Muller J, Urabe K, Wang N, Gorelik E, Impairment of the 
Melanogenic Pathway in B16 Melanoma Cells Transfected with Class I H-2 Genes (1995) 
Meanoma Res 5,15-25
Propper DJ, Chao D, Braybooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N, 
Gatter K, Talbot DC, Harris AL, Ganesan TS, Low-Dose IFN-gamma Induces Tumour 
MHC Expression in Metastatic Malignant Melanoma (2003) Clin Cancer Res 9, 84-92
Piitzer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL, Interleukin 12 and B7.1 
Costimulatory Molecule Expressed By an Adenovirus Vector Act Synergistically to 
Facilitate Tumour Regression (1997) PNAS 94,10889-10894
Qian HN, Liu GZ, Cao SJ, Feng J, Ye X, The Experimental Study of Ovarian Carcinoma 
Vaccine Modified By Human B7-1 and IFN-gamma Genes (2002) Int J Gynecol Cancer 
12, 80-85
Rabinowitz JE, Samulski RJ, Building a Better Vector: The Manipulation of AAV Virions
(2000) Virology 278, 301-308
Rakhmilevich AL, Janssen K, Turner J, Culp J, Yan NS, Cytokine Gene Therapy of Cancer 
Using Gene Gun Technology: Superior Antitumour Activity of Interleukin-12 (1997) Hum 
Gene Ther 8,1303-1311
Redlinger RE, Mailliard RB, Barksdale EM, Advanced Neuroblastoma Impairs Dendritic 
Cell Function in Adoptive Immunotherapy (2003a) J Pediatr Surg 38, 857-862
Redlinger RE, Shimizu T, Remy T, Alber S, Watkins SC, Barksdale EM, Cellular 
Mechanisms of Interleukin-12-Mediated Neuroblastoma Regression (2003b) J Pediatr Surg 
38,199-204
Redlinger RE, Mailliard RB, Lotze MT, Barksdale EM, Synergistic Interleukin-18 and Low 
Dose Interleukin-2 Promote Regression of Established Murine Neuroblastoma In Vivo 
(2003c) J Pediatr Surg 38, 301-307
Reff ME, Hariharan K, Braslawsky G, Future of Monoclonal Antibodies in the Treatment 
of Haematologic Malignancies (2002) Cancer Control 9,152-166
Reis e Sousa C, Hieny S, Scharton-Kersten T, Jankovic D, Charest H, Germain RN, Sher 
A, In Vivo Microbial Stimulation Induces Rapid CD40 Ligand-Independent Production of 
Interleukin-12 by Dendritic Cells and Their Redistribution to T-cell Areas (1997) J Exp 
Med 186,1819-1829
252
References
Reynolds JV, Shou J, Choi H, Sigal R, Ziegler MM, Daly JM, The Influence of Natural 
Killer Cells in Neuroblastoma (1989) Arch Surg 124,235-238
Reynolds T, Rockwell S, Glazer PM, Genetic Instability Induced by the Tumor 
Microenvironment (1996) Cancer Res 56, 5754-5757
Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, Ponzoni M, In Vivo 
Angiogenic Activity of Neuroblastoma Correlates with M YCN  Oncogene Overexpression 
(2002a) Int J Cancer 102, 351-354
Ribatti D, Vacca A, Nico B, De Falco G, Giuseppe Montaldo P, Ponzoni M, Angiogenesis 
and Anti-angiogenesis in Neuroblastoma (2002b) Eur. J Cancer 38, 750-757
Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, 
Steinberg S, Rosenberg S, Marincola F, Immune Selection After Antigen-Specific 
Immunotherapy of Melanoma (1999) Surgery 126,112-120
Ritz U, Momberg F, Pilch H, Huber C, Maeurer MJ, Seliger B, Deficient Expression of 
Components of the MHC Class I Antigen Processing Machinery in Human Cervical 
Carcinoma (2001) Int J Oncol 19,1211-1220
Roninson IB, Dokmanovic M, Induction of Senescence-Associated Growth Inhibitors in 
the Tumour-suppressive Function of Retinoids (2003) J Cell Biochem 88, 83-94
Rosen D, Li JH, Keidar S, Markon I, Orda R, Berke G, Tumour Immunity in Perforin- 
Deficient Mice: A Role for CD95 (Fas/APO-1) (2000) J Immunol 164, 3229-3235
Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M, Anticancer Antibodies (2003) Am J Clin 
Pathol 119,472-485
Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) Gene and Protein in Breast Cancer (1999) 
Am J Clin Pathol 112 (supplement 1), S53-S67
Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, 
Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, 
Dolormente MM, Han Cl, Martin FD, Yen N, Xu K, Stephen LC, McDonnell TJ 
Mukhopadhyay T, Cai D, Retrovirus-Mediated Wild-Type p53 Gene Transfer to Tumours 
of Patients with Lung Cancer (1996) Nat Med 2, 985-991
Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders WE, Cole DJ, Systemic 
Administration of IL-15 Augments the Antigen-Specific Primary CD8+ T Cell Response 
Following Vaccination with Peptide-Pulsed Dendritic Cells (2002) J Immunol 169, 4928- 
4935
Russell DW, Miller AD, Alexander IE, Adeno-Associated Virus Vectors Preferentially 
Transduce Cells in S Phase (1994) PNAS 91, 8915-8919
Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, 
Nomura T, Toda M, Takahashi T, Immunologic Tolerance Maintained By CD25+ CD4+
253
References
Regulatory T-Cells: Their Common Role in Controlling Autoimmunity, Tumour 
Immunity, and Transplantation Tolerance (2001) Immunol Rev 182,18-32
Salvesen GS, Dixit VM, Caspase Activation: The Induced-Proximity Model (1999) PNAS 
96,10964-10967
Sanches R, Kuiper M, Penault-Llorca F, Aunoble B, D’lncan C, Bignon YJ, Antitumoural 
Effect of Interleukin-12-Secreting Fibroblasts in a Mouse Model of Ovarian Cancer: 
Implication for the use of Ovarian Cancer-derived Fibroblasts as a Vehicle for Regional 
Gene Therapy (2000) Cancer Gene Ther 7, 707-720
Sandler A, Scott D, Azuhata T, Takamizawa S, O’Dorisio S, The Survivin:Fas Ratio is 
Predictive of Recurrent Disease in Neuroblastoma (2002) J Pediatr Surg 37, 507-511
Sandler AD, Chihara H, Kobayashi G, Zhu X, Miller MA, Scott DL, Kreig AM, CpG 
Oligonucleotides Enhance the Tumour Antigen-Specific Immune Response of a 
Granulocyte Macrophage Colony-Stimulating Factor-Based Vaccine Strategy in 
Neuroblastoma (2003) Cancer Res 63, 394-399
Scherr M, Battmer K, Eder M, Schule S, Hohenberg H, Ganser A, Grez M, Blomer U, 
Efficient Gene Transfer Into the CNS by Lentiviral Vectors Purified by Anion Exchange 
Chromatography (2002) Gene Ther 9,1708-1714
Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, Klein G, Sander J, 
Schwarz K, Treuner J, Zorn U, Michaelis J, Neuroblastoma Screening at One Year of Age 
(2002) NEJM 346,1047-1053
Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, 
Greenberg AS, EngJM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon JJ, van 
den Brink MR, T Cells Require TRAIL for Optimal Graft-Versus-Tumour Activity (2002) 
Nat Med 8,1433-1437
Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A, Tumour Cell 
Lysate-pulsed Human Dendritic Cells Induce a T-Cell Response against Pancreatic 
Carcinoma Cells: an in Vitro Model for the Assessment of Tumour Vaccines (2001) Cancer 
Res 61, 6445-6450
Schonrich G, Kalinke U, Momburg F, Malissen M, Schmitt-Verhulst AM, Malissen B, 
Hammerling GJ, Arnolds B, Down Regulation of T Cell Receptors on Self Reactive T 
Cells as a Novel Mechanism for Extrathymic Tolerance Induction (1991) Cell 65,293-304
Schott M, Feldkamp J, Lettmann M, Simon D, Scherbaum WA, Seissler J, Dendritic Cell 
Immunotherapy in a Neuroendocrine Pancreas Carcinoma (2001) Clin Endocrin 55, 271- 
277
Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F, HIV-1 Integration In The 
Human Genome Favours Active Genes and Local Hotspots (2002) Cell 110, 521-529
Schroers R, Sinha I, Segall H, Schmidt-Wolf IGH, Rooney CM, Brenner MK, Sutton RE, 
Chen SY, Transduction of Human PBMC-Derived Dendritic Cells and Macrophages by 
an HIV-1-Based Lentiviral Vector System (2000) Mol Ther 1,171-179
254
References
Seeger RC, Rosenblatt JD, Duerst RE, Reynolds CP, Villablanca JG, Hasenauer B, Feig 
SA, A Phase I Study of Human Gamma Interferon Gene-Transduced Tumour Cells in 
Patients with Neuroblastoma (1998) Human Gene Ther 9, 379-390
Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman 
RW, Dvorak AM, Dvorak HF, Vascular Permeability Factor (VPF, VEGF) in Tumour 
Biology (1993) Cancer Metastasis Rev 12, 303-324
Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, Dubinett SM, T Cell- 
Derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T Cell and APC 
Function (1999) J Immunol 163, 5020-5028
Shawler DL, Dorigo O, Gjerset RA, Royston I, Sobol RE, Fakhrai H, Comparison of 
Gene Therapy with Interleukin-2 Gene Modified Fibroblasts and Tumour Cell in the 
Murine CT-26 Model of Colorectal Carcinoma (1995) J Immunother Emphasis Tumour 
Immunol 17, 201-208
Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A, Efficient 
Gene Transfer Into Human CD34+ Cells By a Retargeted Adenovirus Vector (2000) J 
Virol 74, 2567-2583
Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A, Induction of 
Antitumour Immunity with Fas/APO-1 Ligand (CD95L)-Transfected Neuroblastoma 
Neuro-2a Cells (1999) J Immunol 162, 7350-7357
Shimizu T, Berhanu A, Redlinger RE, Watkins S, Lotze MT, Barksdale EM, Interleukin-12 
Transduced Dendritic Cells Induce Regression of Established Murine Neuroblastoma 
(2001) J Pediatr Surg 36,1285-1292
Shin MS, Kim HS, Kang CS, Park WS, Kim SY, Lee SN, Lee JH, Park JY, Jang JJ, Kim 
CW, Kim SH, Lee JY, Yoo NJ, Lee SH, Inactivating Mutations of CASP10 Gene in Non- 
Hodgkin Lymphomas (2002) Blood 99, 4094-4099
Shurin GV, Shutin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM, 
Neuroblastoma-Derived Gangliosides Inhibit Dendritic Cell Generation and Function
(2001) Cancer Res 61, 363-369
Siapati E, PhD thesis “Neuroblastoma Immunotherapy Using A Novel Vector System” 
UCL, University of London, 2001
Siapati KE, Barker S, Kinnon C, Michalski A, Anderson R, Brickell P, Thrasher AJ, Hart 
SL, Improved Antitumour Immunity in Murine Neuroblastoma Using a Combination of 
ID2 and IL-12 (2003) Br J Cancer 88,1641-1648
Sivanandham M, Stavropoulos Cl, Kim EM, Mancke B, Wallack MK, Therapeutic Effect 
of Colon Tumour Cells Expressing FLT-3 Ligand Plus Systemic IL-2 in Mice with 
Syngeneic Colon Cancer (2002) Cancer Immunol Immunother 51, 63-71
Smith KA, Rational Interleukin-2 Therapy (1997) Cancer J Sci Am 3, SI 37-140
255
References
Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MRM, Yagita H, Nature’s 
TRAIL — On a Path to Cancer Immunotherapy (2003) Immunity 18,1-6
Sobol RE, Shawler DL, Carson C, Van Beveran S, Mercola D, Fakhrai H, Garrett MA, 
Barone R, Goldfarb P, Bartholomew RM, Brostoff S, Carlo DJ, Royston I, Gold DP, 
Interleukin 2 Gene Therapy of Colorectal Carcinoma with Autologous Irradiated Tumour 
Cells and Genetically Engineered Fibroblasts: A Phase I Study (1999) Clin Cancer Res 5, 
2359-2365
Somia N, Verma IM Gene Therapy: Trials and Tribulations (2000) Nat Rev Genet 1,91-99
Son YI, Dallal RM, Lotze MT, Combined Treatment with Interleukin-18 and Low-Dose 
Interleukin-2 Induced Regression of a Murine Sarcoma and Memory Response (2003) J 
Immunother 26,234-240
Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL, Lotze MT, Interleukin-18 Synergises 
with IL-2 to Enhance Cytotoxicity, Interferon-gamma Production, and Expansion of 
Natural Killer Cells (2001) Cancer Res 61, 884-888
Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MAS, Crystal RG, 
Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for 
a Model Antigen Induce Protective and Therapeutic Antitumour Immunity (1997) J Exp 
Med 186,1247-1256
Spack EG, Sorgi FL, Developing Non-viral DNA Delivery Systems for Cancer and 
Infectious Disease (2001) Drug Discovery Today 6,186-197
Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P, 
Dendritic Cells Retrovirally Transduced with a Model Antigen Gene are Therapeutically 
Effective Against Established Pulmonary Metastases (1997) J Exp Med 186,1213-1221
Stamenkovic I, Matrix Metalloproteinases in Tumour Invasion and Metastasis (2000) 
Semin Cancer Biol 10, 415-433
Strobel I, Krumbholz M, Menke A, Hoffmann E, Dunbar PR, Bender A, Hobom G, 
Steinkasserer A, Schuler G, Grassmann R, Efficient Expression of the Tumour-Associated 
Antigen MAGE-3 in Human Dendritic Cells, Using an Avian Influenza Virus Vector 
(2000) Hum Gene Ther 11,2207-2218
Summerford C, Samulski RJ, Membrane-Associated Heparan Sulphate Proteoglycan is a 
Receptor for Adeno-Associated Virus Type 2 Virions (1998) J Virol 72,1438-1445
Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, McKinney TG, Schreiber RD, Gubler U, 
Robbins PD, Lotze MT, Effective Eradication of Established Murine Tumours with IL-12 
Gene Therapy Using a Polycistronic Retroviral Vector (1995) J Immunol 154, 6466-6474
Tai TS, Fang LW, Lai MZ, c-FLICE Inhibitory Protein Expression Inhibits T-Cell 
Activation (2004) Cell Death Diff 11, 69-79
256
References
Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okomura K, 
Critical; Role for Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand in Immune 
Surveillance Against Tumour Development (2002) J Exp Med 195,161-169
Tanaka M, Saijo Y, Sato G, Suzuki T, Tazawa R, Satoh K, Nukiwa T, Induction of 
Antitumour Immunity by Combined Immunogene Therapy using IL-2 and IL-12 in Low 
Antigenic Lewis Lung Carcinoma (2000) Cancer Gene Ther 7,1481-1490
Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, 
Lahti JM, Kidd VJ, Caspase 8 is Deleted or Silenced Preferentially in Childhood 
Neuroblastomas with Amplification of MYCN (2000) Nat Med 6, 529-535
Telander DG, Malvey EN, Mueller DL, Evidence for Repression of IL-2 Gene Activation 
in Anergic T Cells (1999) J Immunol 162,1460-1465
Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, 
Paul WE, Berzofsky JA, NKT Cell-Mediated Repression of Tumour Immunosurveillance 
by IL-13 and the IL-4R-STAT6 Pathway (2000) Nature Immunol 1, 515-520
Terheyden P, Straten P, Brocker EB, Kampgen E, Becker JC, CD40-Ligated Dendritic 
Cells Effectively Expand Melanoma-Specific CD8+ CTLs and CD4+ IFN-y-Producing T 
Cells from Tumour-Infiltrating Lymphocytes (2000) J Immunol 164, 6633-6639
Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB, Identification 
of a New Endothelial Cell Growth Factor Receptor Tyrosine Kinase (1991) Oncogene 6, 
1677-1683
Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, 
Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN, Requirement for STAT4 in 
Interleukin-12-Mediated Responses of Natural Killer and T-Cells (1996) Nature 382, 171- 
174
Thomas CE, Ehrhardt A, Kay MA, Progress and Problems With The Use of Viral Vectors 
For Gene Therapy (2003) Nat Rev Genet 4, 346-358
Thomas MC, Greten TF, Pardoll DM, Jaffee EM, Enhanced Tumour Protection by 
Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an 
Allogeneic Vaccine (1998) Hum Gene Ther 9, 835-843
Thomas PB, Delatte SJ, Sutphin A, Frankel AE, Tagge EP, Effective Targeted 
Cytotoxicity of Neuroblastoma Cells (2002) J Pediatr Surg 37, 539-544
Thumer B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, 
Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen 
E, Schuler G, Vaccination with MAGE-3A1 Peptide-pulsed Mature, Monocyte-derived 
Dendritic Cells Expands Specific Cytotoxic T cells and Induces Regression of Some 
Metastases in Advanced Stage IV Melanoma (1999) J Exp Med 190,1669-1678
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH, Loss of 
CTLA-4 Leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, 
Revealing a Critical Negative Regulatory Role of CTLA-4 (1995) Immunity 3, 541-547
257
References
Tobias CA, Shumsky JS, Shibata M, Tuszynski MH, Fischer I, Tessler A, Murray M, 
Delayed Grafting of BDNF and NT-3 Producing Fibroblasts into the Injured Spinal Cord 
Stimulates Sprouting, Partially Rescues Axotomised Red Nucleus Neurons from Loss and 
Atrophy, and Provides Limited Regeneration (2003) Exp Neurol 184, 97-113
Toda M, Martuza RL, Rabkin SD, Tumour Growth Inhibition By Intratumoural 
Inoculation of Defective Herpes Simplex Virus Vectors Expressing Granulocyte- 
Macrophage Colony-Stimulating Factor (2000) Mol Ther 2, 324-329
Todaro GJ & Green H, Quantitative Studies of the Growth of Mouse Embryo Cells in 
Culture and Their Development Into Established Lines (1963) J Cell Biol 17,299-313
Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS, A Role For Survivin in 
Chemoresistance of Endothelial Cells Mediated by VEGF (2002) PNAS 99, 4349-4354
Trinchieri G, Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory 
Functions that Bridge Innate Resistance and Antigen-Specific Adaptive Immunity (1995) 
Ann Rev Immunol 13,251-276
Trinchieri G, Interleukin-12 and the Regulation of Innate Resistance and Adaptive 
Immunity (2003) Nat Rev Immunol 3,133-146
Tsuji H, Kawaguchi S, Wada T, Nagoya S, Inobe M, Yamashita T, Ishii S, Uede T, 
Adenovirus-Mediated In Vivo B7-1 Gene Transfer Induces Anti-Tumour Immunity 
Against Pre-Established Primary Tumour and Pulmonary Metastasis of Rat Osteosarcoma
(2002) Cancer Gene Ther 9, 747-755
Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA, IL-12 Induces T Helper 1- 
Directed Antitumour Response (1997) J Immunol 158, 3359-3365
Uherek J, Fominaya J, Weis W, A Modular DNA Carrier Protein Based On The Structure 
of Diphtheria Toxin Mediates Target Cell-Specific Gene Delivery (1998) J Biol Chem 273, 
8835-8841
Valteau D, Scott V, Carcelain G, Hartmann O, Escudier B, Hercend T, Triebel F, T-Cell 
Receptor Repertoire in Neuroblastoma Patients (1996) Cancer Res 56, 362-369
van’t Veer LJ, Beijersbergen RL, Bernards R, N-myc Suppresses Major Histocompatibility 
Complex Class I Gene Expression Through Down-Regulation of the p50 Subunit of NF- 
kB (1993) EMBO J 12,195-200
Vendetti S, Chai JG, Dyson J, Simpson E, Lombardi G, Lechler R, Anergic T Cells Inhibit 
the Antigen-Presenting Function of Dendritic Cells (2000) J Immunol 165,1175-1181
Versteeg R, Kruse-Wolters KM, Plomp AC, van Leeuwen A, Stam NJ, Ploegh HL, Ruiter 
DJ, Schrier PI, Suppression of Class I Human Histocompatibility Leukocyte Antigen By c- 
mycis Locus Specific (1989) J Exp Med 170, 621-635
258
References
Voorhess ML, Gardner IS, Urinary Excretion of Norepinephrine, Epinephrine and 3- 
methoxy-4-hydroxymandelic acid by Children with Neuroblastoma (1961) J Clin Endocrin 
Metabol 21, 321-335
Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y, An Infectious Transfer 
and Expression System For Genomic DNA Loci in Human and Mouse Cells (2001) Nat 
Biotechnol 19,1067-1070
Wagner E, Curiel D, Cotton M, Delivery of Drugs, Proteins and Genes Into Cells Using 
Transferrin as a Ligand For Receptor Mediated Endocytosis (1994) Adv Drug Deliv Rev 
14,113-135
Wagner E, Zenke M, Cotten M, Beug H, Bimstiel ML, Transferrin-Polycation Conjugates 
as Carriers for DNA Uptake into Cells (1990) PNAS 87, 3410-3414
Wakamatsu Y, Watanabe Y, Nakamura H, Kondoh H, Regulation of the Neural Crest Cell 
Fate by N-myc: Promotion of Ventral Migration and Neuronal Differentiation (1997) 
Development 124,1953-1962
Waldmann TA, O’Shea J, The Use of Antibodies Against the IL-2 Receptor in 
Transplantation (1998) Curr Opin Immunol 10, 507-512
Wang KS, Frank DA, Ritz J., Interleukin-2 Enhances the Response of Natural Killer Cells 
to Interleukin-12 Through Up-Regulation of the Interleukin-12 Receptor and STAT4
(2000) Blood 95, 3183-3190
Ward CM, Read ML, Seymour LW, Systemic Circulation of Poly-(L-Lysine)/DNA 
Vectors is Influenced by Polycation Molecular Weight and Type of DNA: Differential 
Circulation in Mice and Rats and the Implications for Human Gene Therapy (2001) Blood 
97, 2221-2229
Weiner LP, Atalla LR, Kochounian HA, Du J, Wei W, Hinton DR, Gordon EM, 
Anderson WF, McMillan M, Gene Therapy in a Murine Model for Clinical Application to 
Multiple Sclerosis (2004) Ann Neurol 55, 390-399
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR, Integrins avP3 and (XvP5 Promote 
Adenovirus Internalisation But Not Virus Attachment (1993) Cell 73, 309-319
Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ, CD40-Ligand 
(CD154) Gene Therapy for Chronic Lymphocytic Leukaemia (2000) Blood 96,2917-2924
Wigginton JM, Kuhns DB, Back TC, Brunda MJ, Wiltrout RH, Cox GW, Interleukin-12 
Primes Macrophages for Nitric Oxide Production In Vivo and Restores Depressed Nitric 
Oxide by Macrophages From Tumour-Bearing Mice: Implications for the Antitumour 
Activity of Interleukin 12 and/or Interleukin-2 (1996) Cancer Res 56,1131-1136
Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW, Interleukin-2 Receptor a  
Chain Regulates the Size and Content of the Peripheral Lymphoid Compartment (1995) 
Immunity 3, 521-530
259
References
Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, 
Lord EM, Frelinger JG, Dendritic Cells Transduced with HSV-1 Amplicons Expressing 
Prostate-specific Antigen Generate Anti-tumour Immunity in Mice (2001) Hum Gene 
Ther 12,1867-1879
Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Feigner PL, Direct Gene 
Transfer into Mouse Muscle In Vivo (1990) Science 247,1465-1468
Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double j, Embleton J, 
Newell D, Raymond R, Stables J, Stephens T, Wallace J, United Kingdom Co-ordinating 
Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals In 
Experimental Neoplasia (Second Edition) (1998) Br J Cancer 77,1-10
Wu G, Wu C, Receptor-Mediated In Vitro Gene Transformation by a Soluble DNA 
Carrier System (1987) J Biol Chem 262,4429-4432
Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dorken B, Ludwig WD, 
Karawajew L, In Vitro Susceptibility to TRAIL-Induced Apoptosis of Acute Leukaemia 
Cells in the Context of TRAIL receptor Gene Expression and Constitutive NF-kappaB 
Activity (2001) Leukaemia 15,921-928
Xia DJ, Zhang WP, Zheng S, Wang J, Pan JP, Wang Q, Zhang LH, Hamada H, Cao X, 
Lymphotactin Cotransfection Enhances the Therapeutic Efficacy of Dendritic Cells 
Genetically Modified With Melanoma Antigen gplOO (2002) Gene Ther 9, 592-601
Xu R, Sun X, Tse LY, Li H, Chan PC, Xu S, Xiao W, Kung HF, Krissansen GW, Fan ST, 
Long-term Expression of Angiostatin Suppresses Metastatic Liver Cancer in Mice (2003) 
Hepatology 37,1451-1460
Yan P, Muhlethaler A, Balmas Bourloud K, Nenadov Beck M, Gross N, 
Hypermethylation-Mediated Regulation of CD44 Gene Expression in Human 
Neuroblastoma (2003) Gene Chrom Cancer 36,129-138
Yang NS, Wang JH, Turner J, Molecular Strategies for Improving Cytokine Transgene 
Expression in Normal and Malignant Tissues (2004) Gene Ther 11,100-108
Yee JK, Miyanohara A, LaPorte P, Bouic K, Bums JC, Friedmann T, A General Method 
for the Generation of High-Titre, Pantropic Retroviral Vectors: Highly Efficient Infection 
of Primary Hepatocytes (1994) PNAS 91, 9564-9568
Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM, CpG Motifs in 
Bacterial DNA Activate Leukocytes Through the pH-Dependent Generation of Reactive 
Oxygen Species (1998) J Immunol. 160, 4755-4761
Young JL, Miller RW, Incidence of Malignant Tumours in U.S. Children (1975) J Pediatr 
86,254-258
Yu D, Thomas-Tikhonenko A, Intratumoural Delivery of Interferon Gamma Retrovirus- 
Producing Cells Inhibits Growth of a Murine Melanoma by a Non-Immune Mechanism
(2001) Cancer Lett 13,145-154
260
References
Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U, Anderson WF, 
Wagner EF, Gilboa E, Self-Inactivating Retroviral Vectors Designed for Transfer of 
Whole Genes Into Mammalian Cells (1986) PNAS 83, 3194-3198
Zal T, Volkmann A, Stockinger B, Mechanisms of Tolerance Induction in Major 
Histocompatibility Complex Class II-Restricted T Cells Specific for a Blood-Bome Self- 
Antigen (1994) J Exp Med 180,2089-2099
Zeidler R, Eissner G, Meissner P, Uebel S, Tampe R, Lazis S, Hammerschmidt W, 
Downregulation of TAPI in B Lymphocytes by Cellular and Epstein-Barr Virus-Encoded 
Interleukin-10 (1997) Blood 90, 2390-2397
Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Chameau P, HIV-1 Genome 
Nuclear Import is Mediated by a Central DNA Flap (2000) Cell 101,173-185
Zhang S, Zeng G, Wilkes DS, Reed GE, McGarry RC, Eble JN, Cheng L, Dendritic Cells 
Transfected with Interleukin-12 and Pulsed With Tumour Extract Inhibit Growth of 
Murine Prostatic Carcinoma In Vivo (2003a) The Prostate 55,292-298
Zhang X, Chen Z, Chen Y, Tong, Delivering Antisense Telomerase RNA by a Hybrid 
Adenovirus/Adeno-Associated Virus Significantly Suppresses the Malignant Phenotype 
and Enhances Cell Apoptosis of Human Breast Cancer Cells (2003b) Oncogene 22, 2405- 
2416
Zhang XS, Zhu XF, Gao JS, Qian CN, Kuang ZJ Liu ZC, Zeng YX, Multiple Drug 
Resistance Phenotype of Human Endothelial Cells Induced by Vascular Endothelial 
Growth Factor 165 (2001) Acta Pharmacol Sin 22, 731-735
Zhu X, Wimmer K, Kuick R, Lamb BJ, Motyka S, Jasty R, Castle VP, Hanash SM, N-myc 
Modulates Expression of p73 in Neuroblastoma (2002) Neoplasia 4, 432-439
Ziegler MM, Naito H, McCarrick JW, Topolian SL, Ricci JL, Fox A et a I., C-1300 Murine 
Neuroblastoma: A Suitable Animal Model of Human Disease (1986) In: Brooks B. F., 
Malignant Tumours of Childhood. Austin: University of Texas Press, 114-126
Ziegler MM, Ishizu H, Nagabuchi E, Takada N, Arya G, A Comparative Review of the 
Immunobiology of Murine Neuroblastoma and Human Neuroblastoma (1997) Cancer 79, 
1757-1766
Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, Lotze MT, 
Cancer Immunotherapy of Established Tumours with IL-12: Effective Delivery by 
Genetically Modified Fibroblasts (1995) J Immunol 155,1393-1403
Zufferey R, Donello JE, Trono D, Hope TJ, Woodchuck Hepatitis Virus Post- 
Transcriptional Regulatory Element Enhances Expression of Transgenes Delivered by 
Retroviral Vectors (1999) J Virol 73,2286-2892
zur Hausen H, Papillomaviruses Causing Cancer: Evasion From host-Cell Control in Early 
Events in Carcinogenesis (2000) J Natl Cancer Inst 92, 690-698
261
Appendix
Appendix 1: Plasmids used for LPD transfections
1A: pCI-Luciferase
Amp. Res.
IB: Enhanced Green Fluorescent Protein-Nl
BgBl (5689)
CMV IE promoter
(831)
Intron
(1053) 
Xhd (1059) 
BgBl (1063)
Luciferase
F1 origin
BaniO (3031) 
PolyA signal
Xbd. (2769) 
Not! (2786)
pEGFP-NI
4733 bp
SV40 origin
pUC origin
CMV promoter
-  '(5 9 2 )
(610)
Xhd. (614) 
EccRl (630)
HSV TK poly A eGFP
Notl (1402) 
Xbd (1412. 
SV40 Poly AKan. Res/Neo. Res.
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1C: pCI-human Interleukin-2
BgiI (4492)
ampR
CMV I.E. Enhancer/Promo
Intron
pCI-hlL2
4496 bp
hlL-2
Nod (1589)
SV40 late PolyA Signal 1
f1 ori
ID: pCI-single chain murine Interleukin-12
B gil (5702) CMV IE Promoter
AmpR
pClsclL12
5863 bp
PsA (2284)BanHl (3044)
HirdLU (592)
P s i (674)
Nhd (896) 
Hirtffil (912) 
Kprl (922) 
BanHl (930; 
E cdd (953) 
\ P si (962) 
N o i (980) 
p35 
Xbd (1505; 
X bd (2008)
P si (2756)
Xhd (2791)
N oi (2799)
SV40 late PolyA Signal 1
2 6 3
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IE: pCMV-murine complement protein 5
Scd (11300) 
AmpR
BgiII (13)
Narl (8580) 
Neo-R
Smd (7490) 
BGH polyA
Xbd (7227)
pcmv-mC5
11700 bp
CMV Promoter
H irtm  (900)
Intron A
Hind ill (1800) 
(1806) 
BgiI (2710) 
Smd (2910)
Hindlll (3691; 
Smd (3900) 
EccKV (4121) 
mC5 cDNA 
Hintm (5481)
IF: pCI
amp R
B gil (4002)
H inm i
CMV IE Promoter
(749)
(831)
(1053)
(1059)
E cda (1064)
Kpri (1080)
(1082)
N o i (1099)
SV40 late PolyA Signal 
BanHl (1344)
2 6 4
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Appendix 2: Phenotype o f MACS separated DC compared with  
unseparated DC
Surface
Marker
Unseparated 
immature DC
Unseparated 
mature DC
MACS separated 
immature DC
MACS separated 
mature DC
CD40 14.3% 72.4% 10.5% 87.1%
CD80 21.2% 31.4% 17.5% 35.8%
CD86 18.1% 41% 17.1% 50.6%
MHC II 24.9% 51% 21.5% 49.0%
Comparison of the phenotype of unseparated DC or DC separated by positive selection 
on MACS C D llc microbeads. Cells were analysed by flow cytometry in their immature 
state or after maturation by incubation overnight in the presence of lpg/ ml LPS. Double 
staining with CDllc-PE and antibodies against CD80-FITC, CD86-FITC, MHC II-FITC 
or CD40-biotin and streptavidin-CyChrome identified the DC fraction of the unseparated 
cells. This data shows that the MACS separation procedure itself does not affect the DC 
phenotype, and neither does it affect the ability of the DC to mature in response to 
stimulus.
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A ppendix 3: Effect of fluorescently-labelled peptide on transfection
9000000 - 
8000000 - 
7000000 - 
6000000 -W)
^  5000000 - 
P
g  4000000 - 
3000000 - 
2000000 -  
1000000 - 
0 -
Transfection with a luciferase reporter gene was performed to investigate whether 
peptide 6 labelled with Texas Red used for the confocal microscopy experiments 
would interfere with the transfection process. The representative data shown here 
shows that transfection with labelled peptide results in a slight reduction in transgene 
expression, but no substantial detrimental effect is observed. Error bars represent 
standard deviations from triplicate transfections.
Unlabelled pep6 Texas Red labelled pep 6
2 6 6
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Appendix 4: Prelim inary M EF reporter gene transfections
30000
25000 -
20000 -tons
3 15000 -—as
10000 -
5000 -
0 - ]
HAJ3.1 
■  AJ3.4
Pep6 0.5 Pepl 0.5 Pep6 1 Pepl 1 Pep6 1.5 Pepl 1.5 Pep6 2 Pepl 2
Two MEF cultures were established with the morphology of fibroblasts, AJ3.1 and 
AJ3.4. Preliminary transfections were performed to determine which cell line would 
be used for all future experiments. A luciferase reporter gene was used to test 
peptides 1 and 6 at a charge ratio of +7, and amounts of DNA were varied between 
0.5-2pg per well. Cells were analysed by luciferase assay 24 hours after transfection. 
Representative data is shown and error bars indicate standard deviations of triplicate 
transfections.
The data clearly shows that AJ3.1 expressed higher levels of transgene than AJ3.4 
under every condition tested. Peptide 6 mediated higher luciferase expression than 
peptide 1 at equal amounts of DNA. Therefore, AJ3.1 was used in all subsequent 
experiments with syngeneic MEFs, and peptide 6 was used for comparison with other 
targeting peptides.
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A ppendix 5A: Cytokine expression of irradiated N IH -3T 3 cells used in 
first tum ourigenicity experim ent using allogeneic fibroblasts
1400
IL12
IL-2
1200 -
■  1000 - 
800 -
_=$ 600 -
M
0 400 -
200 -
0 2 3 5 6 7 81 4
days post injection
Expression of EL-2 and IL-12 by NIH-3T3 cells used in the first tumourigenicity 
experiment using allogeneic fibroblasts. These cells were transfected, and irradiated 
with 2500 rads shortly before s.c. administration with live wild-type N2a cells.
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Appendix 5B: Cytokine expression of live transfected N IH -3T 3 cells 
and  transfected N 2a cells used in second tum ourigenicity experim ent 
using  allogeneic fibroblasts
IL-12p70
1400
»  1200 U
-O 100°
£  800Tf<N
® 600 Cl
3 400
 ^ 200
0 1 2 3 5 6 7 84
Days post injection
hIL-2
500
NIH-3T3-IL-2-IL12
N2a-IL2-IL12.  400 
v
300£a
2  200
JS60
a 100
70 1 2 3 5 6 84
Days post injection
Expression o f IL-2 and IL-12 by NIH-3T3 cells and N2a cells used in the second 
tumourigenicity experiment using allogeneic fibroblasts. These cells were 
transfected and administered s.c. together with live wild-type N2a cells as a live cell 
vaccine.
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A ppendix 5C: Cytokine expression of live transfected AJ3.1 fibroblasts 
and  transfected N 2a cells used in the first tum ourigenicity experim ent 
using  syngeneic fibroblasts
2000
N2a 2+12 
AJ3:1 2+12
V
^  1500 -
X
5  1000 -
J) 500 -
3oc
0 2 3 5 7 81 4 6
Days post transfection
500
N2a 2+12 
AJ 3:1 2+12=3 400 -u
\  300 -x3
cj 200 - 
2
100 -
0 2 3 5 6 7 81 4
Days post transfection
Cytokine expression of transfected AJ3.1 and N2a cells used in first tumourigenicity 
experiment with syngeneic fibroblasts.
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A ppendix 5D: Cytokine expression from transfected irradiated AJ3.1 
fibroblasts in the second tum ourigenicity experim ent using syngeneic 
fibroblasts
300
200 -
150 -
^  100 -
50 -
0 21 3 4 5 6
Days post transfection
80
AJ3.1-IL2-IL12
60
o
3  40
20
0
0 1 2 3 4 5 6
Days post transfection
Expression of IL-2 and IL-12 by AJ3.1 cells used in the second tumourigenicity 
experiment using syngeneic fibroblasts. These cells were transfected, and irradiated 
with 2500 rads shortly before s.c. administration with live wild-type N2a cells.
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A ppendix 5E: Cytokine expression of transfected AJ3.1 fibroblasts and 
N 2a cells used in the eradication experim ent
Injection 1 IL-12p70 hIL-2
AJ3.1-IL2-
IL12
N2a-IL2-ILI2
2500
2000
d  1500
1000
500
0 2 84 6
400
AJ3.1-IL2-IL12
300
3  200
e 100
0 2 6 84
D a y s  p o s t  th a w in g D a y s  p o s t  th a w in g
Injection 2
N2a-IL2-IL!2
AJ3.1-EL2-IL12
1200
1
©
1000
s 800c*
g  600 
£
Jj 400“St>
200
0 2 6 84
Injection 3
D ay s  p o s t  th a w in g
250
N2a-IL2-ILI2
•AJ3.1-IL2-IL12200
2  150
«  100
2 6 80 4
800
600
400
200
0 2 4 6 8
D ay s p o s t  th aw in g
600
•N2a-H2-IL12
•AJ3.1-IL2-ILI2500
400
200
100
D ays p ost thaw ing
2 4 6
D ays p o s t thaw ing
272
Appendix
A ppendix 6: Cytokine expression of irradiated cytokine-transfected 
AJ3.1 fibroblasts
IL-12p70
1000
AJ3.1-IL2-IL12
» 800 -
r  600 -
3  400 -
0 2 4 6 8
Days post transfection
hIL-2
300
250 -
CO
200 -
|  150
2  1 0 0 -  
W>c
0 4 6 8
Days post transfection
Cytokine-transfected AJ3.1 cells were irradiated with 2500 rads 24h after 
transfection, then cultured in vitro and supernatant harvest over 24h periods and 
analysed by ELISA for expression of IL12 and IL-2. Cytokine expression is 
comparable with that from live cytokine-transfected AJ3.1 and was maintained for 
over 7 days.
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Appendix 7: Cytokine expression from frozen transfected cells
IL-12p70
1600 -j
AJ3.1-IL2-IL-12
N2a-IL2-IL12
« 1400 -
J* 1200 -
1000 -
d  800 -
|  600 -
400 -
SX)
c  2 0 0  -
0 1 2 3 5 74 6 8
Days post transfection
hIL-2
700
AJ3.1-IL2-IL12
N2a-IL2-IL12
600 -JS
500 -
ja 400 -
i
300 -
Jj
200 -
100 -
0 1 2 3 5 6 7 84
Days post transfection
Cytokine expression from AJ3.1 fibroblasts and N2a cells transfected with lLr2 and 
IL-12, then frozen down to —80°C 24h after transfection. One week later, cells were 
thawed, and cultured at 37°C. Supernatant was collected over 24h intervals for 7 days. 
Cytokine expression is equivalent to that obtained from freshly transfected cells.
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